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Summary
Diabetes is a disease that undermines the normal regulation of glucose levels in the
blood. In people with diabetes, the body does not secrete insulin (Type 1 diabetes)
or derangements occur in both insulin secretion and action (Type 2 diabetes). In
spite of the therapy, which is mainly based on controlled regimens of insulin and drug
administration, diet, and physical exercise, tuned according to self-monitoring of blood
glucose (SMBG) levels 3-4 times a day, blood glucose concentration often exceeds the
normal range thresholds of 70-180 mg/dL. While hyperglycaemia mostly affects long-term
complications (such as neuropathy, retinopathy, cardiovascular, and heart diseases),
hypoglycaemia can be very dangerous in the short-term and, in the worst-case scenario,
may bring the patient into hypoglycaemic coma. New scenarios in diabetes treatment
have been opened in the last 15 years, when continuous glucose monitoring (CGM) sensors,
able to monitor glucose concentration continuously (i.e. with a reading every 1 to 5 min)
over several days, entered clinical research. CGM sensors can be used both retrospectively,
e.g., to optimize the metabolic control, and in real-time applications, e.g., in the “smart”
CGM sensors, able to generate alerts when glucose concentrations are predicted to exceed
the normal range thresholds or in the so-called “artificial pancreas”. Most CGM sensors
exploit needles and are thus invasive, although minimally. In order to improve patients
comfort, Non-Invasive Continuous Glucose Monitoring (NI-CGM) technologies have been
widely investigated in the last years and their ability to monitor glucose changes in the
human body has been demonstrated under highly controlled (e.g. in-clinic) conditions.
As soon as these conditions become less favourable (e.g. in daily-life use) several problems
have been experienced that can be associated with physiological and environmental
perturbations. To tackle this issue, the multisensor concept received greater attention in
the last few years. A multisensor consists in the embedding of sensors of different nature
within the same device, allowing the measurement of endogenous (glucose, skin perfusion,
sweating, movement, etc.) as well as exogenous (temperature, humidity, etc.) factors.
The main glucose related signals and those measuring specific detrimental processes
have to be combined through a suitable mathematical model with the final goal of
estimating glucose non-invasively. White-box models, where differential equations are
used to describe the internal behavior of the system, can be rarely considered to combine
multisensor measurements because a physical/mechanistic model linking multisensor data
to glucose is not easily available. A more viable approach considers black-box models,
which do not describe the internal mechanisms of the system under study, but rather
depict how the inputs (channels from the non-invasive device) determine the output
(estimated glucose values) through a transfer function (which we restrict to the class
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of multivariate linear models). Unfortunately, numerical problems usually arise in the
identification of model parameters, since the multisensor channels are highly correlated
(especially for spectroscopy based devices) and for the potentially high dimension of the
measurement space.
The aim of the thesis is to investigate and evaluate different techniques usable for the
identification of the multivariate linear regression models parameters linking multisensor
data and glucose. In particular, the following methods are considered: Ordinary Least
Squares (OLS); Partial Least Squares (PLS); the Least Absolute Shrinkage and Selection
Operator (LASSO) based on `1 norm regularization; Ridge regression based on `2 norm
regularization; Elastic Net (EN), based on the combination of the two previous norms.
As a case study, we consider data from the Multisensor device mainly based on dielectric
and optical sensors developed by Solianis Monitoring AG (Zurich, Switzerland) which
partially sponsored the PhD scholarship. Solianis Monitoring AG IP portfolio is now
held by Biovotion AG (Zurich, Switzerland). Forty-five recording sessions provided by
Solianis Monitoring AG and collected in 6 diabetic human beings undertaken hypo and
hyperglycaemic protocols performed at the University Hospital Zurich are considered.
The models identified with the aforementioned techniques using a data subset are then
assessed against an independent test data subset. Results show that methods controlling
complexity outperform OLS during model test. In general, regularization techniques
outperform PLS, especially those embedding the `1 norm (LASSO end EN), because
they set many channel weights to zero thus resulting more robust to occasional spikes
occurring in the Multisensor channels. In particular, the EN model results the best one,
sharing both the properties of sparseness and the grouping effect induced by the `1 and
`2 norms respectively. In general, results indicate that, although the performance, in
terms of overall accuracy, is not yet comparable with that of SMBG enzyme-based needle
sensors, the Multisensor platform combined with the Elastic-Net (EN) models is a valid
tool for the real-time monitoring of glycaemic trends. An effective application concerns
the complement of sparse SMBG measures with glucose trend information within the
recently developed concept of dynamic risk for the correct judgment of dangerous events
such as hypoglycaemia.
The body of the thesis is organized into three main parts: Part I (including Chapters
1 to 4), first gives an introduction of the diabetes disease and of the current technologies
for NI-CGM (including the Multisensor device by Solianis) and then states the aims of
the thesis; Part II (which includes Chapters 5 to 9), first describes some of the issues to
be faced in high dimensional regression problems, and then presents OLS, PLS, LASSO,
Ridge and EN using a tutorial example to highlight their advantages and drawbacks;
vFinally, Part III (including Chapters 10-12), presents the case study with the data set and
results. Some concluding remarks and possible future developments end the thesis. In
particular, a Monte Carlo procedure to evaluate robustness of the calibration procedure
for the Solianis Multisensor device is proposed, together with a new cost function to be
used for identifying models.
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Sommario
Il diabete e` una malattia che compromette la normale regolazione dei livelli di
glucosio nel sangue. Nelle persone diabetiche, il corpo non secerne insulina (diabete di
tipo 1) o si verificano delle alterazioni sia nella secrezione che nell’azione dell’insulina
stessa (diabete di tipo 2). La terapia si basa principalmente su somministrazione di
insulina e farmaci, dieta ed esercizio fisico, modulati in base alla misurazione dei livelli di
glucosio nel sangue 3-4 volte al giorno attraverso metodo finger-prick. Nonostante cio`, la
concentrazione di glucosio nel sangue supera spesso le soglie di normalita` di 70-180 mg/dL.
Mentre l’iperglicemia implica complicanze a lungo termine (come ad esempio neuropatia,
retinopatia, malattie cardiovascolari e cardiache), l’ipoglicemia puo` essere molto pericolosa
nel breve termine e, nel peggiore dei casi, portare il paziente in coma ipoglicemico. Nuovi
scenari nella cura del diabete si sono affacciati negli ultimi 10 anni, quando sensori
per il monitoraggio continuo della glucemia sono entrati nella fase di sperimentazione
clinica. Questi sensori sono in grado di monitorare le concentrazioni di glucosio nel
sangue con una lettura ogni 1-5 minuti per diversi giorni, permettendo un analisi sia
retrospettiva, ad esempio per ottimizzare il controllo metabolico, che in tempo reale, per
generare avvisi quando viene predetta l’uscita dalla normale banda euglicemica, e nel
cosiddetto pancreas artificiale. La maggior parte di questi sensori per il monitoraggio
continuo della glicemia sono minimatmente invasivi perche` sfruttano un piccolo ago
inserito sottocute. Gli ultimi anni hanno visto un crescente interesse verso tecnologie
non invasive per il monitoraggio continuo della glicemia, con l’obiettivo di migliorare il
comfort del paziente. La loro capacita` di monitorare i cambiamenti di glucosio nel corpo
umano e` stata dimostrata in condizioni altamente controllate tipiche di un’infrastruttura
clinica. Non appena queste condizioni diventano meno favorevoli (ad esempio durante un
uso quotidiano di queste tecnologie), sorgono diversi problemi associati a perturbazioni
fisiologiche ed ambientali. Per affrontare questo problema, negli ultimi anni il concetto
di “multisensore” ha ottenuto un crescente interesse. Esso consiste nell’integrazione di
sensori di diversa natura all’interno dello stesso dispositivo, permettendo la misurazione
di fattori endogeni (glucosio, perfusione del sangue, sudorazione, movimento, ecc) ed
esogeni (temperatura, umidita`, ecc). I segnali maggiormente correlati con il glucosio e
quelli legati agli altri processi sono combinati con un opportuno modello matematico con
l’obiettivo finale di stimare la glicemia in modo non invasivo. Modelli di sistema (o a
“scatola bianca”), nei quali equazioni differenziali descrivono il comportamento interno del
sistema, possono essere considerati raramente. Infatti, un modello fisico/meccanicistico
legante i dati misurati dal multisensore con il glucosio non e` facilmente disponibile. Un
differente approccio vede l’impiego di modelli di dati (o a “scatola nera”) che descrivono
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il sistema in esame in termini di ingressi (canali misurati dal dispositivo non invasivo),
uscita (valori stimati di glucosio) e funzione di trasferimento (che in questa tesi si limita
alla classe dei modelli di regressione lineari multivariati). In fase di identificazione dei
parametri del modello potrebbero insorgere problemi numerici legati alla collinearita` tra
sottoinsiemi dei canali misurati dai multisensori (in particolare per i dispositivi basati su
spettroscopia) e per la dimensione potenzialmente elevata dello spazio delle misure.
L’obiettivo della tesi di dottorato e` di investigare e valutare diverse tecniche per
l’identificazione del modello di regressione lineare multivariata con lo scopo di stimare i
livelli di glicemia non invasivamente. In particolare, i seguenti metodi sono considerati:
Ordinary Least Squares (OLS), Partial Least Squares (PLS), the Least Absolute Shrinkage
and Selection Operator (LASSO) basato sulla regolarizzazione con norma `1; Ridge basato
sulla regolarizzazione con norma `2; Elastic-Net (EN) basato sulla combinazione delle
due norme precedenti. Come caso di studio per l’applicazione delle metodologie proposte,
consideriamo i dati misurati dal dispositivo multisensore, principalmente basato su sensori
dielettrici ed ottici, sviluppato dall’azienda Solianis Monitoring AG (Zurigo, Svizzera),
che ha parzialmente sostenuto gli oneri finanziari legati al progetto di dottorato durante
il quale questa tesi e` stata sviluppata. La tecnologia del multisensore e la proprieta`
intellettuale di Solianis sono ora detenute da Biovotion AG (Zurigo, Svizzera). Solianis
Monitoring AG ha fornito quarantacinque sessioni sperimentali collezionate da 6 pazienti
soggetti a protocolli ipo ed iperglicemici presso l’University Hospital Zurich. I modelli
identificati con le tecniche di cui sopra, sono testati con un insieme di dati diverso
da quello utilizzato per l’identificazione dei modelli stessi. I risultati dimostrano che
i metodi di controllo della complessita` hanno accuratezza maggiore rispetto ad OLS.
In generale, le tecniche basate su regolarizzazione sono migliori rispetto a PLS. In
particolare, quelle che sfruttano la norma `1 (LASSO ed EN), pongono molti coefficienti
del modello a zero rendendo i profili stimati di glucosio piu` robusti a rumore occasionale
che interessa alcuni canali del multi-sensore. In particolare, il modello EN risulta il
migliore, condividendo sia le proprieta` di sparsita` e l’effetto raggruppamento indotte
rispettivamente dalle norme `1 ed `2. In generale, i risultati indicano che, anche se le
prestazioni, in termini di accuratezza dei profili di glucosio stimati, non sono ancora
confrontabili con quelle dei sensori basati su aghi, la piattaforma multisensore combinata
con il modello EN e` un valido strumento per il monitoraggio in tempo reale dei trend
glicemici. Una possibile applicazione si basa sull’utilizzo del’informazione dei trend
glicemici per completare misure rade effettuate con metodi finger-prick. Sfruttando
il concetto di rischio dinamico recentemente sviluppato, e’ possibile dare una corretta
valutazione di eventi potenzialmente pericolosi come l’ipoglicemia.
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La tesi si articola in tre parti principali: Parte I (che comprende i Capitoli 1-4),
fornisce inizialmente un’introduzione sul diabete, una recensione delle attuali tecnologie
per il monitoraggio non-invasivo della glicemia (incluso il dispositivo multisensore di
Solianis) e gli obiettivi della tesi; Parte II (che comprende i Capitoli 5-9), presenta alcune
delle difficolta` affrontate quando si lavora con problemi di regressione su dati di grandi
dimensioni, per poi presentare OLS, PLS, LASSO, Ridge e EN sfruttando un esempio
tutorial per evidenziarne vantaggi e svantaggi. Infine, Parte III, (Capitoli 10-12) presenta
il set di dati del caso di studio ed i risultati. Alcune note conclusive e possibili sviluppi
futuri terminano la tesi. In particolare, vengono brevemente illustrate una metodologia
basata su simulazioni Monte Carlo per valutare la robustezza della calibrazione del
modello e l’utilizzo di un nuova nuova funzione obiettivo per l’identificazione dei modelli.
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Part I
Background and Aim of the
Thesis

1
Diabetes and Continuous Glucose Monitoring
According to the World Health Organization (WHO), diabetes is estimated to currently
affect 347 million of people in the world and this number is expected to increase by
two third in 2030 [1]. Diabetes and its complications are considered major causes of
early death in most countries, with over four million deaths per year [2]. From an
economic point of view, the cost of diabetes ranges from 6 to 15 % of the budget of
national health systems in the EU, explaining why it is considered one of the most
challenging socio-health emergencies of the 3rd millennium [3]. This chapter gives an
overview of the diabetes disease and of its therapy. In this context, the importance of
Continuous Glucose Monitoring (CGM) sensors is highlighted, together with a proposal
of classification according to their degree of invasiveness.
1.1 The Diabetes Disease
1.1.1 The Glucose-Insulin Regulatory System
The glucose substrate represents the main source of fuel for the human body. Thanks to
a complex regulatory mechanism, glucose concentration in blood of healthy subjects is
tightly kept in a limited rage, i.e. 70-180 mg/dL, although it is subject to fluctuations
due to utilization and production processes. Different hormones are involved in this
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regulation. The most important one is insulin, which is produced by the beta-cells of
the pancreas, and is responsible for lowering the glucose concentrations. Insulin is also
the principal control signal for conversion of glucose to glycogen for internal storage in
liver [4].
As depicted in Figure 1.1, glucose is used by many organs, tissues and cells. Some,
like brain or red blood cells, consume glucose continuously and independently of insulin
and the interruption of this supplying may cause severe damages. For muscles, fatty
tissue and liver the absorption of glucose is proportional to insulin concentration.
Glucose in blood derives both from intestinal absorption of carbohydrates and from
internal production. In particular, the latter consists in the conversion to glucose of
glycogen stored in the liver or in the so-called gluconeogenesis (the “re-construction” of
glucose using substrate derived from glucose degradation).
Figure 1.1: Scheme of the glucose-insulin regulatory system. Continuous arrows represent
fluxes. In particular, brown ones are referred to glucose, while black ones to insulin. Dashed
arrows represent the positive and negative control, indicated with “+” and “-” respectively.
The green dotted arrows highlight the self-control employed by a substance, while red dotted
arrows indicate the control of a substance over the other one. The blue dotted line represents
the measurement site.
An increase in blood glucose concentration causes an increase in insulin secretion.
Glucose and insulin concentration have the same effect on the glucose production and
utilization: an increase in insulin (or glucose) concentration causes a decrease of glucose
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production and an increase of glucose utilization by muscle, while there is no influence
on glucose utilization by brain.
1.1.2 Types of Diabetes
In people with diabetes, either the pancreas produces little or no insulin (type 1 diabetes),
or the cells do not respond appropriately to the insulin that is produced (type 2 diabetes).
In particular, “Type 1 diabetes”, or Insulin Dependent Diabetes Mellitus (IDDM) is
characterized by loss of the insulin-producing beta cells or the islets of Langherhans in the
pancreas leading to insulin deficiency. In most cases, type 1 diabetes has an autoimmune
origin and affects children or young adults, and in fact it is also called “juvenile diabetes”.
Instead, “Type 2 diabetes”, or Non-Insulin Dependent Diabetes Mellitus (NIDDM), is
characterized by insulin resistance which may be combined with relatively reduced insulin
secretion. Insulin resistance corresponds to a loss of efficacy of insulin action, causing
a reduced transport of glucose from the bloodstream into the cells. It is frequently
associated with obesity and a sedentary lifestyle. Type 2 is the most common diabetes
type (90% of cases) and mostly affects adult people.
1.1.3 Diabetes-Related Complications
A failure of glucose counter-regulatory system causes Blood Glucose Levels (BGL) to
exceed the euglycaemic range. Hypoglycaemia and hyperglycaemia might lead to short
and long term complications, respectively.
Hyperglycaemia has no immediate damaging consequence on organism, but, if this
state is frequent and persist for long time, can lead to several invalidating complications.
These long term complications include micro-vascular complications (involving small
blood vessels) and macro-vascular complications (involving large blood vessels) [5]. The
former, like neuropathy, nephropathy and retinopathy can lead to nerves damage, renal
failure and blindness respectively, the latter to coronary heart disease, strokes and
peripheral vascular disease. In order to prevent the onset of these complications, diabetes
therapies attempt to keep BGL within the euglycemic range. This can usually be done
with close dietary management, physical activity and use of appropriate medications, like
insulin injections before meals. The association of faulty glucose regulatory system and
neglectfully therapy could cause, principally during sleep hours and physical activity, an
even more dangerous unfavorable effect, i.e. hypoglycemia (i.e. too low blood glucose
level).
Hypoglycemia affects mostly the brain, given its continuous glucose demand. There-
fore, when glucose levels fall, brain functions diminish and people may lose cognitive
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abilities and in the worst case scenario go into the so-called hypoglycaemic coma. Hypo-
glycemia, at the opposite of hyperglycemia, has mainly short-term effects [6] and could
be classified according to the level of awareness:
• mild hypoglycemia (blood glucose levels between 55 and 70 mg/dL) is characterized
by palpitations, extreme hunger, trembling, cold or excessive sweating and visual
paleness, due to blood redirection to the vital organs and minimization of the
peripheral blood circulation. In this case a small amount of carbohydrates eaten or
drunk could restore normal levels;
• moderate hypoglycemia (between 55 and 40 mg/dL), whose symptoms include mood
changes, irritability, confusion, blurred vision, weakness and drowsiness since it
affects the central nervous system;
• severe hypoglycemia (less than 40 mg/dL) is characterized by convulsions, loss of
consciousness, coma, and hypothermia. If this condition is prolonged in time could
cause irreversible brain damages and heart problems, or even death. In this case,
intravenous dextrose or an injection of glucagon is required.
1.1.4 Diabetes Therapies and Glucose Monitoring
In the near future, new technologies will play a crucial role in diabetes management to
contrast human and socio-economical costs of this disease [7].
For type 1 diabetes, conventional therapies consist in insulin injections for compen-
sating the lack of insulin secretion and have the goal to restore euglycaemic levels. A
suitable dosage is determined using information on food intakes and current BGL. In the
early stage of type 2 diabetes, a diet modification and physical exercise, associated with
medications improving insulin sensitivity, may be sufficient to control glycaemic levels. If
diabetes proceeds, exogenous insulin injections may be needed. In both cases, monitoring
BGL is important. Indeed, several clinical studies demonstrated that long and short term
complications can be reduced through a therapy based on diet, physical exercise, and
drug delivery (including subcutaneous injections of exogenous insulin), tuned according
to the monitoring of individual parameters [2]. The most used approach is based on
the measure of glycaemia 3-4 times per day. This is referred as Self-Monitoring Blood
Glucose (SMBG), i.e. the patients have to take a finger-prick blood sample on specific
strips and measure BGL with a dedicated device [8]. SMBG measures are collected by
the patient and then analyzed and interpreted retrospectively by the physician during
periodic visits where the current therapy is revised accordingly. SMBG traces can also
be analyzed retrospectively for assessing glucose variability [9]. However, a suitable time
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window of several months must be considered for having a reasonable number of data
points.
A SMBG measure can also be used in real-time by the patient to assess the current
glycaemic state. However, the sparseness of these measures does not give a complete
information about the glycaemic range excursion and dynamics, leading to potentially
dangerous hypo/hyper glycaemic events without any patient’s awareness [10].
Self Monitoring Blood Glucose
The most common test for measuring BGL involves pricking a finger with a lancet
device to obtain a small blood sample, applying a drop of blood onto a reagent test-strip,
and determining the glucose concentration by inserting the strip into a measurement
device. Different manufacturers use different technologies, but most systems measure an
electrical characteristic proportional to the amount of glucose in the blood sample [8].
Intermittent glucose sampling can be achieved also through other physiological fluids,
such as saliva, urine, sweat or tears [11]. However, in these cases, delay in the appearance
of glucose in these fluids must be taken into account.
SMBG systems make a direct measure, i.e. they measure a specific property of glucose.
This means that if the same property is investigated for another kind of substance, a
significantly different output is produced than the one obtained from glucose. Spectral,
chemical and competitive binding properties of glucose are considered to infer on blood
glucose concentrations.
Direct measurements tend to be more stable than indirect ones because the signal
being measured is usually unique and interferences more predictable. In fact, indirect
measurements are affected by the presence of other chemicals and substances within
the body that may produce the same signal, since they measure glucose effect on some
secondary process [12].
Continuous Glucose Monitoring
The main drawback of SMBG is the lack of glucose measures during sleeping or
daily-life activities, leading to time intervals with no informations on the glucose levels.
During these intervals, dangerous hypo-/hyper-glycaemic excursions may happen without
awareness for the patient. With the aim of preventing these episodes, in the last decade
many devices for CGM have been developed allowing to monitor glucose fluctuations
continuously with a minimum level of invasiveness.
The main advantage of CGM is the possibility to monitor BGL in a nearly continuous
way, i.e. every 1 to 5 minutes, for a long period of time, i.e. 7 consecutive days. CGM
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time-series have been studied retrospectively for analyzing glucose variability [13, 14].
Moreover, the clinical benefit of wearing CGM devices has been demonstrated in [15, 16],
showing an improvement of the glycaemic control with a decreasing of the glycated
hemoglobin HbA1c (a marker of the glycamic control predictive of diabetes related
complications).
More appealing are on-line applications of such technologies. In the last years, several
algorithms and signal processing techniques have been developed or adapted from other
fields to improve accuracy and reliability of CGM data, see [17, 18, 19]. An example
is the so-called “smart” CGM architecture [20]. It consists in a cascade of independent
software modules down line of the commercial CGM sensor which allow to de-noise,
enhance and predict glucose levels, see e.g. [21, 22, 23, 24, 25, 26, 27, 28, 29] for examples
of on-line algorithms developed for CGM. CGM are fundamental in the development of
artificial pancreas, which implements a closed-loop control that has the aim to infuse
the correct amount of insulin subcutaneously using a micro-infusor driven by a control
algorithm, which, in turn, exploits the measurements provided by a CGM sensor as its
input [30, 31, 32].
CGM are appealing for several reasons related to their degree of invasiveness and the
quasi continuous information they provide. However, given their current performance
they are still considered a complement and not a replacement of SMBG devices [33].
1.2 A Classification of Sensors for Continuous Glucose
Monitoring (CGM)
CGM sensors can be classified according to: a) the kind of measure (direct or indirect);
b) to the level of invasiveness; c) to the physical principle the sensor is based on. In
Figure 1.2 we propose a classification scheme of existing CGM sensors according to their
level of invasiveness, highlighting the physical principle or technology each sensor is based
on. The following review is far from being exhaustive and a complete descriptions and
reviews on the working principle, pros and cons, and future perspectives on CGM sensors
can be found in [34, 35, 36, 37, 38].
1.2.1 Invasive CGM Sensors
As shown in Figure 1.2, a direct measurement of BGL could be obtained invasively
by using sensors implanted into the body [39]. These sensors are extremely accurate,
but given their level of invasiveness they are particularly suited for Operating Rooms
and Intensive Care Units [40]. There are different technologies allowing to transduce
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Figure 1.2: A Proposed CGM sensors classification.
glucose concentration into an electrical signal, most of them are based on glucose-oxidase
principle. Other sensors are based on competitive binding of glucose with other molecules
or glucose spectral properties [12].
Intravenous Implantable
Glucose oxidase-based sensors technology depends on the reaction of glucose with
oxygen in presence of glucose oxidase to create gluconic acid. The limitation of using
this method is that the reaction requires one oxygen molecule for each glucose molecule.
Since glucose is more present in the body than oxygen, the limiting reagent results to be
the oxygen. For this reason, the sensor would measure oxygen levels instead of glucose
levels. To avoid this problem, sensors must give oxygen an advantage over glucose, using
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alternative electron donors, called mediators.
The competitive binding-based sensor measures fluorescence of a binding molecule:
the more glucose is bound to this molecule, the less intense is the fluorescent signal so
that if glucose levels increase the measure decreases. This technique has still problems
related to biocompatibility and to the risk inherent to surgical placement of these devices
in blood vessels, hence it is not widely applied [41]. An additional fluorescence-based
intravenous glucose sensor is presented in [42].
A new intravascular continuous glucose monitoring system is under development,
using a glucose-sensitive hydrogel. When this hydrogel is bound with glucose, it changes
in volume. The result is a measurable change in the hydrogel impedance that is correlated
to glucose concentration. Preliminary studies have been made on a prototype of the
sensor, integrated with stents as antennas for wireless data transfer from within the
body [43].
1.2.2 Minimally-Invasive CGM Sensors (with needle)
There is no unanimous agreement in the literature about which kind of CGM sensors
should be considered as minimally-invasive. According to the proposed sensor classification
scheme, we will refer to minimally-invasive sensors (with needle), those requiring a needle
inserted in the subcutis, such as subcutaneous and microdialysis (see Section 1.2.2). On
the other side, minimally-invasive sensors (without needle) will be those requiring the
creation of microscopic holes in the skin to perform the measurement without the need
to insert needles under the skin (see Section 1.2.3).
A common limitation of all these sensors is the delay between plasma and interstitial
glucose concentration. This phenomenon is due to the glucose transport from plasma
to interstitium that act as a low pass filter, see [44] for details of plasma-to-interstitium
glucose kinetics.
1.2.2.1 Subcutaneous Sensors
Instead of implanting the sensor into the body, a subcutaneous needle may be used to sense
glucose. Usually these systems are based on enzyme electrodes, most of time exploiting a
glucose-oxidase principle. Subcutaneous needles provide much more information about
dynamics and glucose excursions if they are compared to a finger-prick system, providing
readings every 1-5 minutes for up to 7 days. These sensors require frequent calibration
to compensate drifts due to protein and cell coating of the sensor, variable tissue oxygen
tension and wound response to the sensor, which alters local blood flow. From a signal
processing point of view, several algorithms have been developed to deal with these
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calibration issues, see [18, 19] for a review. To perform periodic calibrations of the sensor,
a measurement using traditional SMBG systems is usually required.
Examples of commercially available subcutaneous sensors include the FreeStyle
Navigator TM(Abbott Laboratories, Alameda, CA, USA), the MiniMed Guardian Real-
Time (Medtronic MiniMed, Northridge, CA, USA) and the the Dexcom R© Seven R© and
SevenPlus R© (DexCom Inc., San Diego, CA, USA) R©, to mention but a few.
Figure 1.3: FreeStyle Navigator CGM System[45]. Miniature electrochemical sensor placed
in the subcutaneous adipose tissue (bottom left), a disposable sensor delivery unit (top right),
a radiofrequency transmitter connected to the sensor (bottom right), and a hand-held receiver
to display continuous glucose values.
The FreeStyle Navigator TMCGM System consists of four components (see Figure
1.3): a miniature electrochemical sensor placed in the subcutaneous adipose tissue, a
disposable sensor delivery unit, a radiofrequency transmitter connected to the sensor, and
a hand-held receiver to display continuous glucose values [46]. The sensor can be used for
5 days, the glucose data on the receiver are updated once a minute and include a trend
arrow to indicate the direction and rate of change averaged over the preceding 15 min.
The user interface of the receiver allows the threshold alarms to be set at different glucose
levels. The receiver contains a built-in Free-Style blood glucose meter for calibration of
the sensor as well as for confirmatory blood glucose measurements. The sensor requires
four calibrations over the 5-day wearing period at 10, 12, 24, and 72 h after sensor
insertion. It was approved by FDA in 2008 [47].
The DexCom R© SevenPlus R© sensor consists of three parts (see Figure 1.4): a small
sensor placed in the subcutaneous adipose tissue, a wireless transmitter and a receiver [48].
It performs a new measure every 5 minutes for 7 days. The receiver displays the sensor
glucose value along with a graph showing glucose trend of the last 1, 3 or 9 hours.
The receiver contains memory up to 30 days of continuous glucose information and
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Figure 1.4: DexCom R© SevenPlusR© sensor. The receiver(left) and the and transmitter
(right). The subcutaneous sensor is not shown [48].
has programmable high and low glucose alerts and a non-changeable low glucose alarm
set at 55 mg/dL. It must be calibrated every 12 hours. It was approved by FDA in
2009 [49]. The same company recently produced the DexCom R© G4 PLATINUM, a
CGM sensor with improved performance with respect to the SevenPlus R©, according to
their website [48].
Figure 1.5: The Guardian REAL-Time [50]. REAL-Time CGM System monitor (left), the
MiniLink REAL-Time Transmitter together with the glucose sensor inserted in the subcutis
(right).
The Guardian Real-Time device consists of the Guardian R© REAL-Time CGM System
monitor (Figure 1.5, left), the MiniLink REAL-Time Transmitter (Figure 1.5, right) and
of the glucose sensor inserted in the subcutis. This sensor performs a new measure every
5 minutes for 3 days [50]. The receiver contains memory up to 21 days of continuous
glucose information and has alerts if a glucose level falls below or rises above preset values.
It must be calibrated every 12 hours either manually or automatically via telemetry.
It was approved by FDA in 2005. This sensor, integrated with an insulin delivery
device composes the MiniMed Paradigm REAL-Time system, that was launched in 2006.
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Recently, the CGM has been complemented with an insulin pump to provide the MiniMed
Paradigm Real-Time Insulin Pump and Glucose Monitoring System [51].
1.2.2.2 Microdialysis
Another type of minimally invasive subcutaneous CGM sensor exploiting a needle is
based on a microdialysis system, which uses a fine, hollow microdialysis fibre placed
subcutaneously. This probe is perfused with isotonic fluid from an external pool, while
glucose, present in the interstitial fluid, freely diffuses into the fibre, where it is pumped
out of body to a glucose-oxidase based sensor [52]. The main problem related to this kind
of sensor consists in modifications of chemical and physical properties of the membrane,
caused by modifications in tissues characteristics such as pressure, volume, temperature
and hydration. These modifications affect flow rate and composition of perfusate, which
may influence glucose concentration.
The GlucoDay R© by Menarini Diagnostics (Florence, Italy) is a microdialysis-based
glucose monitoring system [53]. It is based on enzymatic-amperometric measurement
analyzing the fluid coming from the subcutis of the abdominal region. The system
comprises a walkman-size apparatus, and a sensor fibre as well as two plastic bags (one
for the buffer solution, one for the waste products) as disposables. The apparatus contains
also a measurement cell and a peristaltic pump. The buffer solution is pumped from a
bag into the subcutaneous tissue through the microfibre and rinses the interstitial fluid,
from which the measurements are obtained every 3 min and stored in memory. Data are
downloaded after monitoring (maximum monitoring time, 48 h) via a serial or infrared
connection to a standard PC for further analysis. It incorporates safety alarms for hypo
or hyperglycaemia events and requires one daily calibration. Recently, the same company
launched the GlucoMen R©Day (currently waiting the CE mark), which overcomes various
shortcomings of its predecessor [54]. It is smaller and more compact, and has a longer
lifetime (100 hours), is more stable and embeds different algorithms for signal processing
and data management [55, 56].
The SCGM 1 sensor (Roche Diagnostics, Mannheim, Germany) is also based on a
microdialysis principle [57].
1.2.3 Minimally-Invasive CGM Sensors (without needle)
This section presents minimally-invasive sensors not presenting needles, but exploiting
technologies for creating microscopic holes allowing glucose molecules to pass through.
For this reason, this class of sensors is not regarded as fully non-invasive.
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1.2.3.1 Micropores and Microneedle
Micropores techniques perforate the stratum corneum without penetrating the full
thickness of the skin. A pulsed laser or the local application of heat are considered to
form micropores allowing the collection of interstitial fluid applying vacuum. A measure
of glucose concentration is then derived from this sample.
SpectRx is made mainly of two units. The first unit is a handheld laser, which creates
micropores (size of a hair) in the stratum corneum of the skin. The interstitial fluid,
containing glucose, flows through the micropores and is collected by a patch. Then, it
reaches a traditional glucose sensor, which is the second unit. The meter also includes
a transmitter that sends wirelessly the glucose measurements to a handheld display
device [37].
Similarly capillary blood could be sampled using a hollow microneedle, which is
almost sensation-less and analyses blood using an enzyme-based system.
1.2.3.2 Iontophoresis and Sonophoresis
Among minimally invasive sensors, we also include transdermal methods, which stimulate
the skin exploiting different interaction fenomena in order to extract glucose from the
skin micropores for its direct measures. This group comprises different techniques like
reverse iontophoresis and sonophoresis [37].
Iontophoresis Principle
The first method is based on the flow of a low electrical current applied across the
skin between an anode and a cathode positioned on the skin surface [38]. The application
of an electrical potential causes the migration of sodium and chloride ions from beneath
the skin towards the cathode and anode respectively, at rates significantly grater than
passive permeability. The convective flow induced by this technique carries out neutral
molecules, including glucose, along with sodium. Thus, interstitial glucose is transported
across the skin towards the cathode, where it is collected and measured by a glucose
oxidase-based electrode. The concentration of glucose is low so oxygen is not a limiting
factor to glucose oxidase. This technique tends to generate skin irritation and cannot
be used if the subject is sweating significantly; in addition it needs a long warm-up and
calibration. Skin irritation may be limited by shortening the time interval of the electrical
potential application. However, a minimum duration is required to get sufficient amount
of glucose for measurement.
Iontophoresis-Based Sensors
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The GlucoWatch R© by Cygnus Inc. (approved by FDA in 2002, but withdrawn from
the market in 2007) device is based on reverse iontophoresis technology [58]. It has a
wrist-watch format and measures glucose through the skin using a disposable pad, which
clips into the back of the meter. The pad uses an adhesive to stick to the skin allowing it
to come in contact with a small electrical current, which causes the reverse iontophoresis,
and then the glucose levels in the interstitial fluid can be estimated. Compared with
finger-stick readings, the meter measurements have a 15-min lag time. The meter is
intended for use to supplement, but not to replace, information obtained from a standard
blood glucose meter. The meter has 2-3 h warm-up period, to remove the glucose on the
superficial epidermis and to onset a continuous convective flow. A single-point calibration,
performed using a fingerstick blood glucose measurement, accounts for variability in both
biosensor sensitivity and skin permeability and is used to convert subsequent biosensor
measurements into glucose readings. Afterwards, the meter provides readings every
10 min: 3 min of electrical stimulation (glucose extraction), then 7 min of glucose
measurement. The meter has a memory that can store up to 8500 records and the
data can be download to a PC for a subsequent analysis. An alarm also occurs in the
case of a rapid change is seen in the blood sugar, in the case of sweating, and for any
measurements above or below the patient’s target levels. A trend indicator appears to
show the direction of the blood sugar when the current measurement is more than 18
mg/dl higher or lower than the previous measurements. Event markers can be recorded
for activities like meals, insulin intake and exercise. However, the meter had several
limitations. In fact, the measurements could fail or be inaccurate, if the patient was
sweating, or in cases of rapid temperature changes, excessive movement of the meter, or
strenuous exercise. Most users reported that the electrical discharge is quite noticeable
during the first use of the meter, although it becomes less noticeable on subsequent use.
Moreover the disposable pad must be replaced every 12-13 h of monitoring time to ensure
continued accuracy; the meter must then go through the warm-up period and calibration
again. In addition, it may take more than one try to calibrate the meter, thus requiring
additional finger-stick tests. Finally, the meter causes skin irritation to some extent,
which limits reuse of the same site to a week or two[59, 60].
A new Reverse Iontophoresis based Glucose Monitoring Device (RIGMD) has been
developed in Korea [61]. It measures a weak electric current that is dependent on glucose
concentration in the interstitial fluid, by using an electrochemical enzymatic sensor
located on the forearm skin. The sensor is made up of electrodes and a gelatinous
material which contains glucose oxidase. A current is produced between the electrodes
causing reverse iontophoresis [60].
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In [62], it is described the results of preliminary experiments for the development
of a mediated glucose biosensor incorporated with reverse iontophoresis function for
noninvasive glucose monitoring, using an optimum combination of glucose oxidase and
ferrocene.
Sonophoresis Principle
The sonophoresis based technologies use low-frequency ultrasounds to create an
array of microscopic holes on human skin which increase its permeability and allow the
migration of glucose contained in interstitial fluid through the skin to a glucose sensor
placed in contact with the skin. Thus a direct measure is feasible [38].
Sonophoresis-Based Sensors
Echo Therapeutics produces a device based on sonophoresis technique [63]. The
meter is made essentially of two units: an ultrasonic device (SonoPrep), coupled with
the skin through an aqueous medium, which increases skin permeation, and a glucose
sensor (Symphony), which measure glucose in the interstitial fluid reaching the sensor
through the micropathways generated on the skin.
SonoPrep is an ultrasonic skin preparation generator, controlled by a microprocessor.
This device delivers low-frequency ultrasound (53-56 kHz), which creates a cavitating
force at the point of contact with the skin surface. This force reduces transiently the
normally robust lipid barrier of normal intact skin, causing the outermost layer of
skin to become increasingly conductive and permeable. Since the relationship between
skin conductance and skin permeability, the active ultrasound is terminated when the
skin reaches the predetermined level of permeability by continuously measuring skin
conductance. This ensures that the site is properly prepared without pain, trauma (such
as burn), or irritation. It is claimed that the application of the ultrasonic device for 15 s
is enough to make the skin permeable for several hours (between 12 and 24 hours) [64].
Prelude SkinPrep System is a new skin preparation device under development (see
Figure 1.6, right), that can be used in alternative to SonoPrep. The system consists
of a disposable abrasive end driven by an electrical motor in a standalone hand piece.
Instead of ultrasounds,Prelude utilizes a mechanical mean to remove stratum corneum,
with the process controlled by the same conductance-based feedback mechanism used in
SonoPrep [65]. The Symphony is a fully functional prototype sensor instrument designed
to measure glucose through permeated skin (see Figure 1.6, left). The sensor is able
to maintain reliable fluid contact with the skin through a proprietary biocompatible
hydrogel, which utilizes glucose oxidase to measure glucose concentration. The sensor is
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Figure 1.6: Right:Prelude SkinPrep System. Left: Symphony [63].
housed in a wireless transmitter, which acquires, stores, and transmits coded data to the
receiver/monitor to display a reading every minute in addition to trends and alarms for
excessively high and low BGL [65].
1.2.4 Non-Invasive Continuous Glucose Monitoring NI-CGM Sensors
Non-invasive Continuous Glucose Monitoring NI-CGM sensors measure glucose concen-
tration through the skin without extracting blood or interstitial fluid or without a needle
penetrating the skin for reaching these fluids. Hence, these sensors are more comfortable
for the patient than the previously described sensors and do not cause displeasing phys-
iological reactions. However, the measure is affected by different confounding factors,
making more difficult to perform an accurate measurement.
NI-CGM sensors measure different physical properties of the skin and underlying
tissues (optical, thermal, acoustic and electrical) which are modulated by glucose concen-
tration changes. Given the special importance of these sensors in the present thesis, the
physical principles of these sensors will be described in detail in the next chapter. For
each technology, an example of its application for CGM will be presented. Particular
attention will be paid to the multisensor system proposed by Solianis Monitoring AG
(Zurich, Switzerland).
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2
Non-Invasive Continuous Glucose Monitoring
(NI-CGM) Sensors
Non Invasive Continuous Glucose Monitoring (NI-CGM) devices are appealing for obvious
reasons related to patient’s comfort. Even if they do not present accuracy comparable
with that of subcutaneous or microdialisys-based devices yet, in the last years there
has been an increasing attention concerning these non invasive technologies and several
new prototypes have been designed and developed [37, 60, 66, 38]. For each of these
technologies, physical principles and examples of application will be described in the
following.
2.1 Physical Principles beyond NI-CGM and Prototypes
NI-CGM sensors measure glucose concentration without extracting blood or interstitial
fluid or without a needle penetrating the skin for reaching these fluids. Thus, the
measure is performed through the skin that is a particular multi-layer biological tissue.
Consequently, to understand the characteristics of these sensors, it is convenient to have
a clue of skin morphology and the non-uniform blood distribution within the layers.
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2.1.1 Skin Properties
The skin is composed by several distinctive layers as illustrated in Figure 2.1. The
uppermost skin layer is the stratum corneum of epidermis, composed of dead keratinized
cells, followed by the living epidermis and the connective tissue of the dermis. The
subcutaneous tissue is composed by an underlying fat layer and muscle. The dermis can
be subdivided into three different layers: the upper vascular plexus, the reticular dermis
and the deep vascular plexus. The epidermis does not have its own vasculature. The
volume fraction occupied by blood vessels in the dermis is in the range of 1-20% and
is concentrated in the upper and deep vascular plexus. Most of NI-CGM sensors, e.g.
Figure 2.1: Representation of the skin layered structure highlighting the distribution of
blood vasculature (left) and description of the most representative skin layers (right) [67].
Diasensor [60], TANGTEST [68], OrSense [69], Sentris-100 [70] and other prototypes in
development, are optical transducers that use light in variable frequencies to track glucose.
They exploit different properties of light to interact with glucose molecules, returning a
measure of some optical property proportional to glucose concentration. These optical
sensors monitor glucose variations in the dermal blood; hence, the radiation needs to
penetrate at least through the epidermis to reach the vascularised compartments of the
dermis. Along with these optical sensors, other non-invasive approaches exploit thermal,
acoustic and electrical properties. This classification follows the scheme previously
proposed in Figure 1.2.
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2.1.2 Optical Techniques for NI-CGM
A beam of light interacts in different ways when it passes through a multilayer tissue
like skin. A portion of the beam is reflected by the stratum corneum, another part is
absorbed from the tissue and the remaining part is scattered (i.e. it is deviated from the
straight trajectory) and diffused into a number of different directions. Figure 2.2 shows a
general scheme that summarizes the different kinds of interaction of light with skin.
Light
source
Reflection
Scattering
Stratum
corneum
Absorption
Figure 2.2: Optical properties of light utilized in glucose detection [71]. The light source
(left) emits a beam of light which is partially reflected, scattered and absorbed.
Spectroscopy analyses the optical properties of light in relation to the wavelength
of the radiation. Spectroscopy also provides a precise analytical method for finding the
constituents (and their concentration) in materials having unknown chemical composition,
since each substance exhibits characteristic spectra, which may be interpreted as the
“fingerprint” of that substance. The different types of spectroscopy may be classified
according to which optical properties of the light is employed.
2.1.2.1 MIR/NIR Spectroscopy
Infrared absorption spectroscopy is based on absorption phenomena: changes in glucose
concentration can influence the absorption coefficient of tissues and thus the absorption
bands [37].
MIR/NIR Spectroscopy Principle
In particular, the so-called Near InfraRed (NIR) spectroscopy uses light in the near
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infrared range (750-2000 nm). Specific spectra are chosen in order to minimize background
absorption, in particular by water. The light in these wavelengths passes through the
stratum corneum and epidermis into the subcutaneous space, allowing to measure in the
deep tissues (in the range of 1 to 100 mm of depth). Perturbing factors that may interfere
with glucose measurement include all the variables that influence absorption coefficient,
like blood pressure, body temperature and skin hydration. Errors can also occur due to
environmental variations such as changes in temperature, humidity, carbon dioxide, and
atmospheric pressure. The absorption coefficient of glucose in the NIR band is low and is
much smaller than that of water given the large disparity in their respective concentrations.
Thus, in NIR measurements, the weak glucose spectral bands not only overlap with the
stronger bands of water, but also with those of molecules such as hemoglobin, proteins,
and fats [72]. Changes in glucose may affect the measurement process also in other
indirect ways: for example, hyperglycaemia causes increased perfusion, which influences
the spectrum and can be considered as a confounding factor. Furthermore, diabetic
subjects can exhibit “thick skin” and “yellow skin” [73]. Thus, light reflected from skin
of a diabetic patient may differ from that of a healthy subject at equal level of glycaemia.
In contrast to NIR, Mid InfraRed (MIR) spectroscopy utilizes light at a wavelength
between 2500-10000 nm. With respect to NIR, MIR exhibits less scattering phenomena
and greater absorption. Hence the tissue penetration of light in MIR can reach only the
stratum corneum, but the glucose spectra is less perturbed from interferences from other
molecules.
MIR/NIR Spectroscopy-Based Sensors
The TANGTEST Blood Glucose Meter seems to be based on NIR technology. This
prototype measures glycemia by analyzing intensity variations in the spectrum of a weak
light (about 0.1 W) transmitted through the tested hand finger (middle or index finger).
In [68], the developers of the device claim that the signal noise due to other tissues is
avoided by using the optical signal of pulsatile microcirculation: the signal obtained
by the meter is in fact divided into a pulsatile and a direct component. The pulsatile
component, which is synchronized with heart rate, is used to monitor blood glucose [74].
The Diasensor device is based on operates by placing the patient’s forearm on the
arm tray of the meter. The dimensions of the meter are relevant compared with other
meters, but it is still sufficiently compact to be used in a domiciliary environment for
intermittent glucose monitoring. The blood glucose test is obtained in less than 2 minutes.
However, it is not intended as a replacement for the traditional invasive blood glucose
meter. It seems that the distributor was EuroSurgical Ltd., UK. However, the web site
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of the company does not currently mention Diasensor, and hence it can be speculated
that it is not on sale anymore [60].
InLight Solutions is developing a device based on NIR spectroscopy and multi-variate
analysis to make quantitative and qualitative measurements. Appropriate optic and
software have been develop to clearly distinguish glucose molecules from water molecules.
The devices are made up of three components: a light source, an optical detector, and a
spectrometer. The measures are performed using the differences between the light that
was sent into the skin and the light that the detector collects [75].
Other companies developing NI-CGM devices are Pignolo Spa developing a NIR
based device, the Glycolaser R© [76] and MedOptixTM [77] developing a sensor based on
proprietary technology at the edge between NIR and MIR spectroscopy.
2.1.2.2 Raman Spectroscopy
Raman Spectroscopy Principle
Raman spectroscopy measures the small fraction of scattered light that shows wave-
lengths different from the one of the exciting beam. This fraction is dependent on
rotational or vibrational energy states within a molecule. Raman spectroscopy shows
highly specific absorption bands and, compared with MIR and NIR spectroscopy, it has
the benefit of suffering of lower interference from water. However, the Raman signal is
weaker than its counterpart in other technologies due to the fact that measured pho-
tons normally have lower intensity than the original light and thus requires powerful
detectors [66].
Recently, an improvement in traditional Raman spectroscopy has been proposed
(surface-enhanced Raman spectroscopy), which may increase the sensitivity of the acqui-
sition. However, it has only been tested in rats [78].
Raman Spectroscopy-Based Sensors
A prototype of sensor based on Raman spectroscopy has been described and tested
by Enejder and coworkers [79]. Raman spectra were collected by means of a specially
designed instrument, optimized to collect Raman light emitted from a scattering medium
(tissue) with high efficiency and a diode laser as the Raman excitation source.
C8 Medisensor has recently developed a device based on Raman spectroscopy and
is currently waiting for CE mark approval [80]. It implements three optical sources,
accessed through an optical switch, for obtaining information about glucose as well as
water and white light for normalization purposes.
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2.1.2.3 Occlusion Spectroscopy
Occlusion Spectroscopy Principle
Another technique that measures scattered light is occlusion spectroscopy [71], which
is based on the property of glucose to decrease the diffusion coefficient and on the
enhanced transmission of light due to erythrocyte aggregation that can be reproduced in
vivo by applying a pressure to the fingertip for 2-3 seconds, greater than the systolic one.
One signal is collected when no pressure is applied and it is combined with the occlusion
signal in order to calculate glucose concentration thanks to a specific algorithm. The
advantage of this method is that it measures arterial glucose level. However, intrinsic
erythrocyte aggregation and free fatty acid concentration may interfere with the measure.
Calibration is needed for glucose predicting parameters using four blood glucose reference
points in the first three hours, and an additional reading after 8 hours.
Occlusion Spectroscopy-Based Sensors
A Device based on this technology is the OrSense NBM-200G [81], which obtained
the European CE mark in 2007.
Figure 2.3: OrSense NBM-200G [82]. On the right are visible the annular probe linked to
the computation unit.
The measurement is performed using an annular probe, which is positioned on
the finger’s root and contains light sources, detectors and pneumatic cuffs producing
oversystolic pressure to occlude blood flow. The optimization of sensitivity and specificity
is achieved by the following:
• Transmission mode. In the transmission mode the light traverses the whole organ
(finger), and the photons typically encounter many more glucose molecules along
their paths than in the reflection mode. This strategy enhances the sensitivity
to glucose and reduces the influence of local factors such as skin morphology and
pigmentation.
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• Dynamic signal. Occlusion spectroscopy is based on the generation of an optical
signal that changes with time. The signal is induced by oversystolic occlusion at
the finger’s root, which causes cessation of blood flow throughout the finger. This
strategy allows us to collect not only one data point per wavelength, but rather a
whole function. It results in a better signal-to-noise ratio.
• Multispectral data. Multiple wavelengths of light sources are used. This is beneficial
for specificity/selectivity, as the different behaviour of the optical signal among
wavelengths allows cleaning the influence of unwanted interferences, such as the
absorption of hemoglobin and changes of oxygen saturation.
• Sophisticated algorithms. The data are processed with sophisticated algorithms,
which use only a small number of parameters, hence avoiding overfitting and false
correlations [69].
2.1.2.4 Optical Coherence Tomography
Other types of NI-CGM sensors are based on Optical Coherence Tomography (OCT)
that was originally developed to perform the tomographic imaging of the eye.
Optical Coherence Tomography Principle
An OCT system uses a low-power laser source, an interferometer with two arms
(reference and sample) and a photodetector to measure the interferometric signal [71, 83].
The skin is irradiated with a low coherence light (light in which the emitted photons
are synchronized in time and space). Backscattered radiations from tissues are combined
with light returned from reference arm and the resulting interferometric signal is detected
by the photodetector. Basically, it measures the delay correlation between the two original
signals. Using this technique, glucose concentration in the dermis can be determined,
since an increase of glucose concentration in the interstitial fluid causes an increase in
the refractive index, thus determining a decrease in the refractive index mismatch.
This technique is affected by motion artifacts. In addition, while small changes in
skin temperature have negligible effects, changes of several degrees have a significant
influence on the signal.
Optical Coherence Tomography-Based Sensors
The Sentris-100 device is based on optical coherence tomography technology , ex-
ploiting infrared light to scan a cylindrical volume of skin in several steps from the skin
surface down to the subcutaneous tissue. Acute changes in protein (collagen and myosin)
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conformation occur in response to glucose concentration changes and creates a high
sensitivity in the optical coherence tomography signal; localization of signal detection to
blood vessel walls minimizes any observed signal lag [60, 70].
Figure 2.4: The Sentris-100.
2.1.2.5 Fluorescence
Fluorescence technology has also been proposed for glucose monitoring and is based
on the generation of fluorescence by human tissue when excited by lights at specific
frequencies.
Fluorescence Principle
These sensors are able to measure glucose levels exploiting the dependence between
fluorescence intensity and glucose concentration in the solution. Other fluorescence-
based glucose sensors are based upon the affinity sensor principle, where glucose and a
fluorescein-labelled analogue bind competitively with a receptor site specific for both
ligands. Thus, an increase in glucose concentration causes a decrease in the binding of
receptor with fluorescein-labelled analogue resulting in a decreased light emission [71].
Fluorescence-Based Sensors
A glucose-sensing contact lens has been developed using boronic acid to measure
lachrymal glucose concentration [84]. The main drawback of this system is that it requires
a hand-held external light source/detector. Thus, even if theoretically the lens is able to
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monitor continuously the glucose concentration, the information is carried out only with
the detector usage.
Recently an injectable hydrogel microbeads has been developed for fluorescence-based
in vivo continuous glucose monitoring. A fluorescent monomer based on diboronic acid
has been developed. It enables reversible responsiveness to glucose without any reagents
and enzymes. The fluorescent monomer has long, hydrophilic spacers and polymerization
sites to bind flexible supports. The fluorescent monomer has sufficient intensity for in
vivo transdermal monitoring; even when it is immobilized in a solid support (microbeads).
Due to the virtue of their small size, the fluorescent microbeads are injectable, minimally
invasive, and rapidly respond to glucose change. The microbeads have been tested with
success in rats [85].
Another application of this technology is for sensing glucose from skin measurements,
presenting several limitations due to epidermal tickness, skin pigmentation and other
parameters [86, 87].
2.1.2.6 Polarimetry
Polarimetry is based on the optical properties of glucose, due to its chemical structure
that makes glucose a chiral molecule.
Polarimetry Principle
When polarized light (light with all waves oscillating in the same plane) passes through
a solution containing optically active solutes, such as chiral molecules, its polarization
plane is rotated by a certain angle, which depends on solutes concentration. Measuring
the rotation angle with a polarimeter allows calculating glucose concentration. This
technique is sensitive to scattering properties of tissues that depolarizes light. However,
skin cannot be investigated by polarimetry since it shows high scattering due in particular
to the stratum corneum. For this reason the preferred measurement site is the eye, in
particular the aqueous humor beneath the cornea, which has low scattering properties.
However, this particular measurement site raise a second problem: a time delay between
glucose concentration in aqueous humor and blood. Although polarimetry is unaffected
by temperature and pH fluctuations, it suffers from motion artifacts and optical noise of
other substances [66].
Polarimetry-Based Sensors
A new real-time optical polarimetric approach for glucose sensing utilizing two
wavelengths is presented in [88]. Only in vitro experiments have been reported. In fact an
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efficient eye coupling mechanism has not been developed yet, allowing in vivo experiments
on rabbits eyes.
2.1.3 Thermal Emission Spectroscopy
Thermal emission spectroscopy measures IR signals generated in the human body as a
result of glucose concentrations changes. The tympanic membrane is used as measuring
site, since this membrane shares the blood supply with the centre of temperature regulation
in the hypothalamus [89]. Body movements and ambient temperature, also induced by
pathophisiological factors, are the most significant sources of noise [90].
2.1.4 Photoacoustic Spectroscopy
Photoacoustic Spectroscopy Principle
Photoacoustic spectroscopy uses the principle that absorption of a laser light causes
consequent acoustic response. Tissue is illuminated by a short laser pulse, at a specific
wavelength, and the absorbed radiation causes localised heating. The small temperature
increase is dependent on the specific heat capacity of the tissue irradiated. Volumetric
expansion due to heating generates an ultrasound pulse, which can be detected by a
microphone. Increasing tissue glucose concentrations reduce the specific heat capacity
of tissue and thus increase the velocity of the generated pulse making photoacoustic
spectroscopy an indirect technique for glucose estimation [37].
Besides this, the photoacoustic spectrum considered as a function of laser light
wavelength mimics the absorption spectrum in clear media (i.e. optically thin) and has
the advantage to present higher sensitivity in the determination of glucose, thanks to the
poor photoacoustic response of water.
The main limitation of this technique is its sensitiveness to chemical interferences
from some biological compounds and to physical interferences from temperature and
pressure changes.
Photoacoustic Spectroscopy-Based Sensors
The Aprise device is based on photoacoustic technology. It exploits in fact the
photoacoustic properties of the blood and tissues to estimate the prevailing glucose levels.
The sensor is attached to the skin above a blood vessel, and it generates ultrasound waves
by illuminating the tissue with laser pulses. Analysis of the acoustic signals provides
information on the absorbance of light in the tissue at different depths, which is influenced
by glucose concentration. An ultrasonic image of the optical properties of tissue directly
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beneath the sensor is obtained. The ultrasonic image resolves the blood vessel from the
tissue layers around it, enabling separated analysis of changes in optical properties of
blood and surrounding tissues [91].
2.1.5 Electromagnetic
Electromagnetic Principle
Another technique for investigating dielectric parameters of blood utilizes the elec-
tromagnetic coupling between two inductors turned around the medium under study.
The coupling is influenced by variations in the dielectric parameters of the solution,
which are modified by glucose. This method is based on the application of a voltage
signal with proper frequency to the primary inductor and for electromagnetic coupling a
signal will be produced on the secondary inductor. There exists an optimal frequency,
where the sensitivity to glucose change is maximal, but it is significantly influenced by
temperature. The main problem of this technique is that several other components may
have an influence upon the blood dielectric parameters and not only upon glucose [37].
Electromagnetic-Based Sensors
A new electromagnetic sensor is described in [92]. Its in vitro ability to estimate
variations in glucose concentration of different solutions with similarities to blood (sodium
chloride and Ringer-lactate solutions) has been tested, differing though in the lack of any
cellular components. The sensor was able to detect the effect of glucose variations over a
wide range of concentrations.
The Glucoband is a non-invasive glucose monitor that uses bio-electromagnetic reso-
nance to measure the blood glucose levels of the human body. This device is worn like a
wrist watch and displays results of the test on an LCD screen. The initial measurement
process takes only a few minutes. However, in the monitoring mode, measurements
can be continuous. Since each concentration of glucose has its unique electromagnetic
molecular self-oscillation signature-wave, the Glucoband perform the measure matching
the self-oscillation frequencies of glucose molecules with those of hundreds of reference
solutions with different levels of glucose stored in an internal database of “signatures”.
2.1.6 Impedance Spectroscopy
Impedance Spectroscopy Principle
A different kind of spectroscopy investigates the dielectric properties of a tissue using
a current flow instead of a light beam. It is called Dielectric Spectroscopy (DS) or
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Impedance Spectroscopy (IS). The impedance of a tissue can be obtained applying
a current of known intensity and measuring the resulting current flowed through the
tissue [93]. The cell membrane is semipermeable to ions, thus certain ions can pass
thought it while others cannot. This makes the membrane behave like a leaky capacitor.
Moreover, the intra and extra-cellular environments consists of electrolyte showing
resistive properties. The impedance of a tissue can thus be decomposed into a resistive
and capacitive part Z = R + iX, being frequency dependent, formally described in
terms of a resistance R [ohm] and reactance X [ohm]. A different expression is obtained
considering polar coordinates using the magnitude |Z| [ohm] and phase θ [deg] according
to Z = |Z|eiθ. Repeating IS measurements for different frequencies of the initial electrical
current allows to obtain the so-called dielectric spectrum, describing the impedance
as a function of frequency. Section 2.1.1 highlighted how the complex multilayer skin
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Figure 2.5: Dispersions. Magnitude of the impedance Z [ohm] as a function of the
frequency of the exiting current. Adapted from [94].
structure influenced optical based technologies for glucose sensing. In the same way,
the tissue structure and chemical composition of a biological material in general, and
of the skin in particular, may correlate with its electrical properties, thus presenting
frequency dependent characteristics. In particular, low frequency and direct current
must pass around the cell, in the extracellular environment, given the high capacitance
of the cell membranes. On the other hand, high frequency currents penetrate through
cell membranes by polarization, charging and uncharging the barrier as a capacitor.
Thus, different frequency bands contain information, in terms of impedance, affected
by different properties of the tissue. Figure 2.5 shows an example of the impedance
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magnitude as a function of the frequency [94]. The regions presenting a variation of the
impedance corresponds to specific electrochemical processes, called dispersions. Four
main dispersions have been identified: α, β, δ, and γ. Different mechanisms account
for low frequency (α), radiofrequency (β), and microwave frequency (γ) dispersions [95].
The α-dispersion is generally considered to be associated with interfacial polarization
linked with electrical double layers and surface ionic conduction effects of electrolyte at
membrane boundaries. The β-dispersion has essentially two components arising from
two different mechanisms: the capacitive shorting out of membrane resistances and
rotational relaxations of biomolecules. Cell suspensions such as blood will typically
exhibit a significant β-dispersion in the radiofrequency range between 100 kHz and 10
MHz. In addition, reorientation of free water molecules causes γ-dispersion. Water bound
to protein and internal protein motion will also cause a subsidiary process, called the
δ-dispersion, that is observed in the frequency region between the β and γ-dispersion.
DISPERSION FREQUENCIES ORIGIN
α low(10-100Hz) electrical double layers and electrolytes
at membrane boundaries
β radio(100kHz-10MHz) cell suspension(blood)
δ radio(10MHz-1GHz) water bound to protein and internal
protein motion
γ microwave(1-100GHz) reorientation of free water molecules
Table 2.1: Relaxation processes of biological materials.
IS-based techniques cannot measure glucose concentrations directly, since changes in
glucose levels do not directly affect the dielectric properties of skin and the underlying
tissue in the kHz and MHz frequency band. However, variations in plasma glucose lead
to changes in the electrolyte balance in blood, cells and interstitial fluid. An increased
concentration of glucose in blood involves a cellular biochemical response, which leads to
changes of membrane components, nucleotide and ionic rearrangement. In particular,
as a consequence of water movement, there is a decrease of sodium and an increase of
potassium inside the erythrocyte. This variation of the electrolyte balance has an influence
over the erythrocyte membrane potential and capacitance, which causes changes in the
ac and dc conductivity and tissue permittivity that can be measured using IS [93, 96, 97].
A sensor based on IS uses electromagnetic waves in the selected frequency band that
interact with the skin and the underlying tissue for monitoring these electrical properties.
Impedance Spectroscopy-Based Sensors
Several studies have been carried out and prototypes have been developed to prove
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the feasibility of this technology for NI-CGM. In-vitro studies have been performed to
monitor glucose concentrations in different solutions [98], while recently a prototype has
been developed embedding fringing field capacitive electrodes working in the 1-160 MHz
frequency range [99].
2.2 Multisensor Approaches for NI-CGM
Multisensor Principle
NI-CGM provides reliable estimates of the glucose levels in highly restricted, i.e. in
clinic conditions [100, 101, 102]. As soon as these conditions become less favourable, i.e.
in daily life use, several disturbances can affect and interfere with the glucose sensing
technology under use and impair the estimate of BGL. To overcome this problem, in the
last years the multi-sensor approach gained larger attention [18]. It consists in the com-
bination of some of the aforementioned NI-CGM technologies for a broader bio-physical
characterization of the skin and underlying tissues. In practice, this concept translates
in the embedding within the same device of different technologies able to track either
properties of the skin related to glucose levels changes and environmental (temperature,
humidity) and physiological (blood perfusion, body temperature) perturbations that can
affect the main glucose related signals.
Multisensor-Based Sensors
An example of device based on a multi-sensor platform is the GlucoTrack R© developed
by Integrity Applications [103] and displayed in Figure 2.6. It resorts to a combination
of thermal, acoustic and electromagnetic technologies for performing intermittent glucose
monitoring, given its embedding within a ear clip that need to be wear each time
a measured is performed. Data from the different sensors are processed through an
algorithmic routine. Each one of the three technologies provide a signal that is converted
into a glucose level with a suitable model. If at least two of the three estimated glucose
levels agree then the device display the glucose value to the user, otherwise the measure
is repeated.
A second example of device, at a prototype stage, is developed by Amaral and
coworkers [105]. This device resorts to a combination of IS and MIR technologies
combined through a suitable combination of linear and non-linear models (see Section
4.1).
In the last years, a Swiss medical company, Solianis Monitoring AG (Zurich, Switzer-
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Figure 2.6: The GlucoTrackR© consisting of the main unit (bottom) and the ear clip (top)
featuring the thermal, acoustic and electromagnetic technologies [104].
land), developed a multisensor approach for NI-CGM mainly based on IS [102], whose
capabilities in monitoring glucose level changes in-vivo has been recently demonstrated
under clinical conditions [102]. Chapter 3 is devoted to the description of this particular
device, since it provides the data that will be used in Part II of this thesis to test the
proposed techniques for model identification.
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3
The Multisensor Approach to CGM by Solianis
Monitoring AG
This chapter will focus on the description of the multisensor approach pursued by Solianis
Monitoring AG (Zurich, Switzerland), whose IP and technology have been recently
acquired by Biovotion AG (Zurich, Switzerland), for providing an overview of the data
that will be used in the last part of this thesis. Solianis Monitoring AG has also been
partially funding the Ph.D. position during which this thesis has been developed. From
this point of the thesis, we will refer to “Multisensor” (with capital M) for indicating the
specific device developed by Solianis, and to “multisensor” to indicate the concept.
3.1 Description of the Solianis Multisensor
Earlier work in [106, 107] showed promising results in monitoring changes in blood
glucose levels in clinical experiments in highly controlled, i.e. in clinical conditions,
using IS. As soon as these conditions become less favourable, going towards a daily
life use, this technique exhibits its limitations, mainly related ti deleterious effects of
many perturbing factors, such as temperature fluctuations, variations of skin moisture
and sweat, changes in cutaneous blood perfusion and body movements affecting the
sensor-skin contact surface [108]. Consequently, all these perturbations affecting the
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main glucose related signals have to be identified, characterised and compensated for. As
better discussed in the following, this suggested in [102] the development of a Multisensor
Glucose Monitoring System, where the multisensor concept means a system that includes
several sensors embedded within the same sensor substrate in contact with skin, allowing a
broader bio-physical characterization of the skin and underlying tissues. The Multisensor
performs continuous glucose monitoring collecting a set of signals measured through the
Multisensor channels with a sampling time of 20 seconds. As shown in Figure 3.1 the
Multisensor is attached to the upper arm of the patient with a flexible band and it is
powered with a battery pack.
IS electrodes
As described in Section 2.1.6, changes in blood glucose levels cause dielectric changes
of skin and underlying tissues within the frequency range of 0.1-100 MHz, which is
measured utilizing particular capacitive fringing-field electrodes [102]. In order to achieve
different penetration depths of the electromagnetic field into the various tissue layers, three
electrodes with different characteristic geometries are used in the Solianis Multisensor.
The interaction between an applied electromagnetic field and the skin depends not only on
the frequency band, but also on the geometric properties of the electrode. The differences
between the three IS electrodes consist in the distance between the active electrode and
the ground potential. In particular, a distance of 0.3, 1.5 and 4 mm is associated with
shallow, mid and deep penetration respectively and the sensors are referred as short,
middle and long, respectively (see Figure 3.1) .
Figure 3.1: Left : Optical and dielectric sensors composing the Solianis Multisensor. Right :
Solianis Multisensor attached to the upper arm with a flexible band.
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The short electrode penetrates only the upper skin layers, thus it cannot yield
information about glucose levels, but it may still contain information about perturbing
effects related to the uppermost layers. Data from long and middle electrodes are
regarded as primary signals, since they penetrate also the lower skin layers that are well
micro-vascularised (see Figure 2.1) and hence particularly affected by glucose variations.
Optical sensors
As mentioned before, other sensors are used with the aim of obtaining useful informa-
tion to compensate the perturbing factors: two optical sensors are embedded within the
Multisensor substrate for the measurement of skin blood perfusion, which is a perturbing
factor for dielectric signals [67]. Each optical sensor features 3 LEDs, located closely to
each other, with the following wavelength: green (568 nm), red (660 nm) and infrared (798
nm). Light reflected back from the skin is detected by two photo-detectors (signal diodes),
while the variation of emitted LEDs intensity are monitoring by two reference diodes
(monitoring diodes) located near the LEDs. Simulation studies have been conducted to
design the optimal position of the optical sensors within the Multisensor substrate as
well as their relative distance for sampling the optimal measuring site [109].
Sweat sensors
An interdigitated electrode is used to measure the dielectric response at lower frequen-
cies in the range of 1-200 kHz for obtaining information about sweat events. Moreover,
its particular geometrical shape allow the sampling of the more superficial area of the
skin. Another sensor exploits the frequencies in the range of GHz to estimate hydration
levels of the underlying skin layers, since GHz excite free water molecules (see Table 2.1).
Acceleration sensors
An integrated accelerometer has the aim to monitor continuously the acceleration
and the position relative to the centre of gravity of the device.
Other sensors
Finally, others sensors monitor skin and housing temperature, and ambient humidity
close to the device. This is because IS data showed to be particularly sensitive to
temperature fluctuations [108].
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3.2 Examples of Solianis Multisensor Data
This section gives a clue of the different time-series measured from the Multisensor chan-
nels, highlighting in some cases features of the data that will influence the identification
of the model in Section 3.3. Each sensor embedded on the Multisensor substrate provides
its specific set of signals acquired with a sampling period of 20 seconds. To illustrate the
Multisensor data, we can take advantage from the availability of reference BGL acquired
in parallel with a sampling time of 10 minutes by a laboratory instruments.
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Figure 3.2: Normalized magnitude (top) and phase (bottom) impedance signals
(continuous lines) from the “long” fringing field capacitive electrode vs. normalized reference
BGL samples (magenta stars). Magnitude and phase at different frequencies (in the range
0.1-100 MHz) of the input current are collected with 20 sec time sampling and represented
with different colors.
In Figure 3.2, representative time series, collected from the same electrode (“long”
fringing field capacitive electrode) at different frequencies, are shown together with the
BGL time series. In particular, the impedance at different frequencies is represented
using a parametrization with magnitude (Figure 3.2, top) and phase (Figure 3.2, bottom).
As shown in the top panel the magnitude signals at different frequencies are similar
but not identical, thus presenting strong correlation. The same is for the phase signals,
which are also correlated with the magnitude signals. Since the impedance channels, as
mentioned in the previous section, contain glucose information, they are referred as the
primary “glucose signals” [102].
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Figure 3.3: Normalized magnitude (top) and phase (bottom) impedance signals
(continuous lines) from the interdigitated electrode vs. normalized reference BGL samples
(magenta stars). Magnitude and phase at different frequencies of the input current are
collected with 20 sec time sampling and represented with different colors.
Figure 3.3 shows the time series relative to the magnitude (top) and phase (bottom) of
the impedance measured by the interdigitated electrode which is particularly sensitive to
changes of the surface dielectric properties due to the creation of a saline layer after sweat
events occurred. It is particularly interesting to note how these channels are particularly
responsive to the on-set of the sweat event and of the following creation of the saline
layer.
Figure 3.4 shows channels associated with other sensors embedded within the Solianis
device. In the top panel the skin and the housing temperature are plotted together with
the time-series relative to the humidity sensor, along with ambient humidity. In the
bottom panel an example of optical channels is shown. Some of them seem correlated
with the BGL references. However, they are noisier than impedance channels.
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Figure 3.4: Normalized Multisensor housing temperature (green line), skin temperature
(red line) and humidity (blue line)(top) and some optical (bottom) channels (continuous lines)
vs. normalized reference BGL samples (magenta stars).
3.3 From Multisensor Data to Glucose: the Need of a
Model
The Multisensor data described in the previous section need to properly combined in order
to perform NI-CGM (see Figure 3.5). While some channels measure “glucose-related”
information, others are used to characterise the perturbations affecting the primary
signals, allowing for their compensation. Hence, the Multisensor signals have to be
combined through a relationship, i.e. a model, for linking the measured variables with
BGL.
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Figure 3.5: A model (middle) linking Multisensor data (left) to BGL (right).
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Supposing to collect the Multisensor signals at the t-th time instant whitin X(t), the
unknown relationship can mathematically be expressed as:
BGL(t) = f(X(t),θ) (3.1)
where f(·) represents a generic function used to convert the signals into BGL values and
θ is an unknown vector containing the parameters that characterise this conversion.
The same problem arises for the other multisensor approaches, such as for example
the one developed by Amaral and co-workers [105]. Remarkably, other research fields
have to face similar challenges, mainly those related to chemometrics and dealing with
spectroscopy data analysis [110, 111].
3.4 Concluding Remarks
In the last years, several NI-CGM technologies have been investigated. As also depicted
in Chapter 2, many sensors based on a wide range of technologies have been proposed to
the market, but none of them really achieved accuracy close to that of minimally invasive,
needle-based, sensors. This is because all the presented non-invasive technologies are
affected by many environmental and physiological interferences affecting glucose readings.
In order to measure and compensate for these detrimental effects, the multisensor
approach consists in the embedding of different sensors into the same device for a
complete bio-physical characterization of the skin and underlying tissues.
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4
Open Problems with Model Identification in
Multisensor Approaches and Aim of the Thesis
4.1 Problem Statement
A class of candidate models to be used in Figure 3.5 and described by eq. (3.1) is
tha of white-box models, where differential equations are used to describe the physical
relationships between measured channels and glucose variations. These kind of models
have been widely exploited for modeling physiological processes with the purpose of
improving physiological knowledge [112], extract clinical information [113] as well as
for control purposes [114, 31]. However, in our case, a mechanicistic description for
linking glucose variations with physical quantities measured with the Multisensor is not
yet available. For this reason, we resort to a black-box strategy, where the system is
described in terms of its inputs (Multisensor channels), outputs (glucose) and the type of
model/relationship linking the two. For this reason we must define the structure (e.g.
static or dynamic) and the form (e.g. linear or not) of the function f(·) of Figure 3.5
and eq. (3.1) [115].
The model considered throughout this thesis is a static multivariate linear regression
model, formally described as:
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y = Xβ + β0 (4.1)
where, y is the output variable, i.e. glucose, matrix X collects the data measured from the
Multisensor device and β is the parameter vector that linearly combines the Multisensor
channels in order to give an estimate of the glucose levels apart from an off-set pr basal
value given by β0. To better highlight the notation used, the unknown variable to be
predicted is called output or target, while the measured variables are called inputs, or
regressors (because they contain the information for the regression model) or predictors
(because they are used to predict the output). Thus, the aim of regression is to build and
identify a prediction model. This model can then be used for estimating glucose for, new,
“unseen” data. In the general case, the target variable consists of a multi-dimensional
vector. However, since our purpose is to estimate glucose, throughout this thesis, only the
case of a single output variable will be considered. Hence, the output will be represented
by a column vector y of dimension N × 1, where N is the number of available samples.
In symbols:
y = [y1 y2 . . . yN ]
T (4.2)
where yi denotes the i-th sample of the reference.
The input variables are contained in the matrix X of dimension N × p, where the
element xij represents the i-th sample of the j-th variable.
X =

x11 x12 . . . x1p
x21 x21 . . . x2p
...
...
. . .
xN1 xN2 xNp
 (4.3)
While each row of the matrix X contains the set of p variables corresponding to the
measured Multisensor channels relative to the same i-th time instant (represented by
the row vector Xip (1× p)), each column contains the N samples of the j-th variables
(symbolized using the column vector XjN (N ×1)). Hence, while subscript i ∈ [1, 2 . . . N ]
indicates the sample, subscript j ∈ [1, 2 . . . p] identifies the variable. To distinguish for
example, X1 the set of p variables at the first time instant from X1 the N samples of
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the first variable, a second subscript is added, indicating the dimension of the vector.
X =

x11 . . .|x1j |. . . x1p
... | ... | ...
xi1 . . .| xij |. . . xip
... | ... | ...
xN1 . . .|xNj |. . . xNp

⇒Xip
⇓
XjN
(4.4)
The aim of regression is to find an estimate βˆ of the unknown coefficients β, given
the knowledge of the reference vector y and of the coupled inputs collected in X from
the so called identification data set. After βˆ is determined, it can be used to calculate the
correspondent model prediction of the target yˆ prospectively also on different Multisensor
data than that used in the model identification stage (test data set).
4.1.1 Open Problems
The principal Multisensor signals are those that mostly contain the information about
glucose fluctuations. However, in the everyday life use of the device, these signals are
affected by different perturbing factors (temperature fluctuations, skin moisture, sweat,
blood perfusion, . . .). The multi-sensor concept derives from the necessity of compensating
these perturbations, measuring a high number of channels presenting correlation between
subsets of them. Indeed, spectroscopy data present very similar values at close frequencies.
Thus the difficulties in identifying β in eq. (4.1) are primarily due to:
• High dimension of the measurement space;
• Correlation between subset of Multisensor channels.
These two characteristics of the recorded data make the matrix X rank deficient with
numerical issues arising for the identification of β because the problem is ill-conditioned.
4.2 Aim of the Thesis and Outline
The aim of thesis concerns the investigation and assessment of different techniques for
the identification of a multivariate linear regression model for tracking glucose levels
changes non-invasively. We will consider Ordinary Least Squares (OLS), Partial Least
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Squares (PLS), the regularization technique based on `1 norm, namely Least Absolute
Shrinkage and Selection Operator (LASSO), and a technique based on the `2 norm, i.e.
Ridge regression, and a technique based on their combination, i.e. EN regression. While
our implementation will be focused on the particular Solianis Multisensor platform, the
considered methodologies can have a much wider field of applicability and can be used to
model other multisensor data for NI-CGM as well as for data analysis in chemometrics
and related disciplines where PLS represents the current state-of-art.
The remainder of the thesis is organized into two blocks. In Part II, we explain
rationale of each method, pros and cons, by exploiting a tutorial example. Part III
illustrates the results obtained from the application of the five considered model identifi-
cation techniques to data recorded through the Solianis Multisensor device. Finally, some
hints for future developments is given regarding a Monte Carlo based methodology for
assessing the robustness of the individual calibration parameter (calculated each time the
Multisensor is worn) against a very common source of disturbance in daily-life conditions,
i.e. sweat.
Part II
Techniques for Identification of
Multivariate Models

5
Criteria for Model Identification and Model Test
5.1 Issues of High-Dimensional Regression
This section describes, using the notation of the previous chapter, the issues typically
faced for regression problems when are used high dimensional datasets. Most of the
material originates from the book written by Hastie et al. [116] and is reported here for
sake of completeness.
It could seem reasonable that, if the identification set is large enough, it would be
easy to generalize data behaviour and identify a good prediction model. However this
it not true dealing with high-dimensional data because the large number of correlated
predictors exacerbate the need of available data for identification of the models. This
is exactly what happens in our case study where we will have to deal with more than
150 input variables (the Multisensor measured signals). In presence of high-dimensional
datasets, the algorithms for solving regression problems suffer from the so called curse of
dimensionality [117].
5.1.1 Curse of Dimensionality
Consider a p-dimensional unit hypercube and suppose the N regressors samples to be
uniformly distributed in it. The fraction of samples included in a hypercube with side
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r(< 1) is:
frac = rp
Extracting the side of the hypercube as a function of the desired fraction and the
dimension p, one gets:
r = frac1/p
Hence, for example, to include 10% of the samples, we need a hypercube with side 0.1
for p=1, and a hypercube with side 0.8 for p=10. The different curves plotted in Figure
5.1 show the side of the hypercube as a function of the fraction of included samples for
different values of dimension p.
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Figure 5.1: side of the cube as a function of the fraction of included samples for different
values of dimension p. Adapted from [116].
As shown in Figure 5.1, the hypercube side needed for a given fraction increases even
more as the dimension p increases. Hence, as the number of the regressors increases,
it becomes more difficult to generalize data behaviour. In fact, the samples are more
distant to each other and, in particular, they tend to be close to an edge of the sampling
area, because the prediction is much more difficult near the edges of the training sample.
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One can also formulate the problem considering that the sampling density is pro-
portional to N1/p. In high dimensional datasets, all feasible training samples sparsely
populate the input space. In fact, the density rapidly decreases to zero as p increases.
5.1.2 Overfitting
In addition, high-dimensional regression algorithms have to deal with overfitting, namely,
the risk of fitting a predictive model not only to the information yielded by identification
data but also to noise, with considerable limitations on the generalization properties of
the model. To overcome these problems, our attention will be focused on techniques
based on two strategies: a)dimensionality reduction, which uses M(≤ p) new regressors
calculated from a linear combination of the original ones, or b) regularisation, putting a
price on the values of the unknown coefficients β of model (4.1).
An example of regression technique using dimensionality reduction is Partial Least
Squares (PLS), which will be described in detail in Chapter 6, while an example of
regression technique using regularisation is Least Absolute Shrinkage and Selection
Operator (LASSO), which will be discussed in Chapter 7. Both these methods require
the setting of one parameter related to the model complexity (i.e. describing the new
dimensionality M in PLS and the amount of regularisation in LASSO) as illustrated
below.
5.2 Criteria for Selection of Model Complexity
Model complexity should be selected such that the best performance of the chosen
identification method is achieved when the target variable is estimated from “unseen”
data, i.e. data not used during the model identification stage. The main issue relies on
the right way to evaluate the performance for selection of the model complexity.
5.2.1 The Bias-Variance Dilemma
Considering the identification set, it seems reasonable to assume that if model complexity
increases the model will better describe the target. Hence, the Residual Sum of Squares
(RSS) on identification data (describing the distance between the reference y and its
model prediction yˆ will decrease as model complexity increases.
RSS =
N∑
i=1
(yi − yˆi)2 = ‖y − yˆ‖ (5.1)
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This is a key aspect of the so called “internal validation”. RSS of eq. (5.1) is expected to
have a monotonic decreasing behaviour as model complexity increases (see Figure 5.2).
This means that we cannot use RSS to determine model complexity, since we can always
obtain, for sufficiently complex models, null residuals. The so-determined model usually
fails in predicting new data, different from those of the identification set. In fact, a too
complex model normally fits the reference data but also the noise (overfitting) and is
thus not able to generalize the data behaviour properly.
As a consequence, the performance of the identification method has to be determined
using independent test data. Suppose the measurement y to be modeled as a combination
of a deterministic part f(X) (X is the matrix collecting the inputs or regressors) and a
random part  due to the noise (zero mean, constant variance):
y = f(X) +   ∼ N(0, σ2) (5.2)
The Mean Square Error (MSE) can be defined for measuring errors between the true
value ytrue and the model prediction yˆ :
MSE(yˆ) = E[‖yˆ − ytrue‖22] (5.3)
Equation (5.3) can be divided in two terms, one representing the estimation variance
and the other the bias (difference between the expected value of the estimation and the
true value ytrue):
MSE(yˆ) = trace(V ar(yˆ)) + ‖Bias(yˆ)‖22 (5.4)
The proof of (5.4) can be given in term of its scalar versions since MSE =
∑N
i=1E[(yˆi −
yi,true)
2].
E[(yˆi − yi,true)2] = E[(yˆi − E[yˆi]) + (E[yˆi]− yi,true)2]
= E[(yˆi − E[yˆi])2 + (E[yˆi]− yi,true)2 + (yˆi − E[yˆi])(E[yˆi]− yi,true)]
= V ar(yˆi) +Bias(yˆi)
2 + E[(yˆi − E[yˆi])(E[yˆi]− yi,true)]
= V ar(yˆi) +Bias(yˆi)
2 + E[yˆiE[yˆi]− (E[yˆi])2 − yi,trueyˆi + E[yˆi]yi,true]
= V ar(yˆi) +Bias(yˆi)
2 + (E[yˆi])
2 − (E[yˆi])2 + yi,trueE[yˆi]− yi,trueE[yˆi]
= V ar(yˆi) +Bias(yˆi)
2
Generally, the variance term increases as model complexity gets higher. This can be
explained observing that the more complex the model is, the more is the adherence to
the data and thus the sensitivity of the estimated model parameters to the particular
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realization used to identify them. On the other hand, the bias term decreases as model
complexity increases. As a consequence, even if estimates are influenced by noise,
the effects of the bias term tends to be eliminated by averaging different estimates.
Summarizing, the training error tends to decrease when model complexity is increased.
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Figure 5.2: Test and training error as a function of model complexity [116]. The training
error curve (blue line) and the test error curve (red line).
If the model overfits the data (too high complexity), it will not generalize well and the
estimates will have too high variance. On the other side, if the model is not complex
enough, it may underfit the data and have large bias. This brief discussion highlights
the dilemma of fixing the bias-variance tradeoff and suggests that model complexity
should be chosen in such a way to minimize the error on independent test data. As
shown in Figure 5.2, the prediction error has a monotonic decreasing behaviour as model
complexity increases, when calculated on the training set (blue curve). Hence, it can not
be used to select the correct amount of model complexity. In Figure 5.2 the prediction
error behaviour when calculated on the test set is also plotted (red curve). Usually, it has
concave behaviour, due to the bias-variance trade-off. In this case, the curve minimum
can be used to fix most reasonable model complexity. In the next subsection a method
to construct the test error curve is described.
5.2.2 The Cross-Validation Principle
As far as we observed that the identification data set is not useful to select the model
complexity, another set of data has to be considered (test set). As a consequence, before
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describing how to calculate the prediction error curve on the test set, we have to discuss
how to handle the available data.
In a data-rich situation, the best way to split the available dataset is in three parts:
a training set, a validation set and a test set. The training set is used to fit the model,
the validation set is used to select the complexity parameter and the test set is used for
assessing the generalization error of the final chosen model (Section 5.2). However, if the
data are scarce (as in our case), the previous approach is not applicable.
K-fold cross-validation is a method to estimate test error, using the training set. In
particular, K-fold cross-validation splits the data into K parts of approximately equal
size. Iteratively, one part is left aside to calculate the test error (using MSE), while the
other K − 1 parts are used to identify the coefficients of the model. In this way a test
error upon each K-th part is calculated and, averaging these values, an estimation of the
test error is obtained.
20 sample︷ ︸︸ ︷
Part 1 Part 2 Part 3 Part 4 Part 5
︸ ︷︷ ︸
100 samples
Figure 5.3: Example of dataset division for 5-fold cross-validation.
For example, suppose that a training set of 100 samples is available and that we want
to perform 5-fold cross-validation. The 100 samples are randomly and equally divided in
5 parts, each of about 20 samples as shown in Figure 5.3.
At the first iteration, part 2-3-4-5 of the training set are used to estimate the
coefficients of the model, obtaining βˆ
−1
, where the superscript indicates the part that
was not used in the identification procedure. The estimated coefficients βˆ
−1
are used to
predict the reference of part 1 (y1) from the inputs variable of part 1 (X1):
yˆ1 = X1βˆ
−1
(5.5)
The RSS is then used to calculate the test error on part 1, where the residuals denote
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the distance between the model predictions yˆ1 and the available reference points y1:
RSS1 =
N1∑
i=1
(yˆi1 − yi1)2 = ‖yˆ1 − y1‖2 (5.6)
where N1 is the number of samples included in part 1.
At the second iteration, part 2 is left aside to calculate the RSS2, using the coefficients
estimated from part 1-3-4-5. Similarly, the procedure is iterated for other three times in
order to calculate RSS3, RSS4 and RSS5. These five values of RSS are then averaged in
order to estimate the test error.
Etest = RSS =
5∑
i=1
RSSi
5
(5.7)
The whole procedure is repeated for different values of the complexity parameter in
order to estimate the test error as a function of the model complexity (see Figure 5.2).
Usually, this function has a minimum corresponding to the most reasonable bias-variance
trade-off.
Cross-validation, averaging the RSS calculated on different datasets, allows also to
estimate the confidence interval for the estimated test error. Using the previous example,
considering a 5-fold cross-validation procedure, the confidence interval for a given model
complexity can be calculated as follows:
SD =
√√√√ 5∑
i=1
(RSSi − RSS)2
/
5 (5.8)
As a consequence, instead of choosing the complexity parameter at the minimum of
the test error function, usually “one-standard error” rule is used to choose the model.
This criterion consists in choosing the most parsimonious model whose error is no more
than one standard error above the error of the best model. The model chosen according
to this rule is represented by the green dashed line in Figure 5.4, corresponding to model
complexity 7. A different strategy for choosing the complexity parameter is to identify
its value in correspondence of a significant change of slope of the error curve. In Figure
5.4 this point corresponds to 4, and, as frequently happen, it does not coincide with
the previous. This rule of thumb allows to obtain a more parsimonious model than the
“minimum of the test error plus its standard deviation”, with advantages in generalization
performance on new test data.
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Figure 5.4: Example of test error curve in K-fold cross-validation, where the error s for
each model (with different complexity) are provided by its mean and standard deviation. Red
star is the minimum of the test error. Green dashed line represent the error of the best model.
5.3 Models Test
In this section, how to describe the performance of the selected model will be presented.
5.3.1 Principles for Model Test
In the previous section we described how the identification data set is used in cross-
validation to choose model complexity. Once model complexity is determined the coeffi-
cients of the model can be estimated from the whole identification data set using different
techniques. For instance, OLS (Chapter 6), PLS (Chapter 7) and the regularization based
techniques (Chapter 8), namely, LASSO, Ridge and EN, are considered. The further step
is to determine which identification method best suits for our particular problem. As a
consequence, some indicators have to be defined to evaluate model performance on a test
set of data. Since the error estimated from data used to identify the coefficients of the
model tends to underestimate the real error, the test set must be composed by unseen
data, i.e. data that are not used in cross-validation procedure nor in the identification
procedure. Hence, this procedure is often called “external validation”.
Formally, in external validation, the coefficients of the linear model estimated from
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the identification data set βˆtrain are used to predict the target of the test data ytest:
yˆtest = Xtestβˆid (5.9)
the subscript “id” denotes what is calculated from the identification data set, while the
subscript “test” is appended to test set quantities through the equations. Therefore,
Xtest is the matrix collecting test data.
To quantify the prediction quality, different indicators can be considered. In particular
we introduce two groups of indicators: the first aims at quantifying point accuracy of the
estimated glucose profiles; the second group includes two indicators widely used within
the diabetes community to judge the clinical accuracy of CGM devices. All these indexes
are formally defined in the following section.
5.3.2 Indicators for Point Accuracy
The indicators defined before can be used to evaluate the performance of the identified
model on unseen data (i.e. when the test data set is considered). Hence, they allow the
comparison between different models [10, 118].
MSE was defined as a stochastic quantity in (5.3). However, a realization can be
observed as normalized distance between prediction yˆ and reference data y :
MSE =
N∑
i=1
(yi − yˆi)2
/
N (5.10)
Root Mean Square Error (RMSE) is the square root of (5.10) and thus has the same
units as the quantity being estimated.
Mean Absolute Difference (MAD) is defined as follows:
MAD =
N∑
i=1
|yi − yˆi|
/
N (5.11)
which differs from (5.10) since, instead of summing the squares of the differences, their
absolute values are summed up.
Mean Absolute Relative Difference (MARD) is the same as (5.11), but it is an absolute
indicator, since every difference (yi − yˆi) is divided for the reference value yi:
MARD =
N∑
i=1
∣∣∣∣yi − yˆiyˆi
∣∣∣∣/N (5.12)
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While these three key indicators are based only upon the distance between the test
reference data y and its prediction yˆ , others like for example R2 measures how much
the prediction is a good approximation of the reference variation.
The Pearson correlation coefficient R measures the linear dependence between two
variables, representing the test reference y and prediction yˆ. The general formula for its
calculation is:
R =
N
N∑
i=1
yˆiyi −
N∑
i=1
yˆi
N∑
i=1
yi√√√√N N∑
i=1
yˆi
2 −
(
N∑
i=1
yˆi
)2√√√√N N∑
i=1
yi2 −
(
N∑
i=1
yi
)2 (5.13)
The correlation coefficient R ranges from -1 to +1 included. A value of +1 or -1 implies
a linear relationship between the two variables. In the case R equals +1 it means that if
y increases, yˆi increases too (correlation); in the case R equals -1 a decrease in yˆi will
correspond to an increase of y (anticorrelation). A value of 0 implies that there is no
correlation between the variables.
The square of correlation coefficient, R2, ranges from 0 to +1. Hence, it does not
distinguish negative from positive correlation. This indicator turns out to be useful when
interested to the connection between the variables and not to the sign of the relation.
A key mathematical property of the correlation coefficient is that it is invariant to
changes in location and scale, i.e. if one of the variables is transformed linearly as a+ bx
(with a and b constants) the correlation coefficient does not change its value. This can
be useful to determine if the prediction yˆ has the same fluctuations of the reference
y, without having the same scale. In this case R2 would assume a high value (good
correlation), even if the distance between the reference and test sample is high, causing
bad values for RMSE, MAD or MARD.
Finally, a measure to quantify the smoothness of the estimated glucose profiles
by the different models is considered. In analogy to idea exploited in the context of
regularization [119], the Energy of the Second Order Differences (ESOD) is considered,
which is defined here as the energy of the second order differences of the estimated glucose
profiles normalized by the energy of the second order differences of the reference BGL
values in the same experimental sessions:
ESOD =
∑N
i=1 ∆
2(yˆi)
2∑N
i=1 ∆
2(yi)2
(5.14)
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5.3.3 Indicators for Clinical Accuracy
While the indicators defined in the previous section are suited to give an indication
about the point accuracy of the estimated glucose profiles, they lack in providing suitable
information about the clinical information carried by the CGM traces. In order to fulfill
this gap, the so called Clarke Error Grid has been extensively used among the diabetes
community, initially to measure accuracy of SMBG devices and then of CGM devices.
The Clarke Error Grid shows the scatter plot of reference BGL versus the BGL value
estimated by the device under test [120]. The plot area is broken down into five main
regions as it can be seen in Figure 5.5 (left):
• Region A includes values within 20% of the reference;
• Region B includes values outside the 20% but not leading to inappropriate treatment;
• Region C contains points leading to unnecessary treatment;
• Region D contains points indicating a potentially dangerous failure in detecting
hypo or hyper-glyceamia;
• Region E contains points that would lead to a hypo-treatment when the patient is
actually in hyper-glycaemia and viceversa.
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Figure 5.5: Clarke Error Grid (left), and Rate Error Grid (right).
Thus, a clinically accurate sensor should provide most of the points within the A+B zone
with few, or ideally none, in the C/D/E zones. Current accuracy of minimally-invasive
CGM devices show a range of values between 84.4 and 98.9 of points in the A+B zones,
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with point accuracy values for MARD in the range 10.3-21.5. CGM devices, measuring
BGL every 1 to 5 minutes, provide information also on the trend of the glucose signal,i.e.
stable, rising or falling glycaemia. To evaluate the accuracy in estimating glucose trends,
the so called Rate Error Grid has been developed [121]. This grid is based on the same
concept of the Clarke grid. The area is broken down into regions indicating clinically
relevant information about the glucose trends estimated from the device under test. The
Rate Error Grid focuses on the clinical implications of measurement errors by addressing
the question of what type of clinical outcome might occur if the patient took action based
on BGL rate of change.
5.4 Concluding Remarks
This chapter presented an introduction to the regression problem, with consideration that
algorithms dealing with high-dimensional data suffer from the curse of dimensionality
and overfitting. A general introduction to the methods trying to solve these problems
was presented. As these algorithms usually require the setting of a parameter to adjust
the model complexity, a commonly used procedure for such a scope was illustrated using
K-fold cross-validation.
Finally, at the end of the Chapter, some indicators for the performance comparison
of different models were presented. While, by visual inspection of the estimated profiles
versus reference data, one could only qualitatively guess which model has the best
performance, the indicators presented in Section 5.3.2 and Section 5.3.3 will allow a
quantitative assessment of how much a method works better than the others in identifying
linear models for regression. Further metrics are available in the literature, such as for
example for evaluating the accuracy of prediction algorithms [122], but we believe those
reported in this chapter are exhaustive for describing accuracy of estimated glucose
profiles.
These procedures will be used in this thesis to evaluate the performance of the
regression methods, presented in Chapters (6-8), when applied to the Solianis Multisensor
data (Chapters 10-11).
6
Ordinary Least Squares (OLS)
The most easy and well-known method for finding an estimate of the parameter vector
of the multivariate linear regression model defined in eq. (4.1) β = [β0, β1 . . . , βp], given
the reference vector y and the corresponding inputs X, is Ordinary Least Squares (OLS).
OLS makes no assumption about the validity of the model, but simply finds the best
set of parameters β by adjusting them in order to maximize the adhesion between the
model predictions and the reference data. This chapter will present the characterization
of the OLS identification procedure in a general framework. Then, with the support of a
simple tutorial example (Chapter 9), advantages and drawbacks of OLS will be shown.
Finally, in Chapter 11 the technique will be applied to model NI-CGM Multisensor data.
6.1 Mathematical Definition
OLS determines the estimate βˆ by minimizing the Residual Sum of Squares (RSS),
where the residuals denote the distance between the model predictions (4.1) and the
available reference points yi:
RSS(β) =
N∑
i=1
yi − β0 − p∑
j=1
xijβj
2 (6.1)
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that can be written in matrix form as:
RSS(β) = (y −Xβ)T (y −Xβ) (6.2)
where X is the matrix collecting the input data. It is easy to see that RSS is a quadratic
function of the unknown parameter vector β. Minimizing RSS in (6.2) can thus be done
by setting to zero the first derivative of (6.2) with respect to β:
∂RSS
∂β
= −2XT (y −Xβ) (6.3)
XT (y −Xβ) = 0 (6.4)
The matrix equation (6.4) collects the so-called normal equations. If the matrix XTX
is not singular, a closed formula for the solution βˆ can be obtained as:
βˆ = (XTX)−1XTy (6.5)
The estimated parameter vector βˆ could then be placed into (4.1) to obtain an
estimate of the target yˆ, the so-called “model prediction”:
yˆ = Xβˆ = X(XTX)−1XTy (6.6)
As shown in box Algorithm 1, once the model parameters βˆ are estimated from
the identification set, the linear model of eq. (4.1) can thus be used to predict unseen
data through a linear combination of the inputs. The derivation of the solution is
computed assuming a uniform precision of the reference data yi, thus no weighting matrix
is introduced.
load X, y {load data and standardize}
standardize X,y
βˆ ← inv(XTX)XT y;
(or using QR decomposition)
βˆ ← X\y;
yˆ ← Xβˆ
Algorithm 1: OLS pseudocode.
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6.2 Properties of OLS
A brief overview of the statistical and geometrical properties of the OLS estimator will
be given in this section.
6.2.1 Statistical Properties
Suppose the measurement model to be a combination of a deterministic part (linear
combination of regressors) and a random part (stationary, zero mean and constant
variance i affecting each measure yi):
yi = Xiβ + i  ∼ N(0, σ2)
yi = yi,true + i
(6.7)
The Mean Square Error (MSE) of the estimate yˆ of the true value ytrue is:
MSE(yˆ) = E[‖yˆ − ytrue‖22] (6.8)
Equation (6.8) can be divided in two terms, one representing the estimation error
variance and the other the bias (difference between the expected value of the estimate
and the true value ytrue):
MSE(yˆ) = trace(V ar(yˆ)) + ‖Bias(yˆ)‖22 (6.9)
(see Section 5.2.1. The Gauss-Markov theorem [116] tells us that the OLS estimator of β
has the smallest error variance among all linear unbiased estimators, namely it presents
the lowest possible MSE.
However, it may well exist a biased estimator with smaller MSE. Since this estimator
is biased it must have a very small variance in order to have smaller MSE than OLS (that
is unbiased) as we will show in Chapter 7 and 8. Methods that shrink (or set) to zero
some of the components of β may result in a biased estimate but with lower variance
than the OLS estimator.
6.2.2 Geometrical Properties
OLS has a geometrical interpretation which is illustrated by means of Figure 6.1, that
represents the simple case of two different input variables, X1 and X2.
The input vectors X1 and X2, define a vector space S (yellow) while the target
vector is represented by y. Using the linear model, the estimation yˆ could be any linear
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Figure 6.1: geometrical interpretation of OLS. Target vector y, estimation of target vector
yˆ, input vectors X1 and X2 and in yellow the vector space S generated by the two vector.
Adapted from [116].
combination of the inputs X1 and X2. For this reason the estimate could lie anywhere
in the bi-dimensional subspace S and the RSS represents the squared euclidean distance
between the reference y and its estimation yˆ. Since OLS adjusts the parameters β of
the linear model to minimize the RSS, the OLS model prediction yˆ is the particular
vector lying in the subspace S, which is the closest as possible to the reference y. For
this reason, yˆ corresponds to the orthogonal projection of y onto the subspace S, which
is described mathematically by:
XT (y − yˆ) = 0 (6.10)
Eq. (6.10) represents the orthogonality condition for the vector (y − yˆ) with respect
to the subspace S defined by X.
By substituting (6.6) into (6.10), one gets:
XT (y −Xβˆ) = 0 (6.11)
which corresponds to (6.4) and is solved by the OLS estimate.
6.2.3 Singularity Condition and Solution by QR Decomposition
If the regressors XjN are not linearly independent, X
TX is singular and can not be
inverted to calculate the parameters in (6.5), yielding to a not uniquely defined βˆ.
However, the multiple solutions are still the projection of y onto the column space of X,
6.2 Properties of OLS 65
though there are more ways to express this projection, as there are more ways to define
the subspace S.
The linear dependency of the columns of X is a consequence that one or more inputs
XjN present redundant information. If a couple of columns are nearly to be linearly
dependent, the correlation between the two variables is high and the matrix X is not
full rank. The problem of inverting XTX is thus ill-conditioned, leading to low accuracy
of the estimated vector βˆ. A typical solution for this problem is dropping redundant
columns in X. Other methods, as those described in the next chapters of the present
thesis, provide a regularization term to cope with this low rank issue.
The most common method to recode redundant columns is the QR decomposition of
X:
X = QR (6.12)
where Q is an orthogonal matrix (QTQ = I) of dimension (N × p), while R is an upper
triangular matrix of dimension (p× p). Without going into the details, these matrices are
obtained by recursive orthogonalisation of the inputs, leading to an orthonormal basis
for the column space of X.
The QR decomposition is used to transform model (4.1) in a simpler, more stable
triangular system. From (6.4) we have:
XTXβ = XTy (6.13)
then, substituting (6.12) in (6.13) we get:
RT QTQ︸ ︷︷ ︸
I
Rβ = RTQTy
Rβ = QTy
(6.14)
Using QR decomposition the OLS solution is given by:
βˆ = R−1QTy
yˆ = QQTy
(6.15)
The number of the estimated coefficients that are not zero is equal to the rank of
matrix X and the solution coincide to (6.5) and (6.6) if X has full column rank.
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6.3 Concluding Remarks
OLS is the most popular estimation method for linear regression models. The OLS
solution is mathematically achieved by minimizing the residual sum of squares. This loss
function has a quadratic form that allows to calculate the solution in a closed form in a
very efficient way.
All these advantages make OLS an attractive estimator for linear models. However,
it can lead to unsatisfactory results in several cases. First of all, the solution can
not be calculated, or could be calculated only with a small precision, when there is a
strong correlation between two, or more, inputs variables. In this case, the most common
solution is to remove the redundant variables. In addition, it may happen that a coefficient
associated with a variable results very large, while another coefficient (associated with
a variable correlated with the previous one) compensates it in the opposite direction
(canceling the first variable’s effect). As a consequence, the information carried by one
variable is deleted by the other.
7
Partial Least Squares (PLS)
As said in Chapter 4, algorithms for solving linear regression problems generally suffer
from overfitting when they deal with high-dimensional datasets. This is the case of the
OLS method described in Chapter 6.
In the following, we will present the PLS method and in Chapter 9, advantages and
drawbacks of PLS will be shown with a simple tutorial example. Finally, in Chapter 11,
PLS will be compared to the other identification techniques.
7.1 Mathematical Definition
In order to deal with overfitting, PLS regression technique discussed in this chapter
resorts to dimensionality reduction, i.e. it uses M (≤ p ) new regressors zk, calculated
from a linear combination of the p original ones, to model the target y (N × 1) as:
yˆ = Zθ +  (7.1)
where Z is a (N ×M) matrix, whose columns contain the so-called “latent variables” zk,
θ is the M dimensional vector of the related coefficients (which have to be estimated
along with the new regressors zk( and  is the error term (N × 1).
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7.1.1 Derivation of the PLS estimator
Part of this material can be referred to [116]. Consider an identification set consisting of
a reference vector y (N × 1), containing N samples of the target, and the corresponding
input matrix X (N×p), whose rows represent the input variables Xip, while each column
XjN contains all the samples referred to the j-th variable (see Section 4.1).
Since PLS is not scale invariant, i.e. the estimates depend on the scaling of the
inputs, before starting the construction of the M new regressors z1, z2,. . . , zM , the
input variables XjN have to be normalized, i.e. zero mean and unitary variance. To
avoid the introduction of a new symbol below, we assume that each input variable XjN
is normalized.
As mentioned before, PLS iteratively constructs a set of linear combinations of the
inputs, using both X and y. For this construction, the original inputs XjN are weighted
according to their univariate effect on y.
Since PLS is an iterative procedure in which the input variables XjN are updated at
every iteration, it is useful to add a superscript to the notation indicating the iteration
number. Hence, X
(k)
jN represent the j-th input variables at the k-th iteration and X
(0)
jN
correspond to the original input variables XjN . The same superscript is added to the
estimated target variable yˆ, as it is also updated at every iteration. In particular, at first,
yˆ equals the mean of the reference, represented using y¯ (yˆ(0) = y¯). Then, the estimate yˆ
is adjusted during each iteration, in which a new direction zk is constructed.
PLS begins by computing the correlation ϕˆ1j between the current input variables
X
(0)
jN and the reference y:
ϕˆ1j = X
(0)
jNy (7.2)
where, in the left side, the first value of the subscript of ϕˆ indicates the iteration, while
the second identifies the j-th variable.
Each current input variable X
(0)
jN is weighted by its corresponding correlation ϕˆ1j in
(7.2) to construct the first “derived” input z1 (N x 1):
z1 =
p∑
j=1
ϕˆ1jX
(0)
jN (7.3)
where z1 is called the first partial least squares direction. Subsequently, the reference y
is regressed on z1, obtaining the scalar coefficient θˆ1:
θˆ1 =
zT1 y
zT1 z1
(7.4)
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which is the OLS solution to the regression problem where y is the reference and z1 is
the (only) input variable (compare eq. (7.4) with eq. (6.5)).
The coefficient θˆ1 in (7.4) is used as the multiplier of z1 in (7.3) to update the
reference estimate yˆ:
yˆ(1) = yˆ(0) + θˆ1z1 (7.5)
Using the coefficient θˆ1, each current input variables x
(0)
jN is orthogonalized with
respect to z1, i.e. its contribution to z1 is subtracted from it:
X
(1)
jN = X
(0)
jN − γjz1 where γj =
zT1X
(0)
jN
zT1 z1
(7.6)
Then, the process continues until M ≤ p directions have been obtained.
Since the zk’s, with k = 1, 2, . . . ,M , are linear in the original inputs (see eq. (7.3)
and (7.6)), the reference estimate after M steps, yˆ(M), can be also computed as:
yˆ(M) = Xβˆ
PLS
(7.7)
recovering the coefficients βˆ
PLS
from the sequence of PLS transformation.
As for OLS, once the coefficients βˆ
PLS
are estimated from the training set, they can
be used in the linear model to predict unseen data through a linear combination of the
inputs. It is worth noting that, if M = p (i.e. the number of the PLS directions zk
equals the number of the original input XjN ), the PLS solution is equivalent to the that
of OLS.
7.1.2 Alternative implementation of PLS
Other algorithms have been developed allowing a direct estimation of the coefficients
βˆ
PLS
. Without going into details, it is worth mentioning the SIMPLS algorithm [123],
whose pseudo code for its derivation is depicted within box Algorithm 2, based on the
input approximation using score and loading matrices:
X = ZXTl +E (7.8)
In this case, Z is the (N ×M) matrix of the M extracted score vectors (PLS directions
zk), the (p ×M) matrix X l represents the matrix of loadings and E the matrix of
residuals. The approximation of the target is like in (7.1):
y = Zθ + e (7.9)
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load X, y {load data and standardize}
standardize X,y
yˆ(0) ← 0 {initialization}
X(0) ← X
for k = 1 to M do
ϕˆkj ← X(k−1)TjN y
zk ←
p∑
j=1
ϕˆkjX
(k−1)T
jN
θˆk ← z
T
k y
zTk zk
yˆ(k) ← yˆ(k−1) + θˆkzk
γj ←
zTkX
(k−1)
jN
zTk zk
X
(k+1)
jN ← X(k)jN − γjzk
Algorithm 2: PLS pseudocode.
The key of this algorithm is that it directly estimates a matrix of weights W ,
representing the relationship between the PLS direction in Z with the original matrix X:
XW = Z (7.10)
Then, substituting (7.10) into (7.9), one gets:
y = XWθ + e (7.11)
the approximation of the reference y is directly related to the original inputs X. Hence,
ignoring the contribution of the residual matrix e, the PLS reference estimate yˆ is
obtained as:
yˆ = XWθ (7.12)
By comparing (7.12) with (7.7), one gets:
βˆ
PLS
= Wθ (7.13)
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Hence, the matrix of weight W allows to calculate directly the estimation of the PLS
coefficients βˆ
PLS
, without recovering them from the sequence of PLS transformation
by a back tracking. In fact, W describes how to combine the coefficients of the new
regressors zk, contained in the matrix θ.
7.2 Properties of PLS
7.2.1 Statistical Properties
It can be shown that PLS seeks directions that have high variance and high correlation
with the response variable. Hence, the k-th PLS direction solves the problem:
max
α
corr2(y,Xα)var(Xα) (7.14)
with the two constraints:
‖α‖ = 1 (7.15)
αSϕˆl = 0 with l = 1, 2, . . . , k − 1 (7.16)
where S is the sample covariance matrix of XjN . The condition (7.16) ensures that the
next direction zk is uncorrelated with all the previous ones.
From (7.14), it can be observed that the first chosen PLS direction z1 coincides
with the particular vector that lies in the X space, represented using S, and makes a
compromise between its variation and its correlation with the response y. Similarly, from
(7.6) we can notice that the next space S(1), spanned by the updated input variables
X
(1)
jN , is the subspace of S orthogonal to the first PLS direction z1. As before, the
second PLS direction z2 is that maximising the (7.14) and lying in this subspace S
(1).
Successive directions zk’s are calculated in a similar manner, with the residual subspace
S(k−1) determined by removing from the space S, the space defined by the previous PLS
directions.
7.2.2 Geometrical Properties
Figure 7.1 shows the geometry of PLS. As mentioned in Section 6.2.2, the OLS estimates
yˆols showed as red dashed line in Figure 7.1, is the one minimizing the RSS while the
first principal component indicating the direction of maximum variance of the data in
X1 and X2 is indicated by the green dashed line togheter with the ellipses indicating
directions of the variance of the data. The PLS solution is a trade-off between OLS and
the principal components, represented as the value on the ellipse upon which OLS has
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the longest projection.
y
x2
x1
yols
||yols-Xβ||2
PC
ypls
Figure 7.1: Geometrical interpretation of PLS. Target vector y, estimation of target vector
by OLS yˆols (red dashed line), input vectors X1 and X2. The green dashed line represent
the first principal component and the magenta line the estimation by PLS.
7.3 Concluding Remarks
PLS is a regression technique based on dimensionality reduction, which uses M new
regressors, called PLS directions or latent variables, calculated from a linear combination
of the original input variables depending on their univariate influence on the target.
The PLS solution is iteratively obtained and at each iteration a new PLS direction is
estimated.
This technique for estimating linear models tries to avoid the OLS problem of
overfitting, building orthogonal PLS direction. A further feature of the PLS directions
is that they are estimated maximizing both their variance and the correlation with the
reference. In this way, the PLS directions try to include the informative components of
the original inputs, considering also their relationship with the reference. This may be an
advantage, since, as noticed from the examples, much less PLS directions are sufficient to
obtain similar or even better performance than OLS. PLS will be tested on the tutorial
example of Chapter 9 in order to give a general flavour of its features with respect to the
other techniques. Finally, PLS will be applied in Chapter 11 to NI-CGM Multisensor
data.
8
Regularization-Based Techniques: LASSO, Ridge
Regression and Elastic-Net (EN)
After having presented OLS and PLS, in this chapter we will cover regression techniques
that estimate the parameters of the multivariate linear model exploiting regularization.
As shown below in detail, these methods add a further term to the RSS cost function in
order to penalize complex models and avoid overfitting.
8.1 General Mathematical Definition
According to eq. (6.5) of the OLS estimation, the unknown coefficients of the linear
regression model of eq. (4.1) can be identified minimizing the RSS(β). To reduce the
risk of overfitting and numerical problems for the estimation of β, regularization based
techniques add a further term F (β) to the cost function, tipically putting a price on β in
order to discourage coefficients to become, in absolute value, too large, as it may happen
with OLS (see tutorial example of Chapter 9). Hence, the function to minimize turns
into:
L(β, λ) = RSS(β) + F (β, λ) (8.1)
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and the estimated coefficients are obtained as:
βˆ
REG
= arg min
β
(RSS(β) + F (β, λ)) (8.2)
As we will discuss in detail in the following sections, the term F (β, λ) can incorporate
`1 norm (Least Absolute Shrinkage and Selection Operator (LASSO), Section 8.2), `2
norm (Ridge regression, Section 8.3)) or a combination of the two (Elastic-Net, EN,
Section 8.4), whose effects are controlled by the scalar λ [116]. The parameter λ can be
thought as a parameter controlling the complexity of the model, since it prevents the
model coefficients from becoming too large. According to the regularization form of the
penalty term, different features will be induced on the estimated parameter vector βˆ.
8.2 l1 Norm Regularization (LASSO Regression)
The LASSO solution is found as:
βˆ
lasso
= arg min
β
RSS(β) + λ p∑
j=1
|βj |
 (8.3)
where, in the cost function, the coefficients of the multivariate model are penalized by
considering the sum of their absolute values (λ ≥ 0). Using eq. (6.1), eq. (8.3) becomes:
βˆ
lasso
= arg min
β
 N∑
i=1
yi − β0 − p∑
j=1
Xijβj
2 + λ p∑
j=1
|βj |
 (8.4)
By using Lagrangian multipliers [124], it can be shown that an equivalent way to
write problem (8.4) is as follows:
βˆ
lasso
= arg min
β
N∑
i=1
yi − β0 − p∑
j=1
Xijβj
2
subject to
p∑
j=1
|βj | ≤ t
(8.5)
where t is proportional to λ. Because of the nature of the constrains, making t sufficiently
small will cause some of the coefficients to be exactly zero, leading to a sparse solution.
Unfortunately, eq. (8.4) is not differentiable when β contains zero values. Hence,
a solution of (8.4) in closed form is not available and iterative methods are needed
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to compute an approximated solution. As a consequence, for computing the LASSO
solution, a wide variety of approaches have been proposed in the literature to solve such
a problem. In the next section, some algorithms for computing LASSO solution in an
efficient way will be briefly listed; in Section 8.2.2 particular attention will be given to the
Least Angle Regression (LAR) algorithm that will then be used to analyze the tutorial
example data in Chapter 9 and the Multisensor data in Chapter 11.
8.2.1 Numerical Methods for Computing LASSO Estimates
This subsection gives a brief overview of the numerical methods most currently used
in the literature for computing the LASSO solution. Then, in Section 8.2.2, we will
describe a modification of the LAR procedure for the LASSO implementation along with
its interpretation.
As mentioned above, a closed form solution for estimating the LASSO model is not
available, thus iterative techniques have to be considered based on Newton’s method [125].
These methods update the vector of coefficients β at each iteration using a descent
direction of the form:
βk+1 ← βk − α∇L(βk)/∇2L(βk) (8.6)
where the subscript k indicates the iteration.
Since the gradient ∇L(βk) does not exist if some coefficients βi are zero, different
strategies were proposed to solve this problem.
Sub-gradients based algorithms use sub-gradients of the function at non-differentiable
points [125] and can be classified in three different strategies, according to which variables
are optimized at every iteration: coordinate descent methods [126, 127], that optimize
over one variable at a time, active set methods [128, 129, 130], that optimize all the
non-zero variables at every iteration and orthant-wise descent methods [131], that are
similar to the previous but adds two projection operators.
Unconstrained approximation methods replace the minimization function L(β) with
a twice differentiable surrogate objective function, whose minimizer is sufficiently close to
the minimizer of L(β). The main advantage of this approach is that, since the replaced
function is twice differentiable, we can directly apply an unconstrained optimization
method to minimize the function. See for example [132, 133, 134] where the L1-norm
constrained is replaced with the multi-quadratic functions.
Constrained optimization methods re-formulate problem (8.4) as a differentiable one
with constraints. In this case, each variable βi is represented as the sum of two variables:
βi = β
+
i − β−i (8.7)
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where β+i ≥ 0 and β−i ≥ 0. In this formulation the absolute value function becomes:
|βi| = β+i + β−i (8.8)
An obvious drawback of this approach is that it doubles the number of variables in the
optimization problem. Different methods are based on this approach, for instance: log-
barrier [135], interior-point [136], projected Newton [137] and two-metric projection [138].
8.2.2 LAR Method for Computing LASSO Solution
LAR is an iterative method intimately connected with LASSO. In fact it provides an
extremely efficient algorithm for computing the entire LASSO path, i.e. the behaviour of
the coefficients β for different values of the complexity parameter.
8.2.2.1 The LAR procedure
The LAR algorithm has been developed as a model selection algorithm [139]. It is useful
to define the active set Ak (of dimension m) as the set of the non-zero coefficients at the
k-th step. When Ak is used as a subscript for a matrix or a vector, it selects the values
connected to the active variables at the k-th step. Hence, XAk is the sub-matrix of X
composed by the active variables and βAk is the coefficient vector for these variables. To
simplify the notation, the subscript k will be dropped, if it is clear that we are referring
to the k-th step.
The LAR solution is computed following these steps:
1. set all the coefficients βi to zero;
2. choose the variable XjN most correlated with the reference y;
3. move the correspondent coefficient βj from zero towards its OLS value β
ols
j (in this
way the correlation of the variable XjN with the current residual r = y −XjNβj
decreases);
4. continue the process until another variable X lN has as much correlation with the
current residual as XjN has;
5. add variable X lN to the active set Ak;
6. move the coefficients βAk towards their OLS values, in such a way that their
correlation with the current residual r = y −XAkβAk continues to be the same;
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7. repeat steps 4-6 until Ak has reached the desired dimension or until all the variables
have been included to Ak (in this case the OLS solution is obtained).
Figure 8.1 shows an example of the progression of the absolute correlations during
each step of the LAR procedure. The labels at the top of the plot indicate which variable
enters the active set at each step.
3.4 S rinkage Methods 75
0 5 10 15
0.
0
0.
1
0.
2
0.
3
0.
4
v2 v6 v4 v5 v3 v1
PSfrag replacements
L1 Arc Length
A
b
so
lu
te
C
or
re
la
ti
o
n
s
FIGURE 3.14. Progression of the absolute correlations during each step of the
LAR procedure, using a simulated data set with six predictors. The labels at the
top of the plot indicate which variables enter the active set at each step. The step
length are measured in units of L1 arc length.
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FIGURE 3.15. Left panel shows the LAR coefficient profiles on the simulated
data, as a function of the L1 arc length. The right panel shows the Lasso profile.
They are identical until the dark-blue coefficient crosses zero at an arc length of
about 18.
Figure 8.1: Progression of the absolute correlations during each step of the LAR
procedure [116].
By construction, the coefficients βjs in the LAR algorithm change in a piecewise linear
fashion. Note that we do not need to take small steps and re-check the correlation in
step 4. In fact, using the knowledge of the covariance of the predictors and the piecewise
linearity of the algorithm, the exact step length can be calculated at the beginning of
each step.
8.2.2.2 The LAR Implementation
Having intr duced the guidelines of the LAR algorithm, we can now go into its mathe-
matical details. First of all, let us define some useful notation. XsA is the same as XAk ,
but each regressor is multiplied by the sign sj of its correlation with the current residual
r:
XsA =
[
. . . sjXjN . . .
]
(8.9)
where XjN ∈ Ak. For simplicity, let’s define GA (m×m) as:
GA = XTsAXsA (8.10)
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and the scalar AA as:
AA =
(
1TAGA1A
)−1/2
(8.11)
where 1A (m x 1) is a column vector of ones.
Since the LAR procedure is not scale invariant, data have to be normalized before
starting the iterative procedure. Hence, the initial target estimation yˆ0 is set to zero.
Let yˆk the current target estimation at the k-th step, the current correlation c (m× 1)
of the predictors with the current residual can be written as:
c = XT (y − yˆk) (8.12)
The current active set Ak includes all the variables, whose absolute correlation correspond
to the maximum of all the absolute correlations Cmax:
Ak = {j : |cj | = Cmax} where Cmax = maxj {|cj |} (8.13)
The solution at the next step is updated as follows:
yˆk+1 = yˆk + γuA (8.14)
where uA is a versor (‖uA‖ = 1) defining the direction to which the current target
estimation yˆk is moved. This direction is calculated in such a way that the correlation of
each active variables with the current residual vector equals the correlation of the other
active variables. The versor uA is calculated as follows:
uA = XsAwA where wA = AAG−1A 1A (m x 1) (8.15)
and, since it is an equiangular vector, it enjoys this property:
XTsAuA = AA1A (8.16)
Instead, the coefficients are updated as follows:
βˆk+1 = βˆk + γdA (8.17)
where dA (m x 1) is the vector equaling sjwAj for j ∈ Ak (note the connection with the
versor uA in (8.15) ) and zero elsewhere.
As said before, γ can be exactly computed as to update the variables to the point in
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which another variable enters the active set. In particular, γ is calculated as follows:
γ = min
j∈Ac
+
{
Cmax − cj
AA − aj ,
Cmax + cj
AA + aj
}
where aj = X
T
jNuA (8.18)
where min+ indicates the minimum between the positive values, being γ > 0.
The explanation of (8.18) is obtained by comparing the current correlation of a
variable that is not in the active set with the correlation of the active variables. In
particular, the current correlation of the j-th variable is:
cj(γ) = X
T
jN (y − yˆk+1) (8.19)
then, substituting (8.14) in (8.19) one gets:
cj(γ) = X
T
jN (y − yˆk − γuA) (8.20)
which using (8.12) and (8.18), becomes:
cj(γ) = cj − γaj (8.21)
If the absolute value of (8.21) is referred to an active set variable, using (8.13) and (8.16),
it becomes:
|cj(γ)| = Cmax − γAA (8.22)
then, equalling (8.21) with (8.22) one gets:{
Cmax − γAA = cj − γaj
−Cmax + γAA = cj − γaj
(8.23)
Solving the set of equations in (8.23) for γ, one obtains the values of γ for which the
correlation of a variable that is not in the active set equals the correlation of the active
variables. Since we search the minimum positive value of γ, corresponding to the step of
the first non active variable equalling the correlation of the active ones, we finally get the
(8.18).
8.2.2.3 LAR vs. LASSO
In Figure 8.2 the coefficient profiles are plotted as model complexity increases for both
LAR (left) and LASSO (right). It can be noticed that the profiles are similar to each
other, except when a non-zero variable hits zero (highlighted by a red circle in Figure 8.2).
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In fact, a small modification in LAR procedure allows implementing the LASSO path.
The modification is the following: if a non-zero coefficient hits zero the corresponding
variable is dropped from the active set and the current joint least squares direction
recomputed. Below we explain why LAR and LASSO are so similar.
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FIGURE 3.14. Progression of the absolute correlations during each step of the
LAR procedure, using a simulated data set with six predictors. The labels at the
top f the plot indicate which v riables enter the active set at each step. The step
length are measured in units of L1 arc length.
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FIGURE 3.15. Left panel shows the LAR coefficient profiles on the simulated
data, as a function of the L1 arc length. The right panel shows the Lasso profile.
They are identical until the dark-blue coefficient crosses zero at an arc length of
about 18.
Figure 8.2: Left : LAR coefficie ts pr file as the model complexity increases. R ght : LASSO
coeffi ients profile as the model complexity i creases [116].
The correlation of an active set variable with the current residual can be expressed as:
XTjp(y −Xβ) = γsj ∀j ∈ Ak (8.24)
where sj ∈ {−1, 1} indicates the sign of the correlation and γ is the absolute value of the
correlation.
Since the non-active variables are less correlated to the current residual than the
active variables, we can write:
∣∣XTlp(y −Xβ)∣∣ ≤ γ ∀k /∈ Ak (8.25)
The LASSO minimisation function:
L(β) =
1
2
‖y −Xβ‖2 + λ |β| (8.26)
is differentiable for the active variables. For these variables the stationarity conditions
(first derivative set to zero) are:
XTjp(y −Xβ) = λsgn(βj) ∀j ∈ Ak (8.27)
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which corresponds to (8.24) if the sign of the correlation sj matches the sign of the
coefficients βj . That is why the LAR algorithm and the LASSO start to differ when an
active coefficient passes through zero. The LASSO condition (8.26) is violated for that
variable, which is, thus, kicked out of the active set.
Finally, the stationarity conditions for the non-active variables are:
∣∣XTlp(y −Xβ)∣∣ ≤ γ ∀k /∈ Ak (8.28)
which corresponds to the LAR equation (8.25).
8.2.2.4 LASSO Implementation by LAR modification
load X, y
normalize X, y
yˆ0 ← 0;
βˆ0 ← 0;
c← XT y;
Cmax ← max(c);
j ← find(c = Cmax);
A← xj
while active variables< p do
a = XTuA
γ = min
l∈Ac
+
{
Cmax − cl
AA − al ,
Cmax + cl
AA + al
}
(associated with Xl)
γ˜ = minj(−βˆk/dA)
if γ˜ < γ then
γ = γ˜;
yˆk+1 = yˆk + γuA
βˆk+1 = βˆk + γdA
Cmax = Cmax − γAA
if γ˜ < γ then
drop Xj from A
A← Xl
update uA, dA and AA
c = XT (y − yˆk+1);
Algorithm 3: LASSO pseudocode.
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The only modification of the LAR procedure needed for implementing LASSO is a
check of the γ value calculated in (8.18) [139]. In fact, we have to make sure that during
the LAR step none of the coefficients β changes its sign. In particular, starting from the
updating of the coefficients in (8.18), here reported:
βˆk+1 = βˆk + γdA
a βj will change sign at:
γj = − βˆj
dj
(8.29)
The first change occurs at:
γ˜ = min
γj>0
{γj} (8.30)
corresponding to the j-th variable.
Hence, if γ˜ > γ calculated in (8.18), no sign change will occur and the LAR step does
not violate any LASSO condition. Contrarily, if in (8.18) γ˜ ≤ γ , the updated coefficients
βˆk+1 cannot be a LASSO solution. To avoid this, the LAR step is not completed, but it
is stopped at γ˜ = γ . Then, the j˜-th variable is removed from the active set and a new
equiangular direction in (8.15) is calculated.
The LASSO path can be estimated using the LAR modification. It can be implemented
by the pseudo-code in the box Algorithm 3 (the updates of uA, dA and AA have not
been reported).
8.2.3 Properties of LASSO
8.2.3.1 Geometrical Properties
As for OLS in Chapter 6, we now consider the case of two different input variables X1
and X2 [139], as can be seen from Figure 8.3. LAR builds up the estimates in successive
steps, each step adding one variable to the model, according to the value of its correlation
with the target variable. In the case of two input variables, the current correlations c
depend only on the projection y¯ of y into the plane spanned by X1 and X2:
c = XTy = XT y¯ (8.31)
As shown in Figure 8.3, y¯ makes a smaller angle with X1 than with X2, that corresponds
to a greater correlation with X1 than with X2. Hence, the variable X1 enters the active
set (step 2) and the solution moves in direction of X1, indicated in Figure 8.3 by the
equiangular unit vector u1 (step 3-eq. (8.15)). Representing the moving solution of this
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first iteration with ~y1, the current correlations c with the current residual becomes:
c = XT (y¯ − ~y1) (8.32)
From the Figure 8.3, we can see that the correlation of X1 with the current residual
decreases. This process stops when the current residual is equally correlated with X1 and
X2 (step 4), that happens when the residual vector (y¯ − ~y1) bisects the angle between
X1 and X2. Hence, the variable X2 is added to the active set (step 5). Now the solution
moves in such a direction as to keep equal the two correlations (step 6). This direction is
represented in Figure 8.3 by the equiangular unit vector u2 (eq. (8.15)), that corresponds
to the bisector of the two vectors X1 and X2. In this case all the variables were added
to the active set; hence, at the next iteration, the OLS solution is reached. Note that the
OLS solution corresponds to y¯ (Section 6.2.2). In the general case, subsequent iterations
are taken along equiangular vectors, generalizing the concept of the bisector u2.
X2 X2
0 u1
u2
y1 X1
y
Figure 8.3: Geometrical interpretation of LASSO solution using LAR modification.
Projection of the target vector y¯, input vectors X1 and X2 . Versor u1 and u2 indicating
the equiangular vectors. Adapted from [139].
8.2.3.2 Sparse Solution
As said in the Section 8.2, the regularisation term added to RSS yielded to a sparse
solution. In this Section it will be described the reason why such a constraint lead to a
sparse solution, using, for simplicity, the same example of two input variables X1 and
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X2.
From (8.5) the constraint region defined by LASSO is:
|β1|+ |β2| ≤ t (8.33)
which is represented by a diamond area in the Cartesian space of the coefficients (blue
region in Figure 8.4). As a consequence, all the possible solutions of LASSO lie in this
region.
Plotting in the same Cartesian space the OLS solution (βˆ in Figure 8.4), we can see
how the OLS estimates, minimizing the RSS, fall in the center of the elliptical contours
which represent the RSS behaviour for different estimates of β.
β^2β
β1
Figure 8.4: Interpretation of the sparse solution of LASSO. βˆ represents the OLS solution,
the red ellipses are the contours of the residual sum of squares and the blue areas correspond
to the constraint region |β1|+ |β2| ≤ t (taken from [116]).
The LASSO solution is the first point where the elliptical contour hits the constraint
region. Since the diamond region presents corners, it is probable that the solution occurs
at a corner. In this case, one coefficient is exactly zero, in particular β1 in Figure 8.4. In
addition, when there are more predictors, the diamond becomes a rhomboid, and has
many more corners and flat edges. As a consequence, there are many more opportunities
for the estimated parameters to be zero.
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8.3 l2 Norm Regularization (Ridge Regression)
Ridge regression, from now on “Ridge”, is a technique for the estimation of the parameter
vector βˆ
ridge
. It is defined as the value of βˆ that minimizes a cost function given by RSS
plus a regularization term given by the sum of the squares of the coefficients weighted by
a parameter λ controlling model complexity [116]:
βˆ
ridge
= arg min
β
 N∑
i=1
yi − β0 − p∑
j=1
Xijβj
2 + λ p∑
j=1
β2j
 . (8.34)
Problem (8.34) can also be formulated as a constrained optimization problem, as
happened for LASSO:
βˆ
ridge
= arg min
β
N∑
i=1
yi − β0 − p∑
j=1
Xijβj
2
subject to
p∑
j=1
β2j ≤ t
(8.35)
where t is, as in eq. (8.5), inversely proportional to λ.
λ (≥ 0) is the complexity parameter that control the amount of shrinkage. The
larger its value, the greater the amount of shrinkage. The problem formulated as in
(8.35) makes explicit constraint on the size of the parameters. In the case of correlated
variables in the linear regression model, a large positive coefficient on one variable can be
canceled by a similar large negative coefficient on a correlated predictor. As happened for
LASSO, imposing a size constraint on the coefficients alleviates the problem. Since Ridge
regression is not equivariant under scaling of the inputs, the predictors are centered and
scaled (also to be uniform with the other identification methods).
8.3.1 Definition of Ridge Regression
Equation (8.34) is continuous and derivable thus the Ridge model, βˆ
ridge
, has a closed
form solution that can be obtained by setting to zero the derivative of eq. (8.34). Recalling
the function L(λ,β) = RSS(β) + λβTβ, we have:
∂L(λ,β)
∂β
= −2XT (y −Xβ) + λβ (8.36)
−XT (y −Xβ) + λβ = 0 (8.37)
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By rearranging 8.37, we obtain the estimate of the model parameter vector:
βˆ
ridge
= (XTX + λIp×p)−1XTy (8.38)
where Ip×p is the p× p identity matrix. The solution adds a positive constant (λ) to
the diagonal of XTX before inversion. Thus, even if XTX is not full rank, the matrix
in eq. (8.38) is invertible.
To estimate the complexity parameter λ, the prediction error is plotted against the
degree of freedom (df), a quantity given by:
df(λ) = tr[X(XTX + λI)−1XT ] =
p∑
j=1
d2j
d2j + λ
(8.39)
representing the effective degrees of freedom of the ridge regression fit. Usually, the
degrees of freedom in a linear regression are given by the number of free parameters.
However, since all the p coefficients will be non-zero, a measure of the complexity is
given in term of λ through eq. (8.39), where dj (d1 ≥ d2 ≥ · · · ≥ dp ≥ 0) are the singular
values of X.
The Ridge estimator can be implemented by the pseudo-code depicted in box Algo-
rithm 4. In this case, a Cholesky factorization was used to invert the (XTX+λI) matrix,
creating an upper triangular matrix R, satisfying the equation RTR = XTX + λI.
load X, y
normalize X, y
βˆridge ← inv(XTX + λI)XT y;
(or using a Cholesky decomposition)
R← chol(XTX + λI)
βˆridge ← R\(RT \(XT y));
yˆ ← Xβˆridge
Algorithm 4: Ridge pseudocode.
8.3.2 Properties of Ridge Regression
A comparison between Ridge and LASSO constraints may help to understand the features
of the two methods. Referring to eq. (8.40), the constraint region defined by Ridge
Regression is a disk area in the Cartesian space of the coefficients (blue region in Figure
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8.5):
β21 + β
2
2 ≤ t (8.40)
Since in this case the disk has no corners, there is a lower probability for one coefficient
collected within βˆ
ridge
to be exactly zero. Thus, the `2 norm shrink the model coefficients
but does not induce sparseness properties as the `1 norm does for the LASSO.
β^
1
β2
β
Figure 8.5: Ridge Regression regularised solution. As in 8.4, but here the blue area
corresponds to the constraint β21 + β
2
2 ≤ t (taken from [116]).
8.4 `1 + `2 Norm Regularization: Elastic-Net (EN)
Regression
Considering the usual linear regression model in the form y = Xβ + v, the estimation of
the parameter vector can be obtained minimizing a cost function given by RSS plus a
regularization term given by the combination of the `1 and `2 norms [140].
8.4.1 Definition of Elastic-Net Regression
The term F (β, λ) of the cost function in (8.1) includes two terms [140]:
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F (λ1, λ2) = λ1
p∑
j=1
|βj |+ λ2
p∑
j=1
β2j (8.41)
where λ1 and λ2 represent the two complexity non-negative parameters weighting the
two norms. The Elastic-Net (EN) estimator is defined as:
βˆ
en
= arg min
β
 N∑
i=1
yi − β0 − p∑
j=1
Xijβj
2 + λ1 p∑
j=1
|βj |+ λ2
p∑
j=1
β2j
 (8.42)
An alternative representation of the EN cost function is given by:
L(β, λ, α) =
1
2
N∑
i=1
yi − p∑
j=1
Xijβj
2 + λ p∑
j=1
(
α|βj |+ 1
2
(1− α)β2j
)
(8.43)
The cost function (8.43) introduces some scaling factors (1/2) that will be useful in the
following ( see Section 8.4.3.2). With this new representation, α weighs the contribution
of the two norms, while λ measures the trade-off between adherence to the data and
model complexity.
8.4.2 Properties of EN
In order to understand some of the EN estimator properties, it is useful to consider the
geometrical interpretation of this estimator [116], as was done for LASSO and Ridge in
Section 8.2 and 8.3 respectively. The constraint region defined by the combination of
the `1 and `2 norms with the parameterization defined in 8.43 can be represented as a
contour area, presenting sharp, thus non-differentiable corners, given by the presence
of the `1 norm. This suggests a possible explanation for the properties related to the
EN estimator, that share both properties of sparseness induced by the `1 norm, and a
grouping effect among correlated variables given by the `2 norm.
The parameterization defined in eq. (8.43) states, even more clearly than eq. (8.42),
the trade-off between Ridge and LASSO. By anticipating some properties that will be
more clear analyzing the tutorial example and the application to the multi-sensor data,
EN tends to average input variables highly correlated and then entering the average
contribution into the model, providing a grouping effect.
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q = 1.2 α = 0.2
Lq Elastic Net
FIGURE 3.13. Contours of constant value of
P
j |βj |q for q = 1.2 (left plot),
and the elastic-net penalty
P
j(αβ
2
j+(1−α)|βj |) for α = 0.2 (right plot). Although
visually very similar, the elastic-net has sharp (non-differentiable) corners, while
the q = 1.2 penalty does not.
setting coefficients exactly to zero. Partly for this reason as well as for
computational tractability, Zou and Hastie (2005) introduced the elastic-
net penalty
λ
p∑
j=1
(
αβ2j + (1− α)|βj |
)
, (3.54)
a different compromise between ridge and lasso. Figure 3.13 compares the
Lq penalty with q = 1.2 and the elastic-net penalty with α = 0.2; it is
hard to detect the difference by eye. The elastic-net selects variables like
the lasso, and shrinks together the coefficients of correlated predictors like
ridge. It also has considerable computational advantages over the Lq penal-
ties. We discuss the elastic-net further in Section 18.4.
3.4.4 Least Angle Regression
Least angle regression (LAR) is a relative newcomer (Efron et al., 2004),
and can be viewed as a kind of “democratic” version of forward stepwise
regression (Section 3.3.2). As we will see, LAR is intimately connected
with the lasso, and in fact provides an extremely efficient algorithm for
computing the entire lasso path as in Figure 3.10.
Forward stepwise regression builds a model sequentially, adding one vari-
able at a time. At each step, it identifies the best variable to include in the
active set, and then updates the least squares fit to include all the active
variables.
Least angle regression uses a similar strategy, but only enters “as much”
of a predictor as it deserves. At the first step it identifies the variable
most correlated with the response. Rather than fit this variable completely,
LAR moves the coefficient of this variable continuously toward its least-
squares value (causing its correlation with the evolving residual to decrease
in absolute value). As soon as another variable “catches up” in terms of
correlation with the residual, the process is paused. The second variable
then joins the active set, and their coefficients are moved together in a way
that keeps their correlations tied and decreasing. This process is continued
Figure 8.6: Contour of the EN penalty norm given by eq. (8.43) for α = 0.2, presenting
sharp on-differentiable corners (although not easily visible) (taken from [116]).
8.4.3 Numerical Methods for Computing EN Estimates
The EN solution can be obtained thought different approaches whose derivation depends
on the form of the cost function.
8.4.3.1 LAR-EN
The LAR-EN algorithm for computing the EN solution resorts to the same algorithm
proposed in Section 8.2.2 for solving the LASSO problem and is based on the cost function
defined as in eq. (8.42) where λ1 and λ2 independently weigh the two norms. More in
detail, he a gorithm exploits the LAR proc dure for solving the regularization problem
with the `1 norm (as for the LASSO), but considers an augmented data set in order to
artificially take into account the `2 norm effect. Let’s consider α = λ2/(λ1 + λ2), then
solving eq. (8.42) is equivalent to solve the following optimization problem:
βˆ
en
= arg min
β
N∑
i=1
yi − β0 − p∑
j=1
Xijβj
2
subject to α
p∑
j=1
β2j + (1− α)
p∑
j=1
|βj | ≤ t
(8.44)
Eq. (8.44) is the EN penalty which is a convex combination of the LASSO and ridge
penalties. For α ∈ [0, 1) the EN penalty is ing lar (without first derivative) at 0 and is
strictly convex for all α > 0. We define an artificial data set (y∗,X∗) from the original
one and the couple (λ1, λ2):
X∗(N+p)×p = (1 + λ2)−1/2
(
X√
λ2I
)
,y∗(N+p) =
(
y
0
)
(8.45)
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Let γ = λ1
√
1 + λ2 and β
∗ =
√
1 + λ2β, the EN criterion can be written as:
L(γ,β∗) = L(γ,β∗) =
N+p∑
i=1
yi − β0 − p∑
j=1
Xijβj
2 + γ p∑
j=1
|βj | (8.46)
In this way, we have transformed the EN problem into an equivalent LASSO problem on
augmented data:
βˆ∗ = arg min
β∗
L(γ,β∗) (8.47)
with the solution to the original problem given by:
βˆ
en
=
1√
(1 + λ2)
βˆ∗ (8.48)
Empirical evidence [140] showed that the estimator (8.48) does not perform satisfac-
torily unless it is close to either ridge or the LASSO. Indeed, the βˆ
en
in eq. (8.48) is
referred to as na¨ıve EN because it performs a double shrinkage that does not help to
reduce the variance much and introduces extra bias compared with pure LASSO or Ridge.
This is because the na¨ıve EN solution βˆ is a two stage procedure: the Ridge regression
coefficients are first obtained fixing λ2; then, the LASSO-type problem is solved. The EN
(corrected) estimate of the parameter vector βˆ
en
is defined as βˆ
en
=
√
1 + λ2βˆ
∗ where
βˆ∗ is defined in (8.47). Rearranging and substituting in eq. (8.48) we obtain:
βˆ
en
= (1 + λ2)βˆ
old−en
(8.49)
This scaling preserves the variable selection property of the na¨ıve EN and is the simplest
way to undo the unnecessary shrinkage mentioned above.
To calculate the LASSO-step solution for the problem (8.46), the LAR algorithm used
in Section 8.2.2 can be used on an augmented data set for fixed λ2. In particular, the
step described in (8.10) now consists in calculating GAk = X
∗T
Ak
X∗Ak that, substituted
with (8.45), becomes (at the k-th iteration):
GA =
1
1 + λ2
(
XTAXA + λ2I
)
(8.50)
8.4.3.2 Cyclical Coordinate Descent
Cyclical coordinate descent methods have been proposed several times for solving the
LASSO problem [141, 125]. They belong to the family of sub-gradients strategies that use
sub-gradients of the objective function to minimize at non-differentiable points, namely
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load X, y
normalize X, y
βˆenold = 0
while true do
for k = 1, ..., p do
rik = yi −
∑p
j=1
j 6=k
Xij β˜j
β˜∗k =
∑N
i=1Xikrik
βˆk ← S(β˜
∗
k ,λα)
1+λ(1−α)
if βˆ = βˆenold then
βˆen = βˆ
break
else
βˆenold = βˆ
yˆ ← Xβˆen
Algorithm 5: Pseudo-code of the cyclical coordinate descent method for computing the EN
solution.
where there is a |βj | equal zero. The same strategy can be used to optimize the EN cost
function 8.42, given the presence of the `1 term. In particular, these methods are very
simple because they optimize over one variable βj at the time, applying a soft-thresholding
operator to deal with the non-differentiability points, as widely discussed by Friedman
at al. [142] and Van der Kooij [143]. In practice, the following steps are repeated for
j = 1, 2, k, ..., p, 1, ... until convergence is reached, i.e. coefficients stabilize:
1. a coefficient of the multivariate linear regression model is chosen, for example βk
2. the coefficient βk is updated, with the remaining coefficients fixed
Empirical evidence showed that starting with any values for βk, the sequence converge to
the true solution [141].
The coordinate descent step for solving (8.43) is obtained computing the gradient
at βk = β˜k for βk > 0, assuming to have estimates of β˜j for j 6= k. Thus, partially
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optimizing with respect to βk:
∂L(β, λ, α)
∂βk
∣∣∣∣
β=β˜
= −
N∑
i=1
Xik
yi − p∑
j=1
j 6=k
Xij β˜j −Xikβk
+ λ(1− α)βk + λα (8.51)
where the sum has been broken down to isolate the contribution of the βk coefficient. The
quantity y˜
(k)
i =
∑
j 6=kXij β˜j is the value fitted by the model excluding the contribution
of Xik, so:
yi − y˜(k)i = yi − yˆi +Xikβ˜k
= rik +Xikβ˜k (8.52)
where yˆi is the current fit of the model for observation i, and rik the current residual.
The quantity yi − y˜(k)i represents the partial residual for fitting βk. Moreover, because
of the standardization of the predictors, the first term on the right hand side of (8.51)
becomes:
N∑
i=1
Xik
yi − p∑
j=1
j 6=k
Xij β˜j −Xikβk
 = N∑
i=1
Xik(yi − y˜(k)i ) =
N∑
i=1
Xikrik + β˜k (8.53)
thus, the update of the coefficient β˜k can be obtained setting the gradient of the cost
function to zero and rearranging:
β˜k ←
S
(∑N
i=1Xik(yi − y˜(k)i ), λα
)
1 + λ(1− α) (8.54)
where the operator S(·) indicates the soft-thresholding operator as pointed out in [144],
that showed how the solution of a problem involving `1 norm is a soft-thresholded version
of the least squares estimate:
sign(z)(|z| − γ)+ =

z − γ if z > 0 and γ < |z|
z + γ if z < 0 and γ < |z|
0 if γ ≥ |z|
(8.55)
In practice, from the k-th coefficient calculated by least-squares on the partial
residuals (β˜k), the operator S(·) subtracts λα and, if it hits zero, then β˜k = 0, otherwise
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the coefficient is shrunk by an amount λα.
The EN solution can be obtained implementing the algorithm described in the
previous section which is based on cyclical updates of single coefficients of the parameter
vector β till they stabilize or reach convergence. In the pseudo code of box Algorithm
5, the algorithmic procedure for deriving the EN solution is presented. Notice that the
coordinate descent algorithm can be used for computing the LASSO solution, in the
same way the LAR-EN can be used to identify the EN model. The only modification
consists in the scaling factor in eq. (8.54), as discussed in [141].
8.5 Concluding Remarks
This chapter presented different techniques for the estimation of multivariate linear
regression models based on regularization. In particular, the models are estimated
by minimizing a cost function given by the sum of the RSS plus a term controlling
complexity, penalizing complex models. This additional term can have different forms.
For example, considering the `2 norm, the sum of squares of the coefficients of the
parameter vector β will be penalized, while if the `1 norm is considered, the sum of the
coefficient absolute values will be penalized. A combination of the two norms can also be
used as regularization cost function, providing the so called EN model. Depending on
the form of the regularization term considered, the identified model will have different
features, as shown in the tutorial example of Chapter 9.
The sparseness properties of the LASSO model, identified with a modified LAR based
algorithm, avoid the cancellation effect of correlated predictors occurring with OLS, by
choosing only one important variable and discarding the others. Ridge regression has
a closed form solution, in the opposite of LASSO, and tends to keep all the predictors
but with smaller coefficients with respect to the LASSO model. Thus, similarly to what
happens with PLS, the Ridge model estimates the output taking information potentially
from the whole set of predictors. Finally, EN represents a trade-off between LASSO and
Ridge, obtained with a combination of the two norms. This feature allows to retain the
benefits derived from the use of both norms, shrinking many channel weights to zero and,
at the same time, averaging those predictors with non-zero weights inducing a grouping
effect.
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9
Tutorial Example
While the scope of the present thesis concerns the application of the 5 parameter
identification techniques discussed in Chapters 6-8 to NI-CGM Multisensor data, it is
useful to first present a “tutorial” literature example that will help us to gain some
confidence with the methods and highlight their and potential pros and cons.
9.1 Data Set
The data for this example is taken from a study concerning prostate cancer [145] by
Stamey et al., 1989. They examine the correlation between height clinical measures and
a target variable defined as the logarithm of the prostate-specific antigen (lpsa). The
height variables are: log(cancer volume) (lcavol), log(prostate weight)(lweight), age, the
logarithm of the amount of benign prostatic hyperplasia (lbph), seminal vescicle invasion
(svi), log(capsular penetration) (lcp), Gleason score (Gleason) and percentage Gleason
score 4 or 5 (pgg45). To model this connection, samples referred to 97 different subjects
are available.
The data have been split in two data subsets: one is the identification set consisting
of 67 subjects, which is used to identify the parameters of the model and the other is
used to estimate the prediction error, the so called test set, consisting of 30 subjects.
With reference to the linear model of eq. (4.1), here our target vector y is the measure
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of “prostate-specific antigen”:
y =

lpsa(1)
lpsa(2)
...
lpsa(97)

dp
while the clinical measures, defined above represent our input variables XjN , which are
collected within the matrix X:
X =

lcavol(1) lweight(1) | age(1) | lbph(1) . . . pgg45(1)
lcavol(2) lweight(2) | age(2) | lbph(2) . . . pgg45(2)
...
... | ... | ... ...
lcavol(67) lweight(67)|age(67)|lbph(67) . . . pgg45(67)

⇒ subject 1
⇒ subject 2
⇒subject 67
⇓
age
Thus each column of the matrix X contains one of the height input variables, while
the rows correspond to 67 samples referred to different subjects.
Our aim is to determine the coefficients vector β that describes the influence of the
clinical variables upon the “prostate-specific antigen” target. Since the identification
data have been standardised (mean=0 and standard deviation=1), the offset parameter
β0 can be dropped and the unknown vector β has dimension height:
β =

β1
β2
...
β8

First of all it can be useful to calculate the correlation between the different input
variables.
From Table 9.1 it can be seen that lcp and pgg45 are two of the most correlated
variables, which is also confirmed by a visual inspection of Figure 9.1.
Before using the data for model identification and model test, a pre-processing is
performed standardizing X and y. This is done for allowing a direct comparison of the
estimated coefficients for the different models, since the methods controlling complexity,
i.e. PLS, LASSO, Ridge and EN, are not scale invariant. This introduction of the data
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lweight age lbph svi lcp gleason pgg45
lcavol 0.3002 0.2863 0.0632 0.5929 0.6920 0.4264 0.4832
lweight - 0.3167 0.4370 0.1811 0.1568 0.236 0.0742
age - - 0.2873 0.1289 0.1730 0.3659 0.2758
lbph - - - -0.1391 -0.0885 0.033 -0.0304
svi - - - - 0.6712 0.3069 0.4814
lcp - - - - - 0.4764 0.6625
gleason - - - - - - 0.7571
Table 9.1: Correlation between the different input variables, with highlighted the most
elevated correlations.
set and of its features will turn out to be useful in the following sections to show pros
and cons of the different identification techniques.
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Figure 9.1: Plot of two of the most correlated variables lcp(blue) and pcc45 (green).
9.2 Cross-Validation for Model Complexity Estimation
The methods controlling complexity require the estimation of the complexity parameter(s)
before identifying the coefficients of the model on the identification data set. Figure
9.2 shows in each subplot the error curve for each method estimated by means of the
cross-validation procedure described in Chapter 5. The test error curve is estimated
using 8-fold cross-validation. The identification data are randomly split into 8 parts of
approximately equal size. Iteratively, one part is left aside to calculate the test error
(using MSE), while the other 7 parts are used to “estimate” the coefficients of the model.
In this way a test error upon each of the 8-th parts not used for identify the models
is calculated and, averaging these values, an estimation of the test error is obtained.
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The model complexity is selected using the “one-standard error” rule (Section 5.2.2),
which indicates the best model as the most parsimonious one, whose error is less then
the minimum plus one time its standard deviation.
For PLS, the selected model correspond to the minimum value of the test error curve
at seven directions. However, as mentioned in Section 5.2.2, the complexity parameter
can be chosen as the one where there is a clear drop in the error curve. In our case, the
value of M can be set to 3. Similar considerations can be done for LASSO, Ridge and
EN.
1 2 3 4 5 6 7 80.2
0.3
0.4
0.5
0.6
0.7
0.8
ms
e
# Latent Variables
(a) PLS
1 2 3 4 5 6 7 80.2
0.25
0.3
0.35
0.4
0.45
0.5
0.55
0.6
0.65
# Active Variables
m
se
(b) LASSO
0 0.5 1 1.5 2 2.50.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
ms
e
log(df(λ))
log(df(λ))=1.2=>λ=60
(c) Ridge
−7 −6 −5 −4 −3 −2 −1 00.2
0.4
0.6
0.8
1
1.2
ms
e
log(λ)
λ=0.05
(d) EN
Figure 9.2: 8-fold Cross-validation curves for the choice of the most reasonable complexity
parameters for PLS (a), LASSO (b), Ridge (c) and EN for α = 0.8 (d). The MSE (mean value
and one standard deviation) is represented as a function of the model complexity parameter
for each method. The green cross represents the value of the complexity parameter according
to the “one-standard error” rule (green dotted line), while the most reasonable complexity is
chosen in correspondence of the drop of the error curve and displayed as a red cross..
In particular, for LASSO, the test error curve is plotted as a function of the number
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of active variables, instead of λ. However, the number of the active variables is intuitively
connected to the model complexity, but also to the degrees of freedom of the model (see
[146] for more details). The test error curve has a minimum in correspondence of the
“one-standard error” rule, which also coincides with the point of drop of the test error
curve. Hence, the finally chosen model has 4 active variables.
In subplot (c) of Figure 9.2 the test error curve for the ridge model is reported as a
function of a quantity defined as the degree of freedom which is inversely related to λ.
The complexity parameter should be chosen in correspondence to a value close to 1.25 of
the degree of freedom on the logarithmic scale (corresponding to λ = 300), according to
the “one-standard error” rule. However, this value is too large, and a more reasonable
value to choose for λ is the one where the test error curve presents a drop in slope,
namely, at log(df(λ)) = 1.2 corresponding to λ = 60.
As already mentioned, EN has two parameters for controlling complexity: λ is the
regularization parameter weighting the trade-off between adhesion to the data (low RSS)
and model complexity (discouraging complex models), while α controls the contribution
of the two norms. The cross-validation procedure is used for choosing the complexity
parameters. In particular, a grid of 11 equally spaced αs is considered, in the interval
(0÷ 1). Then, a set of λs equally spaced on the log scale is evaluated for each value of α.
Thus, each cross-validation plot is inspected separately and λ will be chosen according
to the specific α with the one-standard-error rule (see red cross in Figure 9.2) or as an
alternative after the first drop in the error curve, namely when log(λ) ≈ −3 corresponding
to λ = 0.05. In this case, α = 0.8 was chosen, since it was the one giving the lower MSE
with reasonable complexity.
9.3 Model Identification
The models are identified over the same data set used for the cross-validation procedure.
Table 9.2 shows the coefficients for each variable estimated with the proposed identification
techniques. It can be noticed that for OLS, the contribution of the two correlated variables
lcp and pgg45 (see Figure 9.1) to the estimation of βˆ is not relevant, since their relative
coefficients tend to compensate their effects. This phenomenon occurs when OLS deals
with highly correlated variables: their relative coefficients tend to become large but with
opposite signs and thus they compensate each others.
After having fixed M = 3, the PLS estimates can be computed. It is interesting
to compare the estimated OLS coefficients βˆ
ols
with the PLS ones βˆ
pls
, as reported in
Table 9.2. The compensation effect occurring with the variables lcp and pgg45 for OLS
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is not happening using PLS, that weights the variable lcpless. From Table 9.2 and Figure
9.4, we can also notice that the estimated PLS coefficients have, on average, a smaller
absolute value than the OLS ones, indicating the a control of the complexity as been
achieved.
As described before, the LAR procedure allows to create the entire LASSO path (see
Figure 9.3), i.e. the behaviour of the coefficients βˆ as the model complexity increases.
At first all the parameters β are set to zero and enter in the active set according to their
correlation with the current residual. Notice that, at the end of the LASSO path, i.e.
when the selected number of active variables is equal to the number of predictors in the
matrix X, βˆ
lasso
correspond to βˆ
ols
.
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Figure 9.3: LASSO path for prostate cancer data of the “tutorial” example. The coefficients
weighting the different variables (expressed in different colors) are shown as a function of the
model complexity (expressed as the sum of the absolute value coefficients in the model).
Analyzing Figure 9.3 and Table 9.1 we can see the LASSO behaviour when dealing
with correlated variables, e.g. lcp and pgg45. pgg45 (blue dashed line in Figure 9.3)
enters the active set before lcp (yellow continuous line) showing the regularization and
variable selection performed by the `1 norm. As soon as the model complexity increases,
lcp enters the active set and its coefficient becomes large until compensation of the two
variables occurs.
Table 9.2 shows that Ridge estimated coefficients have sum of absolute values
clearly lower than that of the coefficients obtained with OLS (
∑ |βˆolsj | = 1.8716 against
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∑ |βˆridgej | = 0.6686 respectively). This proves the regularization performed by the `2
norm that shrunk the model coefficients. However, the `2 norm does not induce sparsity
on the coefficients, thus allowing all the variables to enter the model. However, they are
individually much smaller that the coefficients of the other methods (see Figure 9.4).
As it can be seen from Table 9.2, the EN model still share the property of sparseness
with LASSO (induced by the `1 norm), but retains more variables (thanks to the `2
norm). Unfortunately, the grouping effect is not visible, probably because of the small
number of predictors and data available.
lcavol lweight age lbph svi lcp gleason pgg45
OLS 0.5931 0.2423 -0.1180 0.1755 0.2563 -0.2393 -0.173 0.2296
PLS 0.4948 0.2594 -0.1520 0.1696 0.2586 -0.0306 0.0053 0.1019
LASSO 0.48 0.2034 0 0.1188 0.1658 0 0 0.0746
Ridge 0.1669 0.1156 0.0195 0.0701 0.1122 0.0688 0.422 0.0713
EN 0.4778 0.2101 -0.0185 0.1309 0.1722 0 0 0.0863
Table 9.2: Estimated coefficients of the parameter vector βˆ for OLS, PLS, LASSO, Ridge
and EN.
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Figure 9.4: Coefficients of the multivariate linear regression model identified by the
different techniques.
9.4 Model Test
As described in Chapter 3, to evaluate the performance of the two different methods, it
is convenient to analyse their behaviour in predicting unseen data. Hence, the previously
estimated coefficients are applied on inputs of the test set and the results are compared
with the test reference. To quantify the performance of the models, the MSE indicator
was computed. Table 9.3 shows, as expected, that OLS is the model with lower accuracy
indicating the occurrence of overfitting.
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As said before, using the OLS estimator, the coefficients of highly correlated variables
tend to grow large in opposite directions compensating each others. It was the case of lcp
and pgg45 which are positively correlated. LASSO choses only one of the two variables,
discarding the other one by shrinking its coefficient to zero. To quantify the performance
of the three methods, the MSE indicator is considered, as shown in Table 9.3. Table 9.3
confirms that the estimators have similar performances.
Despite the regularization, the Ridge model is not able to generalize as well as the
other models do in predicting the target variable from the input data. However, results
remains comparable with those of the other models.
Although the grouping effect is not visible in this tutorial example, the combination
of the two norms allows the EN model to outperform the other two models identified with
a regularization technique (see Table 9.3). Probably due to the few data and predictors
available, performance is not as good as that of PLS, although very close.
MSE
OLS 0.5213
PLS 0.4284
LASSO 0.4593
Ridge 0.5257
EN 0.4583
Table 9.3: MSE indicator for OLS, PLS, LASSO, Ridge and EN on test data.
9.5 Concluding Remarks
This chapter illustrated a procedure for assessing accuracy of different identification
techniques. The same logic will be used in Part III of this thesis to test the same
techniques over the Multisensor data. From data pre-processing, to cross-validation for
setting the more reasonable complexity parameter for each techniques, the models are
finally identified and tested over an independent test data set. Of particular interest is
the effects on the model coefficients induced by those techniques controlling complexity
(see Figure 9.4). In particular, while retaining information from all the predictors, PLS
estimates a model with visually smaller coefficients than OLS, resulting in a less complex
model able of better generalization on test data (see Table 9.3). On the other side, LASSO
induces a sparse model, with 3 coefficients shrunk to zero in a total of 8, obtaining good
prediction performance on test data, not comparable with that of PLS, thought. The
reason could be that with few data available, PLS has better prediction capabilities
because it takes information from all the variables. The `2 norm induces a model (Ridge)
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where all the coefficients are non-zero, as can be easily seen from Figure 9.4. However,
they are individually much smaller that the coefficients of the other methods. Finally,
the EN model is a trade-off between the LASSO and Ridge ones, presenting 2 coefficients
shrunk to zero. Unfortunately, the grouping effect representing its main feature is not fully
visible in this tutorial example, but will be clear in Chapter 11 where the identification
techniques will be applied with the aim of performing NI-CGM.
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Part III
Case Study

10
Data Set
The present chapter illustrates the data set and the relative acquisition protocol that will
be used later in Chapter 11 to assess the performance of the identification techniques
in modeling multi-sensor data. Starting from this chapter, we will refer to a particular
multi-sensor device, namely the Solianis Multisensor, from now on, for sake of brevity,
called “Multisensor” (note the capital M).
10.1 Acquisition Protocol
Data, provided to us by Solianis Monitoring AG, were acquired during an experimental
clinical study conducted at the University Hospital Zurich that included six patients
with Type 1 Diabetes Mellitus (T1DM) (age 44 ± 16 years; body mass index BMI 24.1
± 1.3 kg m−2; duration of diabetes 27 ± 12 years; glycated hemoglobin HbA1c 7.3 ±
1.0), identified by the following labels: “AA02”, “AA03”, “AA04”, “AA05”, “AA06”,
and “AA09”. Each subject performed different recording sessions in different days. Each
recording session had an approximative duration of 8 hours during which plasma glucose
was induced to vary according to a desired profile. In particular, glucose was loaded
either orally or by intra-venous glucose administration to induce different hyper and
hypoglycaemic excursions. In total, four different desired profiles were considered. These
profiles are shown with different colors in Figure 10.1, where the black vertical dashed
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line represent the first 75 minutes of the experiment (that will be later removed from the
study). The rationale of forcing glucose to mimic such a variety of profiles is to assess
the ability of the “Multisensor hardware + model” system to discriminate among both
different glucose rates of change and levels of glucose concentrations.
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Figure 10.1: The four desired glucose profiles considered in the protocol. Time zero
corresponds to intravenous insulin infusion, and the black vertical line the first 75 minutes.
The study was performed in accordance with Good Clinical Practice and the Dec-
laration of Helsinki. All patients signed an informed consent agreement,performed the
screening visit and were then enrolled in the study. After a patient arrived in the clinical
study unit in the morning, blood glucose was measured and an intravenous insulin
infusion was performed. Glucose was administered after a 75 min equilibration time
needed for establishing euglycaemic level and to allow the skin of the subject to adjust
to the application of the sensor. Multisensor data were recorded by placing the device on
the right upper arm. Reference glucose values were acquired in parallel, every 10-20 min,
using a HemoCue Glucose 201 Analyzer (HemoCue AG, Switzerland). On average, seven
recording sessions were performed by each patient (min. 5 and max. 10). This provided
a data set of 45 recording sessions available for the analysis described in the following.
As mentioned in Chapter 3, the Multisensor provides a set of measurements of
different nature, mainly based on dielectric and optical sensors, for a total of more than
150 measured signals. Most of the signals come from the dielectric electrodes (see Figure
10.2), showing a high correlation and exhibiting similar but not identical behaviour.
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Figure 10.2: Example of IS Multisensor data. The first 75 mins (on the left of the dashed
vertical line) are removed for the presence of Multisensor-skin adaptation processes and for
allowing euglycaemic level to be established.
Hence, there are two important characteristics of this dataset: it is a high-dimensional
dataset and there are many correlated variables. Figure 10.2 also clarifies the reason
the first 75 minutes are removed: in this time interval there is a strong influence of
adaptation processes due to Multisensor-skin contact.
10.2 Data Partition Between Model Identification and
Model Test
As said in Chapter 3, it is a good choice to evaluate the performance of the different
models using unseen data. Hence, in order to evaluate the performance in estimating
glucose profiles from Multisensor data not used during the model identification stage,
the data set was split into two parts, in such a way that each subject in each data subset
underwent a similar number of days with a specific profile. Data subsets used in the
following are:
• data subset “part 1”, consisting of 23 recording sessions;
• data subset “part 2”, consisting of 22 recording sessions.
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These two data subsets will be used separately for model identification and model test,
namely, if data subset “part 1” is used for model identification, data subset “part 2” is
used for model test and viceversa. In Chapter 11 we will refer to “internal validation”
results if the model is applied to the same data subset used for its identification, and
“external validation” if the model is applied to a new data subset.
Notice that both the data subsets contain data recorded from different subjects, thus
the identified models will have a “global” or “population” validity since they are not
tailored to a specific subject. In a practical prospective this could be an appealing aspect
since it could allow to use a previously identified population model for estimating glucose
profiles also in subjects whose data did not participated to model building.
10.2.1 Preprocessing
Data for model identification
For each Multisensor channel, the first 75 min of each recording session are removed
since this interval is dominated by an adaptation process due to the Multisensor/skin
contact. Signal channels undergo a causal median filtering (window width of 5 samples)
for the removal of occasional spurious spikes. Signals used for model identification are
standardized to have zero mean and standard deviation one, namely, they are shifted
and scaled with their own sample mean and standard deviation.
Data for model test
The first 75 min of each recording session are removed and the same causal median
filtering above was applied. Then, each signal channel is shifted and scaled using sample
mean and sample standard deviation of its correspondent in the identification data set. In
such a way, the analysis can be considered consistent with a realistic on-line application
of the models. Indeed, in a prospective use of the device, sample mean and standard
deviation cannot be known in advance, and only the values estimated during the model
identification stage can be used.
10.2.2 Determination of Model Complexity
While for OLS the identification data subset is used to identify the model coefficients,
which are then applied on the test data subset to estimate BGL, for the techniques
controlling complexity an additional step is needed before estimating βˆ. In particular,
the complexity parameter(s) need(s) to be fixed exploiting K-fold cross-validation over
the identification data subset (see Section 5.2.2). After having estimated the model
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complexity, PLS, LASSO, Ridge and EN models are identified from the same identification
data subset used for cross-validation and applied on the test data subset for predicting
the BGL values.
10.2.3 Model Calibration
While models obtained during the model identification stage will have a “global” validity
because they are obtained considering identification data subset containing data from
different subjects, during the model test phase an individualized calibration step is
required at the beginning of each experimental session to adjust the baseline of the
estimated glucose profile by the model. Formally, such a calibration is described by
equation:
gˆcal = Xβˆ + b (10.1)
where gˆcal is the (N × 1) vector containing the calibrated glucose profile, from now on
only “glucose profile”, X is the (N×p) matrix collecting Multisensor data, βˆ is the (p×1)
identified parameter vector of the multivariate linear model (no matter which of the 5
parameter identification techniques is adopted) and b is the scalar value representing the
baseline glucose calibration parameter calculated exploiting a single RBG provided by a
“gold standard” technique based on finger prick. This additional parameter is obtained
as the difference between the estimated glucose value given by the multivariate linear
model Xiβˆ and the RBG point at the same time instant ti:
b = Xiβˆ −RBG(ti) (10.2)
In practice, the glucose profile is shifted to the first RBG value available. This initial
adjustment is usually performed after 75 minutes the Multisensor is placed in contact
with the skin, for allowing adaptation processes related to Multisensor-skin contact to
deplete, and then kept fixed for all the duration the Multisensor is worn.
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11
Results
As already mentioned in the previous chapter, the full dataset was split in “part 1” and
“part 2”. Hereafter, if “part 1” is used for model identification, “part 2” is used for model
test and viceversa. The identification data subset used to find the model parameter
vector is also previously used to find the most reasonable complexity parameters for PLS,
LASSO, Ridge and EN.
11.1 Determination of Model Complexity
The “optimal” complexity parameter values are shown in Table 11.1-11.4, for the different
techniques. Their values are determined according to reasonable empirical evidence, i.e.
where the cross-validation curve presents a clear drop in slope (values are reported as red
crosses in Figure 11.1), rather than with the “one-standard error” rule (whose values are
reported as green crosses in Figure 11.1). Figure 11.1 shows the cross-validation results
when data subset “part 1” is considered for model identification, and comparable results
(not shown) are obtained when data subset “part 2” is used.
The cross-validation curve in Figure 11.1 (a) shows the error curve as a function of the
number of latent variables for the PLS technique. The “optimal” complexity parameter
value suggested by the “one-standard error” rule, indicated with a green cross in subplot
(a) at the value of m = 50, is likely to lead to an unnecessary too complex model. Indeed,
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Figure 11.1: 10-fold Cross-validation curves for the choice of the “optimal” complexity
parameters for PLS (a), LASSO (b), Ridge (c) and EN for α = 0.4 (d). The MSE (mean value
and one standard deviation) is represented as a function of the model complexity parameter
for each method. The green cross represents the value of the complexity parameter according
to the one-standard-error rule (horizontal green dashed line), while the red crosses represent
the values according to the drop in the error curve.
visual inspection of the cross-validation plot shows a clear drop of the error curve around
10. The complexity parameter for the different identification techniques suggested by the
“one-standard error” rule is shown in the subplots of Figure 11.1 with green crosses, while
the red crosses is the chosen value according to the drop in the error curve. This empirical
consideration also drives the choice of the complexity parameter for the LASSO model,
indicating a drop of the cross-validation curve around 15 (see subplot (b) in Figure 11.1).
The choice of the complexity parameter for Ridge follows a similar approach. Indeed, the
cross-validation curve shown in subplot (b) of Figure 11.1 has a drop when the degree of
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freedom, defined by eq. (8.39), is approximately 50, corresponding to λ = 5. Similarly
for EN, the ending part of the drop in the error curve can be noticed for log(λ) ≈ −4.5
(subplot (d) of Figure 11.1), corresponding to λ = 0.01. For EN different cross-validation
curves for different values of α where examined. The most reasonable choice seemed
that obtained for α = 0.4. Indeed, this combination of complexity parameters is the one
providing a good trade-off between the `1 and `2 norms allowing a reasonable complexity
for the EN model to be achieved. A value of α = 0.4 can suggest that, although it is
important to shrink channel weights to zero in order to lower the probability of occasional
jumps or spikes entering the model, allowing a grouping effect over correlated predictors
is also important for a more robust estimation of glucose profiles.
11.2 Model Identification
RMSE R2 MAD MARD ESOD EGA [%] CEGA [%]
[mg/dL] [mg/dL] [%] A+B(A) AR +BR(AR)
C\D\E CR\DR\ER
OLS 20.5 0.94 17 13.8 2.1 96.2(78.3) 86.9(58.7)
(7.9) (0.02) (8) (6.1) (1.5) 0\3.8\0 3.5\6.2\3.4
PLS 39.5 0.84 33.3 28.9 1.8 88.9(39) 83.7(56.5)
(m=10) (12.3) (0.09) (12.1) (14.2) (1.7) 4.1\5.7\1.3 7.2\5.2\3.4
LASSO 49.8 0.78 41.8 36.8 0.8 89.9(40.8) 86.9(61.1)
(j=15) (16.7) (0.14) (16.5) (20.1) (0.7) 2.1\6.9\1.1 7.9\3.4\1.8
Ridge 32.7 0.89 27.7 24.4 1.5 91.9(41.6) 83.4(58)
(λ = 5) (11.9) (0.06) (11.4) (12) (1.1) 1.1\5.9\1.1 7.2\5.9\3.5
EN 31.2 0.89 26.4 22.6 1.4 93.0(39.4) 83.9(59.6)
(α = 0.4, λ = 0.01) (11.8) (0.06) (11.2) (10.7) (2.4) 0.7\5.1\1.2 7.9\5.2\3
Table 11.1: Indicators of model performance for internal validation, i.e. when glucose profiles
are estimated from the same data subset “part 1” used for identify the models. In brackets
is the complexity model parameter chosen by means of cross-validation. RMSE root mean
squared error, R2 Pearson coefficient of determination, MAD mean absolute difference, MARD
mean absolute relative difference, ESOD energy of second-order differences, EGA (Clarke)
error grid analysis, CEGA continuous error grid analysis.
In this section, Table 11.1 and Table 11.2 represent the results of the so-called “internal
validation”, namely when glucose profiles are estimated with the same data used to
identify the models. In particular, Table 11.1 shows internal validation results for and
data subset “part 1” and Table 11.2 data subset “part 2”.
Results in terms of accuracy of estimated glucose profiles are presented through
indicators widely discussed in Chapter 5. As expected, Table 11.1 and Table 11.2 indicate
that, in the model identification stage, OLS outperforms the other models. Indeed,
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Figure 11.2: Representative recording sessions of Subjects AA04 (left) and AA05 (right).
OLS, PLS, LASSO, Ridge and EN fit (continuous lines) vs. reference BGL (open bullets).
Bottom panels display two representative channels (#156 an #90 for subject on the left and
on the right respectively) entering the models, where occasional spikes and jumps are evident.
OLS identifies model parameters in such a way as to maximize the adherence to the
identification data without any constraint on the complexity. As we will see in Section
11.3, this will results in a clear overfitting in the model test phase. Figure 11.2 shows
a representative “internal validation” plot for data subsets “part 1” (left subplots) and
data subsets “part 2” (right subplots). By visual inspection, it is possible to note
how the (calibrated) glucose profiles fitted by the OLS model outperforms the other
models. Moreover, Figure 11.2 (right) shows that despite OLS reach better accuracy,
it is more sensitive than the other models to occasional jumps or spikes occurring on
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RMSE R2 MAD MARD ESOD EGA [%] CEGA [%]
[mg/dL] [mg/dL] [%] A+B(A) AR +BR(AR)
C\D\E CR\DR\ER
OLS 27.3 0.93 23.4 19.9 2.5 97.5(68.1) 84.1(58.3)
(11) (0.03) (11.2) (13.8) (2.1) 0\2.5\0 4\8.2\3.7
PLS 44.7 0.85 38.7 30 1.4 94.6(47.7) 88.8(62.7)
(m=15) (22.1) (0.1) (20.9) (18.1) (1.4) 0.9\4.4\0.1 5.3\3.5\2.4
LASSO 55.1 0.78 46.6 34.9 0.4 89.9(44.4) 93.6(69.8)
(j=16) (26.6) (0.19) (24.7) (21.8) (0.1) 2.6\6.4\1.1 4.1\1.5\0.8
Ridge 42.4 0.86 36.3 28 1.1 95.1(51.3) 88.9(65.4)
(λ = 14) (21) (0.11) (11.4) (19.7) (0.8) 0\4.8\0.1 5.2\3.9\2
EN 45.3 0.85 38.8 29.8 0.8 93.9(48.9) 91.6(66.5)
(α = 0.3, λ = 0.05) (24.4) (0.14) (22.8) (19.3) (0.4) 0.7\5.1\0.3 4.5\2.5\1.4
Table 11.2: Indicators of model performance for internal validation, i.e. when glucose profiles
are estimated from the same data subset “part 2” used for identify the models. In brackets is
the complexity model parameter chosen by means of cross-validation.
the Multisensor channels entering the model, as channel # 90 shown in the bottom
panel. This characteristic will be more clear when glucose profiles will be estimated from
Multisensor data not used during model identification. For sake of completeness, the full
“internal validation” plots with all the (22+23 of the two data subsets) recording sessions
are shown in Appendix A.
11.3 Model Test
This section presents the model test phase results, when the identified models in the
previous section over data subsets “part 1” and “part 2” are tested over data subsets
“part 2” and “part 1” respectively.
Indicators reported in Table 11.3 and Table 11.4 show that OLS model is the worst,
confirming the occurrence of overfitting previously speculated. This point is further
strengthened by visual inspection of the box-plots in Figure 11.4 and Figure 11.7. The
OLS model results in indicators more scattered with respect to those of the other models
the other models which limit their complexity. Moreover, as can be seen from the CEGA
analysis of Figure 11.5 and Figure 11.6, the cloud of points (given by the couples of
reference vs. estimated BGL) for OLS is the most scattered, with many points lying
within the dangerous zones C,D and E.
Regularization based methods, i.e. LASSO, Ridge and EN, seem to outperform PLS.
In particular, PLS shows that RMSE, R2, MAD, MARD and ESOD are worse than for
the other models controlling complexity. However, PLS shows EGA and CEGA only
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RMSE R2 MAD MARD ESOD EGA [%] CEGA [%]
[mg/dL] [mg/dL] [%] A+B(A) AR +BR(AR)
C\D\E CR\DR\ER
OLS 94 0.69 76.7 59 10.4 85.3(30) 82.6(53)
(125.2) (0.26) (87.2) (72.2) (36.5) 8\4\2.7 5\7.9\4.5
PLS 61.2 0.65 51.7 40.1 2.7 90.6(51.3) 85.9(60.5)
(m=10) (27.5) (0.25) (24.7) (21.2) (4.4) 0.4\9\0 4.4\6.1\3.6
LASSO 57.9 0.69 48.6 37.8 0.9 89.4(42.2) 89.2(62.1)
(j=15) (27.1) (0.25) (23.7) (20) (1.1) 0.9\9.6\0.1 6.3\2.5\2
Ridge 52.3 0.71 44.1 35 2 91(58.7) 88(63)
(λ = 5) (22.8) (0.21) (19.2) (17.7) (2.7) 0.1\8.9\0 4.9\4.8\2.3
EN 51.8 0.71 43.9 34.1 2 92.3(59.9) 88.6(65)
(α = 0.4, λ = 0.01) (24.3) (0.22) (20.5) (17.2) (2.4) 0.1\7.6\0 4.9\4.4\2.1
Table 11.3: Indicators of model performance when “part 1” of the data set is used for model
identification and “part 2” for model test. In brackets is the complexity model parameter
chosen by means of cross-validation. RMSE root mean squared error, R2 Pearson coefficient
of determination, MAD mean absolute difference, MARD mean absolute relative difference,
ESOD energy of second-order differences, EGA (Clarke) error grid analysis, CEGA continuous
error grid analysis.
slightly worse than the other models, indicating that although it can give good prediction
of glucose trends it is too sensitive to noisy channels (Figure 11.3 (right)). This happens
because the PLS model has all non-zero coefficients, resulting particularly sensitive to
occasional jumps or spikes present in the Multisensor channels, as channel # 167 shown
in the bottom panel of Figure 11.3. This is also confirmed from the higher ESOD values
for PLS in Table 11.3 and Table 11.4 with respect to the other models.
Regularization methods provide, in general, better accuracy performance with respect
to PLS. This point is confirmed when the models are tested in both the test data subsets
(see Table 11.3 and Table 11.4). In particular, the LASSO model is the one estimating
glucose profiles with the lowest ESOD. The reason is two-fold: first, the regularization
performed by the `1 norm prevents the model coefficients from assuming large values thus
predicting glucose profiles that are more ßat than the other models (see for example Figure
11.8 (right)); second, channels more sensitive to noise that contain also glucose-related
information are considered by PLS, and also by Ridge and EN exploiting the effect of
the `2 norm, but are less probable to be selected by LASSO, thus yielding to smoother
estimates (see also box-plots in Figure 11.4 and Figure 11.7). Indeed the `1 norm shrinks
many coefficients to zero according to the value of the parameter j controlling complexity.
This allows an easier interpretation of the results with a reduced number of original
variables, representing the strongest effects, considered important for estimating glucose
11.3 Model Test 119
09:00 12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
Subject: AA03, Session: #8
 
 
OLS
09:00 12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
 
 
PLS
09:00 12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
 
 
LASSO
09:00 12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
 
 
Ridge
09:00 12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
 
 
EN
09:00 12:00 15:00 18:00
−0.5
0
0.5
1
Time [hh:mm]
a.
u.
 
 
Channel #2
12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
Subject: AA06, Session: #3
 
 
OLS
12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
 
 
PLS
12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
 
 
LASSO
12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
 
 
Ridge
12:00 15:00 18:00
0
200
400
glu
co
se
 [m
g/
dL
]
 
 
EN
12:00 15:00 18:00
50
100
150
Time [hh:mm]
a.
u.
 
 
Channel #167
Figure 11.3: Representative recording sessions of Subjects AA03 (left) and AA06 (right).
OLS, PLS, LASSO, Ridge and EN model test over independent test data subset (continuous
lines) vs. reference BGL (open bullets). Bottom panels display two representative channels
(#2 an #167 for subject on the left and on the right respectively) entering the models, where
occasional spikes and jumps are evident.
profiles. This is a typical feature of the LASSO to act as a variable selection method.
Most of the time, a good agreement between glucose estimated profiles and reference
glucose measures is achieved. However, unpredictable events might sometime lead to
signals behaviour different from what is expected, yielding un-physiological glucose
estimated levels by the model. In these cases, a lower limit of 30 mg/dL for estimated
glucose levels is introduced [146]. For instance, Figure 11.3 (right) and Figure 11.8
(left) show two representative recording sessions where the estimated glucose profiles are
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Figure 11.4: Boxplots for 5 indicators in Table 11.3. RMSE (a), R2 (b), MAD (c), MARD
(d) and ESOD (e).
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Figure 11.5: Clarke error grid (top) and Rate error grid (bottom) for the different models
for test data subset “part 2”.
set to the above limit given the presence of a jump affecting some of the Multisensor
channels entering the model (see bottom panels of same figures, where the artifacts in
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Figure 11.6: Clarke error grid (top) and Rate error grid (bottom) for the different models
for test data subset “part 2”.
RMSE R2 MAD MARD ESOD EGA [%] CEGA [%]
[mg/dL] [mg/dL] [%] A+B(A) AR +BR(AR)
C\D\E CR\DR\ER
OLS 80.1 0.65 70.1 57.8 3 73.3(30.2) 79.9(52)
(38.3) (0.27) (35.2) (33.5) (2.4) 16.6\6.8\3.3 6.8\8.3\5
PLS 59.8 0.67 51.3 43.4 1.1 84.7(45.3) 88.3(65)
(m=15) (42.8) (0.24) (39.6) (38.5) (0.7) 9.2\3.6\2.5 5.8\3.9\2
LASSO 57.5 0.7 47.2 39.4 0.4 86.4(43) 92.5(68)
(j=16) (25.1) (0.2) (21.8) (20.1) (0.2) 3.8\8\1.8 5.8\0.9\0.8
Ridge 56.2 0.69 47.1 40.2 0.9 87.3(45.3) 91.1(66.4)
(λ = 14) (37.5) (0.22) (34) (30.6) (0.5) 5.8\5.1\1.8 4.6\2.8\1.5
EN 52.6 0.71 44.2 37.5 0.7 88.6(42.6) 91.7(69.4)
(α = 0.3, λ = 0.05) (31.6) (0.2) (27.3) (23.8) (0.3) 2.7\7.7\1 5\1.9\1.4
Table 11.4: Indicators of model performance when “part 1” of the data set is used for model
identification and “part 2” for model test. In brackets is the complexity model parameter
chosen by means of cross-validation.
the Multisensor channels are clearly visible). Interestingly, the LASSO model seems
more robust than the other models to these jumps in the data, not requiring the onset
of the lower limit cut off, and preserving glucose profile with elevated smoothness and
reasonably accurate trend. This behavior can be attributed to the shrinking properties
of the `1 norm. Finally, by looking at the last columns of Table 11.3 and Table 11.4, it
is interesting to note how the LASSO model is able to estimate glucose profiles with a
better trend accuracy than the other models.
The Ridge model is identified minimizing the RSS cost function subject to a bound on
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the `2 norm of the coefficients. This norm does not have the ability of inducing sparseness
on the coefficients of the multivariate linear regression model, thus a parsimonious model
is not identified and all the predictors are kept in the model. This might cause the
estimated glucose profiles by the Ridge model to be sensitive to occasional spikes or
jumps in the Multisensor channels, as happened for PLS. However, this influence seems
lower than in the PLS model as indicated by the lower ESOD for Ridge and by looking
at Figure 11.3 (right). It can be shown that Ridge is related to PLS, since PLS shrinks
low variance directions inflating the high variance ones, while Ridge shrinks more the
principal components of the predictor matrix X presenting low variance [116]. Estimated
glucose profiles by the Ridge model show accuracy indicators slightly better than those
of LASSO (see Table 11.3 and Table 11.4). This might indicate that channels discharged
by the `1 norm because sensitive to occasional spikes or jumps actually contain useful
glucose related information. Thus, it is reasonable that a combination of the `1 and `2
norms could identify a model sharing both properties of sparseness and grouping effect.
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Figure 11.7: Boxplots for 5 indicators in Table 11.3. RMSE (a), R2 (b), MAD (c), MARD
(d) and ESOD (e).
From Table 11.3 and Table 11.4, one can note that the EN model outperforms the
others in terms of accuracy of estimated glucose profiles. In particular, EN is the model
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Figure 11.8: Representative recording sessions of Subjects AA04 (left) and AA05 (right).
OLS, PLS, LASSO, Ridge and EN model test over independent test data subset (continuous
lines) vs. reference BGL (open bullets). Bottom panels display two representative channels
(#156 an #3 for subject on the left and on the right respectively) entering the models, where
occasional spikes and jumps are evident.
presenting the best indicators and is only slightly worse than LASSO in accuracy for
glucose trends (see CEGA results). Moreover, its clinical accuracy results on the Clarke
Error Grid are substantially close to that of minimally invasive devices that present a
percentage of points within the A+B zone spanning from 84.4 to 98.9 [118].
The good results obtained by the EN model are likely due to the combination of the
`1 and `2 norms, giving to this model both the advantages of LASSO and Ridge. Indeed,
a limitation of the LASSO is that if there is a group of correlated variables, then it tends
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to select only one variable from the group and does not care which one is selected, thus
lacking in the ability of revealing grouping information. On the opposite, the `2 norm
allows all coefficients to enter the model, resulting more sensitive to noisy channels. Thus,
the `1 norm shrinks channel weights to zero (eliminating Multisensor channels not useful
for predicting glucose) while the `2 norm encourages a grouping effect (automatically
including whole groups into the model once one channel among them is selected). This
combination results in indicators outperforming those of the other models (see Figure
11.4 and Figure 11.7) and in estimated glucose profiles with a good trade-off between
sparseness of the model coefficients and robustness due to the grouping effect (see for
example Figure 11.3 (left)). For sake of completeness, all the model test plots for all the
22+23 available recording sessions are shown in the Appendix B.
11.4 Concluding Remarks
This chapter showed the application of the identification techniques illustrated in Part II
of the present thesis to a case study represented by the Solianis Multisensor data with
the aim of estimating glucose profiles. We showed that the OLS model outperforms the
others in “internal validation” conditions at the cost of overfitting. Indeed, OLS is the
worst during model test because the bias of the methods controlling complexity in model
identification leads to a better performance when glucose profiles are obtained from an
independent test data set. PLS performed better than OLS, but slightly worse than
regularization based methods. This is because PLS allows all the Multisensor channels
to enter the model, also those affected by occasional jumps or shifts. The same behavior
was shown by the Ridge model that allowed all the channels to enter the model. On the
opposite, the LASSO model seemed particularly robust to this particular noise, because
it shrunk many channel weights to zero [147]. Finally, we showed that EN is the best
performing model, representing a good trade-off between Ridge and LASSO. EN is robust
to occasional noise occurring in the Multisensor data, sharing the `1 norm properties
with LASSO, but at the same time averages channels with correlated predictors allowing
a more accurate estimation of the glucose profiles, exploiting the same `2 norm properties
of Ridge.
12
Conclusions and Further Developments
12.1 Discussion of the Thesis Main Achievements
In diabetes management, tight monitoring of glycaemic levels is important for avoiding
long and short term complications related to hypo- and hyper-glycaemia excursions. As
reviewed in Chapters 1 and Chapter 2 of the present thesis, many sensors have been
proposed for CGM. Most of them have a certain degree of invasiveness because they
exploit needle based electrodes. On the other side, non-invasive devices are potentially
more appealing, but their development is challenging for several reasons (see Chapter
4). In the last years, a new approach in the development of NI-CGM devices based on
the embedding of sensors of different nature within the same device in order to obtain a
better bio-physical characterization of the skin and underlying tissues gained particular
attention. As seen in Chapter 4, this multisensor concept has been shown to be more
robust in the daily-life use of these devices to possible environmental and physiological
processes that can deteriorate accuracy of estimated glucose profiles [146, 103].
However, a model linking the measured multisensor data to glucose is needed, together
with a set of techniques that can be used to identify the parameters of the multivariate
linear regression model, as OLS, PLS, LASSO, Ridge and EN described in Part II (from
Chapter 6 to 8), that are tested over the recently proposed Multisensor device by Solianis.
The main aim of the thesis was to focus on the problem of identification of suitable
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regression models for modeling multisensor data with the aim of estimating glucose levels
non-invasively (Chapter 11). Results indicate that: as expected, OLS results are superior
only in “internal validation” (see Section 11.2), while overfitting clearly appears when
models are tested on data previously unseen to the model; the PLS model estimates
glucose profiles with reasonable good trends although this model is too sensitive to noisy
channels, presenting an higher ESOD value with respect to the other models; the EN
model outperforms, in general, the other models thanks to the combination of the `1
and `2 norms that allow it to share both the advantages of the LASSO, shrinking many
model weights to zero being more robust to possible occasional jumps or spikes occurring
on the Multisensor data, and of the Ridge model, averaging the contribution of correlated
channels allowing a more robust estimation of glucose profiles.
With respect to the previous literature, this thesis demonstrated that while PLS
is the current state-of-art for regression problems involving spectroscopy data (see
[148, 149, 105] to mention just a few), EN can become very useful when dealing with
regression problem with multisensor data. While retaining information from a group
of variables (as PLS does), it also automatically selects those channels representing the
strongest effects, giving more insights into the specific problem at hand.
Results obtained in the thesis also demonstrated that, while accuracy indexes defined
in Section 5.3.2 are not yet comparable with those of current state of the art, enzyme-
based, needle sensors [118], glucose trends estimated by the considered NI-CGM device
plus a suitable model exhibit a good accuracy (see CEGA results in the last columns
of Table 11.3 and Table 11.4). This result is important in the treatment of diabetes
since the glucose trend can be a valid additional information to complement standard
SMBG devices that measure glucose by fingerprick. Knowing the glucose trend in real
time can greatly help the diabetic patient in preventing the occurrence of critical events,
such as hypoglycaemia. To better illustrate this point, consider the example in Figure
12.1. Top panel shows a portion of data (open bullets are SMBG samples, continuous
line is the glucose concentration estimated by the EN model in a representative subject
(20090806 S4WP4 AA04 in Appendix -see Appendix for label’s meaning-). Bottom panel
shows the estimate of the glucose concentration time-derivative, computable, also in real
time, through regularization algorithms (see [150] for details) starting from the glucose
profile returned by the EN model. By using the static risk (SR) concept introduced
in [151], the SMBG measures can be mapped into a symmetric risk space ranging from
0 (low risk) to 100 (high risk of hypo/hyperglycaemia, respectively). If only SMBG
samples were available, at time 15:00 and subsequent values (labelled as A and B in the
picture) similar SR values, equal to -16.8 and -18.4 respectively, would be estimated.
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Following the ideas presented in [150], a reliable glucose trend estimation can be used to
integrate SMBG information for calculating the dynamic risk (DR) in situations A and
B. DR values in A and B are equal to -39 and -0.4, respectively, and allow the patient to
interpret differently the situation of a glucose level near the hypoglycaemic threshold of
70 mg/dL with a negative (point A) rather than a positive (point B) trend: In situation
A, an alert can be generated to solicit the patient to take sugar to mitigate, or even
prevent, the hypoglycaemic event.
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Figure 12.1: Application of dynamic risk concept exploiting NI-CGM data in diabetes
management. Example of sparse SMBG values (A, B) (Top panel) complemented by
NI-CGM trend information (Bottom panel).
Thus, the NI-CGM multisensor system (Solianis device plus the EN model) can not
be considered yet a replacement of current needle-base glucose sensors. However, the
accuracy in estimating glucose trends makes the system suitable to be used in the current
diabetes therapy as a complement to standard SMBG devices. Promising results obtained
with the EN model makes the system even more appealing given the incremental accuracy
performance achieved.
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12.2 Future Developments: Monte Carlo MC
Methodology to Assess Robustness of Multisensor
Models
As far as possible future developments of the present thesis is concerned, we briefly
discuss a methodology for testing the robustness of the calibration parameter (see Section
10.2.3) against environmental and physiological processes that can occur during daily-life.
The methodology is general and can be used also for multisensor devices for NI-CGM
other than the Solianis Multisensor considered in this thesis.
12.2.1 Case Study: Effects of Sweat Events on Model Calibration
The parameter b in eq. (10.1) discussed in Section 10.2.3 is estimated by the calibration
procedure of eq. (10.2) at the beginning of each experimental session and is not updated
for the entire duration of an experiment, i.e. whilst the Multisensor device remains in
contact with the skin. While this does not necessarily introduce issues in very controlled,
i.e. hospital, conditions, in real life, uncontrollable events may occasionally disturb the
Multisensor monitoring. In particular, a sweat event involves the creation of a conductive
saline layer at the sensor-skin interface. As long as the sweat activity diminishes, the
signal is expected to return to a level close to its initial value. However, as shown in
Figure 12.2 (top), there still could be a large off-set in the signals measuring sweats
(interdigitated electrode in the frequency range 1-200 KHz, from now on identified as
channel #36, black line) that after the occurrence of sweat does not always return to
its value before the sweat event, a condition already observed in the literature [152].
This off-set, together with changes in the hydratation levels of the skin and underlying
tissues resulting from sweat, could also affect the DS electrodes measuring the main
glucose related signals (see Figure 12.2 (top), channel #115, grey line) despite the fact
that these electrodes are designed to sample the most microvascularized area (i.e. the
upper and deep vascular plexus). If effects of sweat events impaired the calibration
parameter calculated at the beginning of each experimental session, glucose levels after
the occurrence of sweats would be estimated with less accuracy.
It is useful to assess potential benefits obtained by recalculating b in eq. (10.2)
exploiting the first reference BGL samples collected after the occurrence of sweat events.
To perform such a study, the first problem is to identify a sweat event using the Multisensor
data that appear more sensitive to sweat. As shown in Figure 12.2, calculating the
derivative (middle panel) of channel #36 (black line in top panel), measured by the
interdigitated electrode with specific geometrical shape and at specific frequency for being
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sensitive to sweat, provides a rough but effective procedure for the on-line detection of
sweat events by setting a proper threshold TH (shown in grey in middle panel). Here the
threshold is chosen, in a pool of candidate values, as the one giving the better trade-off
between missed and identified sweat events. After a sweat event is detected, a new
calculation of the calibration parameter is performed according to eq. (10.2): the new b
is calculated at the time instant ti of the first available reference BGL after the detection
of the sweat event.
The multivariate linear regression model used by the Multisensor is expected to
properly combine the information contained in the Multisensor channels to compensate
non-glucose related physiological processes such as sweat events. However, the compensa-
tion of sweat effects on the main glucose related signals that is expected to occur on the
Multisensor channels # 36 (which contains information about the electrolyte balance
changes on the skin surface) is principally performed by channels exploiting frequencies
in the GHz range, that measure water balance variations in the tissue because sweating
also results in changes in hydratation. Assuming that the model is not able to properly
compensate these sweat related processes, a new calibration point would be needed for
re-adjusting the glucose baseline every time a sweat event is occurring. This need results
in the collection of a new reference BGL sample obtained by blood fingerprick, reducing,
in a practical perspective, the usefulness of NI-CGM.
12.2.2 Assessment of Model Calibration Robustness by Monte Carlo
Methodology
Generally speaking, a MC simulation is a stochastic technique widely used to explore
the distribution of a target outcome when its direct calculation from available inputs
is not feasible. More specifically, when performing a MC simulation, first a pool of
N repeated (and randomly sampled) input vectors from their domain or distribution,
usually with N ≥ 100, is generated. Then, for each input vector, the computation of
the outcome of the system under analysis is deterministically calculated (each of the N
iteration is called simulation). Finally, the distribution of the target outcome is derived
aggregating the result of each simulation. In our specific case, the domain over which the
inputs are sampled corresponds to the set of time instants where reference BGL values
for calibration are available, while the deterministic computation refers to the specific
calibration procedure adopted or under test. The number of iterations considered is
N=1000. At each iteration of the MC simulation, each glucose profile estimated by the
multivariate model in the test data set undergoes the initial calibration (as explained
in Section 10.2.3), which is fixed and does not change from simulation to simulation.
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Figure 12.2: Representative experimental session recalibrated after sweat events. Top: Two
of the 150 Multisensor channels recorded: channel sensitive to sweat events, i.e. channel #36,
(black line) and channel particularly sensitive to glucose changes, i.e. channel #115 (grey
line). Middle: derivative of the channel 36 signal (black line) with the chosen threshold TH
(thin grey line). Bottom: Glucose profiles estimated by using single baseline calibration (black
dashed line) and multiple calibrations (grey line). Reference BGL samples collected in parallel
are also shown to allow qualitative visual assessment of accuracy (black circles).
Then, the calibration parameter b is recalculated, according to (10.2), one or several
times over a grid of random time instants. Note that the number of recalculations of the
parameter b performed at each simulation is fixed and depends on the number of events
that characterizes the scenario under analysis. In the sweat events scenario, b will be
recalculated Ns times in random time instants within the experimental session, where Ns
is the average number of sweat events occurring in the test data experimental sessions.
At the end of each MC iteration, accuracy of glucose profiles is measured through a
subset of indicative indexes RMSE, MAD and MARD measuring point accuracy. Finally,
after all N MC iterations are performed, the sample distribution of the above indexes is
obtained, and compared with the result obtained with the specific calibration procedure
under evaluation.
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12.2.3 Robustness of Model Calibration to Sweat Events: Results
Table 12.1 shows average and standard deviation (in parentheses) of RMSE, MAD and
MARD obtained for the standard working case, i.e. the calibration parameter b is
calculated only once, as baseline value, at the beginning of the experiment (first line in
Table 12.1), and for the multiple calibration strategy under assessment, i.e. b is updated
using the first reference BGL available every time a sweat event is detected (second line
in Table 12.1). These preliminary results are obtained with the LASSO model, given its
earlier use for NI-CGM [147]. Both the test datasets are documented, i.e. test data subset
“part 2” when data subset “part 1” is used for model identification (1 → 2) and test
data subset “part 1” when data subset “part 2” is used for model identification (2→ 1).
Statistical significance of the differences (computed according to the Students t-test) is
also indicated by the p values. Though there is not a statistically significance difference
for all the considered key indicators in both the test sets, the multiple calibration strategy
for compensating sweat events seems to result in a reduction of the variability of the
indicators. To assess if this improvement could be related to the higher number of
reference BGL data points used rather than to a real benefit deriving from recalibrating
exactly after sweat events, the MC simulation described in the previous subsection is
performed.
RMSE [mg/dL] MAD [mg/dL] MARD [%]
1→ 2 2→ 1 1→ 2 2→ 1 1→ 2 2→ 1
p =0.07 p =0.7 p =0.06 p =0.6 p =0.09 p =0.7
Single Baseline Calibration 57.9 57.5 48.6 47.2 37.8 39.4
(27.1) (25.1) (23.7) (21.8) (20) (20.1)
Multiple Baseline Calibrations 50.9 52.8 42 42.2 33.9 34.4
(20.8) (19.5) (19.8) (15.5) (18.8) (10.9)
Table 12.1: Key indicators results for the single and multiple glucose calibration. Average
and standard deviation (in parenthesis) -over experimental sessions- of RMSE, MAD, MARD
obtained when database “part 1” and database “part 2” are used for model identification
and model test, respectively, (1 → 2), or viceversa (2 → 1). Single Baseline Calibration:
parameter b in eq. (10.2) is calculated only at the beginning of the experimental session;
Multiple Calibrations: b in eq. (10.2) is updated everytime a sweat event is detected. The p
value indicates the statistical difference between the two calibration strategies according to
the Student t-test.
For each of the 1000 MC simulations, the mean accuracy of the random multiple
calibrated glucose profiles was evaluated by the same key indicators used above. Then,
the distributions of the key indicators on the 1000 repetitions were compared with the
mean values results in Table 12.1 and showed in Figure 12.3 for RMSE, MAD and MARD,
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respectively, only for one test data subsets (comparable results are obtained switching
identification and test data sets see 2→ 1 in Table 12.1). In Figure 12.3, the distribution
of mean values of the key indexes calculated on the 1000 MC simulations is depicted with
grey bars, while mean value obtained recalculating the calibration parameter after each
sweat event is showed with a red arrow. Interestingly, the peaks of the distributions for
the three indicators are exactly comparable with the results obtained with the proposed
recalibration strategy. In addition, from the bottom panel of Figure 12.3 we can note
that a significant portion of the MC simulations produce a mean value lower than the
one represented by the red arrow (39%, 31% and 27.6% for RMSE, MAD and MARD,
respectively). Thus, the results of the MC simulation suggest that the improvements
(with respect to the single baseline calibration scenario) in terms of accuracy noticed in
Table 12.1 are due to the increased number of reference BGL points used for calibration
rather than to performing recalibration exactly after a sweat event to compensate for
changes in the baseline of the main glucose signals induced by the event.
40 45 50 55 60 650
10
20
30
40
50
60
Multiple Calibrations:
50.9696 mg/dL
Single Baseline Calibrations:
57.9609 mg/dL
RMSE
[mg/dL]
(a)
30 35 40 45 50 550
10
20
30
40
50
60
Multiple Calibrations:
42.0348 mg/dL
Single Baseline Calibrations:
48.6261 mg/dL
MAD
[mg/dL]
(b)
25 30 35 40 450
10
20
30
40
50
60
70
80
Multiple Calibrations:
33.9478 %
Single Baseline Calibrations:
37.8 %
MARD
[%]
(c)
40 45 50 55 60 650
10
20
30
40
50
60
Multiple Calibrations:
52.8 mg/dL
Single Baseline Calibrations:
57.5818 mg/dL
RMSE
[mg/dL]
(d)
30 35 40 45 50 550
10
20
30
40
50
60
Multiple Calibrations:
42.2455 mg/dL
Single Baseline Calibrations:
47.25 mg/dL
MAD
[mg/dL]
(e)
25 30 35 40 450
10
20
30
40
50
60
Multiple Calibrations:
34.45 %
Single Baseline Calibrations:
39.4136 %
MARD
[%]
(f)
Figure 12.3: Histogram of RMSE, MAD and MARD obtained in the Monte Carlo simulation
when data subset “part 2” (top) and “part 1” (bottom) are used for model test respectively.
Green arrows report the value (also presents in Table 12.1 ) of the key indicator considered for
single baseline calibration, while the red arrow for the multiple baseline calibration.
The MC methodology showed that re-calculating the glucose baseline after the
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occurrence of sweat events is not necessary because the multisensor system (device plus
model) is able to compensate for this particular detrimental effect. This is particularly
useful in the therapy of diabetes and appealing for the ever-day use of the device because
a patient do not need to collect a SMBG measure every time a sweat occurs.
12.2.4 Other Possible uses of the MC Simulation Strategy
As we saw in this section, the MC methodology can be a valid tool for assessing the
robustness of model calibration by judging whether the improvement due to a proposed
calibration scheme is really useful or rather due to the increased quantity of information
considered (in previous case more reference BGL used for calibration). Within the same
framework, other possible uses of the proposed MC methodology is to assess the validity
of new strategies for calibration. For example, calibration scheduling are widely used
also by minimally-invasive devices for improving accuracy of estimated glucose profiles
by re-calculating the calibration parameters according to a temporal scheduling [153].
Calibration scheduling is also exploited by NI-CGM devices, such as for example by
Harman-Boehm et al. [103].
12.3 Future Developments: Other Possible Fields of
Investigations
Identification techniques considered in Part II minimize a cost function where the error
term measuring the adherence to the data is given as the sum of the distances between
the target (reference BGL) and model output. However, this cost function does not take
into consideration that errors in glucose estimates do not always have the same clinical
implications, as also depicted from the CGA and CEGA in Chapter 11. For example,
in [154] a new glucose specific metric is introduced that modifies the MSE as defined in
eq. (5.3) of Chapter 5 with a Clark error grid inspired penalty function, which penalizes
overestimation in hypoglycemia and underestimation in hyperglycemia, i.e., the most
harmful conditions on a clinical perspective. This new cost function is formally given by:
gMSE(y, yˆ) = MSE(y, yˆ)Pen(y, yˆ) (12.1)
where y and yˆ represent the reference BGL data and the estimated glucose by the model
respectively, while MSE(·, ·) is the euclidean distance and Pen(·, ·) is the Clarke inspired
loss function. For instance, this new cost function, which is graphically depicted in Figure
??, can replace the RSS used to identify, for example, the regularization based methods,
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Figure 12.4: Clarke error grid inspired cost function gMSE.
i.e. LASSO, Ridge and EN.
Future investigations may also be focused on the application of the methodologies
presented in this thesis to a wider data set possibly obtained in real-life situations, where
environmental conditions are not controllable as those of in-clinic studies. This could
be object of investigation for Biovotion AG (Zurich, Switzerland), the company that
recently acquired IP and technology of the Multisensor data used in this thesis.
A
Full Model Identification Glucose Profiles
This appendix collects the full model identification plots when data subset “part 1” and
“part 2” are used to identify the different models.
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146 Full Model Identification Glucose Profiles
B
Full Model Test Glucose Profiles
This section collects the full model test plots when data subset “part 2” and “part 1” are
used to test the different models.
148 Full Model Test Glucose Profiles
2
4
6
8
t i m
e  [ h o u r s ]
2
4
6
8
t i m
e  [ h o u r s ]
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 5 0 4 _ S 4 W
P 2 _ A A 0 2
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 5 2 5 _ S 4 W
P 2 _ A A 0 2
2
4
6
8
1 0
2 0 0 9 0 9 0 1 _ S 4 W
P 4 _ A A 0 2
2
4
6
8
1 0
2 0 0 9 0 9 0 8 _ S 4 W
P 4 _ A A 0 2
2
4
6
8
1 0
2 0 0 9 0 5 1 2 _ S 4 W
P 2 _ A A 0 3
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 5 1 8 _ S 4 W
P 2 _ A A 0 3
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 6 2 3 _ S 4 W
P 3 _ A A 0 3
2
4
6
8
1 0
2 0 0 9 0 8 1 7 _ S 4 W
P 4 _ A A 0 3
2
4
6
8
1 0
2 0 0 9 0 8 2 5 _ S 4 W
P 4 _ A A 0 3
2
4
6
8
1 0
2 0 0 9 0 5 0 7 _ S 4 W
P 2 _ A A 0 4
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 5 2 8 _ S 4 W
P 2 _ A A 0 4
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 6 1 8 _ S 4 W
P 3 _ A A 0 4
2
4
6
8
1 0
2 0 0 9 0 8 1 3 _ S 4 W
P 4 _ A A 0 4
2
4
6
8
1 0
2 0 0 9 0 9 1 4 _ S 4 W
P 4 _ A A 0 4
2
4
6
8
1 0
2 0 0 9 0 5 1 3 _ S 4 W
P 2 _ A A 0 5
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 6 0 3 _ S 4 W
P 2 _ A A 0 5
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 9 0 9 _ S 4 W
P 3 _ A A 0 5
2
4
6
8
1 0
2 0 0 9 0 8 1 2 _ S 4 W
P 4 _ A A 0 6
2
4
6
8
1 0
2 0 0 9 0 8 2 4 _ S 4 W
P 4 _ A A 0 6
2
4
6
8
1 0
2 0 0 9 0 9 2 3 _ S 4 W
P 3 _ A A 0 6
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 8 1 0 _ S 4 W
P 4 _ A A 0 9
t i m
e  [ h o u r s ]
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 9 0 4 _ S 4 W
P 4 _ A A 0 9
t i m
e  [ h o u r s ]
2
4
6
8
1 0
2 0 0 9 0 9 2 8 _ S 4 W
P 3 _ A A 0 9
t i m
e  [ h o u r s ]
F
ig
u
re
B
.1
:
E
stim
a
ted
g
lu
co
se
p
ro
fi
les
b
y
O
L
S
(co
n
tin
u
o
u
s
b
la
ck
lin
e)
(co
n
tin
u
o
u
s
b
la
ck
lin
e)
a
g
a
in
st
referen
ce
B
G
L
va
lu
es
(b
la
ck
circles)
w
h
en
th
e
sa
m
e
m
u
lti-sen
so
r
d
a
ta
u
sed
fo
r
m
o
d
el
test,
i.e.
d
a
ta
su
b
set
“
p
a
rt
2
”
,
is
co
n
sid
ered
(
“
ex
tern
a
l
va
lid
a
tio
n
”
).
T
h
e
fi
rst
p
a
rt
o
f
th
e
reco
rd
in
g
sessio
n
s’
la
b
els
in
d
ica
tes
th
e
d
a
ta
a
cq
u
isitio
n
d
ay,
th
e
seco
n
d
p
a
rt
is
a
n
in
tern
a
l
n
o
ta
tio
n
,
a
n
d
th
e
th
ird
p
a
rt
sta
tes
su
b
ject’s
id
n
u
m
b
er.
149
2
4
6
8
tim
e 
[h
ou
rs
]
2
4
6
8
tim
e 
[h
ou
rs
]
2
4
6
8
10
07018
0
30
0
40
0
20
09
05
04
_S
4W
P2
_A
A0
2
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
05
25
_S
4W
P2
_A
A0
2
2
4
6
8
10
20
09
09
01
_S
4W
P4
_A
A0
2
2
4
6
8
10
20
09
09
08
_S
4W
P4
_A
A0
2
2
4
6
8
10
20
09
05
12
_S
4W
P2
_A
A0
3
2
4
6
8
10
07018
0
30
0
40
0
20
09
05
18
_S
4W
P2
_A
A0
3
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
06
23
_S
4W
P3
_A
A0
3
2
4
6
8
10
20
09
08
17
_S
4W
P4
_A
A0
3
2
4
6
8
10
20
09
08
25
_S
4W
P4
_A
A0
3
2
4
6
8
10
20
09
05
07
_S
4W
P2
_A
A0
4
2
4
6
8
10
07018
0
30
0
40
0
20
09
05
28
_S
4W
P2
_A
A0
4
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
06
18
_S
4W
P3
_A
A0
4
2
4
6
8
10
20
09
08
13
_S
4W
P4
_A
A0
4
2
4
6
8
10
20
09
09
14
_S
4W
P4
_A
A0
4
2
4
6
8
10
20
09
05
13
_S
4W
P2
_A
A0
5
2
4
6
8
10
07018
0
30
0
40
0
20
09
06
03
_S
4W
P2
_A
A0
5
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
09
09
_S
4W
P3
_A
A0
5
2
4
6
8
10
20
09
08
12
_S
4W
P4
_A
A0
6
2
4
6
8
10
20
09
08
24
_S
4W
P4
_A
A0
6
2
4
6
8
10
20
09
09
23
_S
4W
P3
_A
A0
6
2
4
6
8
10
07018
0
30
0
40
0
20
09
08
10
_S
4W
P4
_A
A0
9
tim
e 
[h
ou
rs
]
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
09
04
_S
4W
P4
_A
A0
9
tim
e 
[h
ou
rs
]
2
4
6
8
10
20
09
09
28
_S
4W
P3
_A
A0
9
tim
e 
[h
ou
rs
]
F
ig
u
re
B
.2
:
E
st
im
a
te
d
g
lu
co
se
p
ro
fi
le
s
b
y
P
L
S
(c
o
n
ti
n
u
o
u
s
b
la
ck
li
n
e)
a
g
a
in
st
re
fe
re
n
ce
B
G
L
va
lu
es
(b
la
ck
ci
rc
le
s)
w
h
en
th
e
sa
m
e
m
u
lt
i-
se
n
so
r
d
a
ta
u
se
d
fo
r
m
o
d
el
id
en
ti
fi
ca
ti
o
n
,
i.
e.
d
a
ta
su
b
se
t
“
p
a
rt
2
”
,
is
co
n
si
d
er
ed
(
“
ex
te
rn
a
l
va
li
d
a
ti
o
n
”
).
T
h
e
fi
rs
t
p
a
rt
o
f
th
e
re
co
rd
in
g
se
ss
io
n
s’
la
b
el
s
in
d
ic
a
te
s
th
e
d
a
ta
a
cq
u
is
it
io
n
d
ay
,
th
e
se
co
n
d
p
a
rt
is
a
n
in
te
rn
a
l
n
o
ta
ti
o
n
,
a
n
d
th
e
th
ir
d
p
a
rt
st
a
te
s
su
b
je
ct
’s
id
n
u
m
b
er
.
150 Full Model Test Glucose Profiles
2
4
6
8
t i m
e  [ h o u r s ]
2
4
6
8
t i m
e  [ h o u r s ]
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 5 0 4 _ S 4 W
P 2 _ A A 0 2
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 5 2 5 _ S 4 W
P 2 _ A A 0 2
2
4
6
8
1 0
2 0 0 9 0 9 0 1 _ S 4 W
P 4 _ A A 0 2
2
4
6
8
1 0
2 0 0 9 0 9 0 8 _ S 4 W
P 4 _ A A 0 2
2
4
6
8
1 0
2 0 0 9 0 5 1 2 _ S 4 W
P 2 _ A A 0 3
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 5 1 8 _ S 4 W
P 2 _ A A 0 3
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 6 2 3 _ S 4 W
P 3 _ A A 0 3
2
4
6
8
1 0
2 0 0 9 0 8 1 7 _ S 4 W
P 4 _ A A 0 3
2
4
6
8
1 0
2 0 0 9 0 8 2 5 _ S 4 W
P 4 _ A A 0 3
2
4
6
8
1 0
2 0 0 9 0 5 0 7 _ S 4 W
P 2 _ A A 0 4
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 5 2 8 _ S 4 W
P 2 _ A A 0 4
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 6 1 8 _ S 4 W
P 3 _ A A 0 4
2
4
6
8
1 0
2 0 0 9 0 8 1 3 _ S 4 W
P 4 _ A A 0 4
2
4
6
8
1 0
2 0 0 9 0 9 1 4 _ S 4 W
P 4 _ A A 0 4
2
4
6
8
1 0
2 0 0 9 0 5 1 3 _ S 4 W
P 2 _ A A 0 5
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 6 0 3 _ S 4 W
P 2 _ A A 0 5
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 9 0 9 _ S 4 W
P 3 _ A A 0 5
2
4
6
8
1 0
2 0 0 9 0 8 1 2 _ S 4 W
P 4 _ A A 0 6
2
4
6
8
1 0
2 0 0 9 0 8 2 4 _ S 4 W
P 4 _ A A 0 6
2
4
6
8
1 0
2 0 0 9 0 9 2 3 _ S 4 W
P 3 _ A A 0 6
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 8 1 0 _ S 4 W
P 4 _ A A 0 9
t i m
e  [ h o u r s ]
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 9 0 4 _ S 4 W
P 4 _ A A 0 9
t i m
e  [ h o u r s ]
2
4
6
8
1 0
2 0 0 9 0 9 2 8 _ S 4 W
P 3 _ A A 0 9
t i m
e  [ h o u r s ]
F
ig
u
re
B
.3
:
E
stim
a
ted
g
lu
co
se
p
ro
fi
les
b
y
L
A
S
S
O
(co
n
tin
u
o
u
s
b
la
ck
lin
e)
a
g
a
in
st
referen
ce
B
G
L
va
lu
es
(b
la
ck
circles)
w
h
en
th
e
sa
m
e
m
u
lti-sen
so
r
d
a
ta
u
sed
fo
r
m
o
d
el
id
en
tifi
ca
tio
n
,
i.e.
d
a
ta
su
b
set
“
p
a
rt
2
”
,
is
co
n
sid
ered
(
“
ex
tern
a
l
va
lid
a
tio
n
”
).
T
h
e
fi
rst
p
a
rt
o
f
th
e
reco
rd
in
g
sessio
n
s’
la
b
els
in
d
ica
tes
th
e
d
a
ta
a
cq
u
isitio
n
d
ay,
th
e
seco
n
d
p
a
rt
is
a
n
in
tern
a
l
n
o
ta
tio
n
,
a
n
d
th
e
th
ird
p
a
rt
sta
tes
su
b
ject’s
id
n
u
m
b
er.
151
2
4
6
8
tim
e 
[h
ou
rs
]
2
4
6
8
tim
e 
[h
ou
rs
]
2
4
6
8
10
07018
0
30
0
40
0
20
09
05
04
_S
4W
P2
_A
A0
2
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
05
25
_S
4W
P2
_A
A0
2
2
4
6
8
10
20
09
09
01
_S
4W
P4
_A
A0
2
2
4
6
8
10
20
09
09
08
_S
4W
P4
_A
A0
2
2
4
6
8
10
20
09
05
12
_S
4W
P2
_A
A0
3
2
4
6
8
10
07018
0
30
0
40
0
20
09
05
18
_S
4W
P2
_A
A0
3
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
06
23
_S
4W
P3
_A
A0
3
2
4
6
8
10
20
09
08
17
_S
4W
P4
_A
A0
3
2
4
6
8
10
20
09
08
25
_S
4W
P4
_A
A0
3
2
4
6
8
10
20
09
05
07
_S
4W
P2
_A
A0
4
2
4
6
8
10
07018
0
30
0
40
0
20
09
05
28
_S
4W
P2
_A
A0
4
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
06
18
_S
4W
P3
_A
A0
4
2
4
6
8
10
20
09
08
13
_S
4W
P4
_A
A0
4
2
4
6
8
10
20
09
09
14
_S
4W
P4
_A
A0
4
2
4
6
8
10
20
09
05
13
_S
4W
P2
_A
A0
5
2
4
6
8
10
07018
0
30
0
40
0
20
09
06
03
_S
4W
P2
_A
A0
5
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
09
09
_S
4W
P3
_A
A0
5
2
4
6
8
10
20
09
08
12
_S
4W
P4
_A
A0
6
2
4
6
8
10
20
09
08
24
_S
4W
P4
_A
A0
6
2
4
6
8
10
20
09
09
23
_S
4W
P3
_A
A0
6
2
4
6
8
10
07018
0
30
0
40
0
20
09
08
10
_S
4W
P4
_A
A0
9
tim
e 
[h
ou
rs
]
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
09
04
_S
4W
P4
_A
A0
9
tim
e 
[h
ou
rs
]
2
4
6
8
10
20
09
09
28
_S
4W
P3
_A
A0
9
tim
e 
[h
ou
rs
]
F
ig
u
re
B
.4
:
E
st
im
a
te
d
g
lu
co
se
p
ro
fi
le
s
b
y
R
id
g
e
(c
o
n
ti
n
u
o
u
s
b
la
ck
li
n
e)
a
g
a
in
st
re
fe
re
n
ce
B
G
L
va
lu
es
(b
la
ck
ci
rc
le
s)
w
h
en
th
e
sa
m
e
m
u
lt
i-
se
n
so
r
d
a
ta
u
se
d
fo
r
m
o
d
el
id
en
ti
fi
ca
ti
o
n
,
i.
e.
d
a
ta
su
b
se
t
“
p
a
rt
2
”
,
is
co
n
si
d
er
ed
(
“
ex
te
rn
a
l
va
li
d
a
ti
o
n
”
).
T
h
e
fi
rs
t
p
a
rt
o
f
th
e
re
co
rd
in
g
se
ss
io
n
s’
la
b
el
s
in
d
ic
a
te
s
th
e
d
a
ta
a
cq
u
is
it
io
n
d
ay
,
th
e
se
co
n
d
p
a
rt
is
a
n
in
te
rn
a
l
n
o
ta
ti
o
n
,
a
n
d
th
e
th
ir
d
p
a
rt
st
a
te
s
su
b
je
ct
’s
id
n
u
m
b
er
.
152 Full Model Test Glucose Profiles
2
4
6
8
t i m
e  [ h o u r s ]
2
4
6
8
t i m
e  [ h o u r s ]
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 5 0 4 _ S 4 W
P 2 _ A A 0 2
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 5 2 5 _ S 4 W
P 2 _ A A 0 2
2
4
6
8
1 0
2 0 0 9 0 9 0 1 _ S 4 W
P 4 _ A A 0 2
2
4
6
8
1 0
2 0 0 9 0 9 0 8 _ S 4 W
P 4 _ A A 0 2
2
4
6
8
1 0
2 0 0 9 0 5 1 2 _ S 4 W
P 2 _ A A 0 3
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 5 1 8 _ S 4 W
P 2 _ A A 0 3
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 6 2 3 _ S 4 W
P 3 _ A A 0 3
2
4
6
8
1 0
2 0 0 9 0 8 1 7 _ S 4 W
P 4 _ A A 0 3
2
4
6
8
1 0
2 0 0 9 0 8 2 5 _ S 4 W
P 4 _ A A 0 3
2
4
6
8
1 0
2 0 0 9 0 5 0 7 _ S 4 W
P 2 _ A A 0 4
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 5 2 8 _ S 4 W
P 2 _ A A 0 4
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 6 1 8 _ S 4 W
P 3 _ A A 0 4
2
4
6
8
1 0
2 0 0 9 0 8 1 3 _ S 4 W
P 4 _ A A 0 4
2
4
6
8
1 0
2 0 0 9 0 9 1 4 _ S 4 W
P 4 _ A A 0 4
2
4
6
8
1 0
2 0 0 9 0 5 1 3 _ S 4 W
P 2 _ A A 0 5
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 6 0 3 _ S 4 W
P 2 _ A A 0 5
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 9 0 9 _ S 4 W
P 3 _ A A 0 5
2
4
6
8
1 0
2 0 0 9 0 8 1 2 _ S 4 W
P 4 _ A A 0 6
2
4
6
8
1 0
2 0 0 9 0 8 2 4 _ S 4 W
P 4 _ A A 0 6
2
4
6
8
1 0
2 0 0 9 0 9 2 3 _ S 4 W
P 3 _ A A 0 6
2
4
6
8
1 0
0 7 0
1 8 0
3 0 0
4 0 0
2 0 0 9 0 8 1 0 _ S 4 W
P 4 _ A A 0 9
t i m
e  [ h o u r s ]
glucose level
   [mg/dL]   
2
4
6
8
1 0
2 0 0 9 0 9 0 4 _ S 4 W
P 4 _ A A 0 9
t i m
e  [ h o u r s ]
2
4
6
8
1 0
2 0 0 9 0 9 2 8 _ S 4 W
P 3 _ A A 0 9
t i m
e  [ h o u r s ]
F
ig
u
re
B
.5
:
E
stim
a
ted
g
lu
co
se
p
ro
fi
les
b
y
E
N
(co
n
tin
u
o
u
s
b
la
ck
lin
e)
a
g
a
in
st
referen
ce
B
G
L
va
lu
es
(b
la
ck
circles)
w
h
en
th
e
sa
m
e
m
u
lti-sen
so
r
d
a
ta
u
sed
fo
r
m
o
d
el
id
en
tifi
ca
tio
n
,
i.e.
d
a
ta
su
b
set
“
p
a
rt
2
”
,
is
co
n
sid
ered
(
“
ex
tern
a
l
va
lid
a
tio
n
”
).
T
h
e
fi
rst
p
a
rt
o
f
th
e
reco
rd
in
g
sessio
n
s’
la
b
els
in
d
ica
tes
th
e
d
a
ta
a
cq
u
isitio
n
d
ay,
th
e
seco
n
d
p
a
rt
is
a
n
in
tern
a
l
n
o
ta
tio
n
,
a
n
d
th
e
th
ird
p
a
rt
sta
tes
su
b
ject’s
id
n
u
m
b
er.
153
2
4
6
8
tim
e 
[h
ou
rs
]
2
4
6
8
tim
e 
[h
ou
rs
]
2
4
6
8
tim
e 
[h
ou
rs
]
2
4
6
8
10
07018
0
30
0
40
0
20
09
04
06
_S
4W
P2
_A
A0
2
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
04
27
_S
4W
P2
_A
A0
2
2
4
6
8
10
20
09
08
20
_S
4W
P4
_A
A0
2
2
4
6
8
10
20
09
08
26
_S
4W
P4
_A
A0
2
2
4
6
8
10
20
09
04
16
_S
4W
P2
_A
A0
3
2
4
6
8
10
07018
0
30
0
40
0
20
09
04
30
_S
4W
P2
_A
A0
3
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
06
10
_S
4W
P3
_A
A0
3
2
4
6
8
10
20
09
07
28
_S
4W
P4
_A
A0
3
2
4
6
8
10
20
09
04
09
_S
4W
P2
_A
A0
4
2
4
6
8
10
20
09
04
23
_S
4W
P2
_A
A0
4
2
4
6
8
10
07018
0
30
0
40
0
20
09
06
09
_S
4W
P3
_A
A0
4
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
07
30
_S
4W
P4
_A
A0
4
2
4
6
8
10
20
09
08
06
_S
4W
P4
_A
A0
4
2
4
6
8
10
20
09
04
08
_S
4W
P2
_A
A0
5
2
4
6
8
10
20
09
04
22
_S
4W
P2
_A
A0
5
2
4
6
8
10
07018
0
30
0
40
0
20
09
06
24
_S
4W
P3
_A
A0
5
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
07
22
_S
4W
P4
_A
A0
5
2
4
6
8
10
20
09
07
06
_S
4W
P3
_A
A0
6
2
4
6
8
10
20
09
07
27
_S
4W
P4
_A
A0
6
2
4
6
8
10
20
09
08
04
_S
4W
P4
_A
A0
6
2
4
6
8
10
07018
0
30
0
40
0
20
09
07
23
_S
4W
P4
_A
A0
9
tim
e 
[h
ou
rs
]
glucose level
   [mg/dL]   
2
4
6
8
10
20
09
09
21
_S
4W
P3
_A
A0
9
tim
e 
[h
ou
rs
]
F
ig
u
re
B
.6
:
E
st
im
a
te
d
g
lu
co
se
p
ro
fi
le
s
b
y
O
L
S
(c
o
n
ti
n
u
o
u
s
b
la
ck
li
n
e)
a
g
a
in
st
re
fe
re
n
ce
B
G
L
va
lu
es
(b
la
ck
ci
rc
le
s)
w
h
en
th
e
sa
m
e
m
u
lt
i-
se
n
so
r
d
a
ta
u
se
d
fo
r
m
o
d
el
id
en
ti
fi
ca
ti
o
n
,
i.
e.
d
a
ta
su
b
se
t
“
p
a
rt
1
”
,
is
co
n
si
d
er
ed
(
“
ex
te
rn
a
l
va
li
d
a
ti
o
n
”
).
T
h
e
fi
rs
t
p
a
rt
o
f
th
e
re
co
rd
in
g
se
ss
io
n
s’
la
b
el
s
in
d
ic
a
te
s
th
e
d
a
ta
a
cq
u
is
it
io
n
d
ay
,
th
e
se
co
n
d
p
a
rt
is
a
n
in
te
rn
a
l
n
o
ta
ti
o
n
,
a
n
d
th
e
th
ir
d
p
a
rt
st
a
te
s
su
b
je
ct
’s
id
n
u
m
b
er
.
154 Full Model Test Glucose Profiles
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